EP4337259A1 - Compounds for degrading alpha-synuclein aggregates and uses thereof - Google Patents
Compounds for degrading alpha-synuclein aggregates and uses thereofInfo
- Publication number
- EP4337259A1 EP4337259A1 EP21726997.6A EP21726997A EP4337259A1 EP 4337259 A1 EP4337259 A1 EP 4337259A1 EP 21726997 A EP21726997 A EP 21726997A EP 4337259 A1 EP4337259 A1 EP 4337259A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- alkyl
- substituted
- compound
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 601
- 108090000185 alpha-Synuclein Proteins 0.000 title abstract description 5
- 102000003802 alpha-Synuclein Human genes 0.000 title abstract 2
- 230000000593 degrading effect Effects 0.000 title description 5
- 230000027455 binding Effects 0.000 claims abstract description 32
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims abstract description 20
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims abstract description 20
- 208000032859 Synucleinopathies Diseases 0.000 claims abstract description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 216
- 229910052760 oxygen Inorganic materials 0.000 claims description 200
- 229910052739 hydrogen Inorganic materials 0.000 claims description 189
- 238000000034 method Methods 0.000 claims description 168
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 164
- 229910052757 nitrogen Inorganic materials 0.000 claims description 147
- 125000005842 heteroatom Chemical group 0.000 claims description 145
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 141
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 137
- 229910052736 halogen Inorganic materials 0.000 claims description 136
- 150000002367 halogens Chemical class 0.000 claims description 136
- 229910052717 sulfur Inorganic materials 0.000 claims description 134
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 119
- 150000002430 hydrocarbons Chemical group 0.000 claims description 115
- 125000003545 alkoxy group Chemical group 0.000 claims description 114
- -1 n-propylene Chemical group 0.000 claims description 104
- 125000003118 aryl group Chemical group 0.000 claims description 96
- 125000005843 halogen group Chemical group 0.000 claims description 89
- 150000003839 salts Chemical class 0.000 claims description 85
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 84
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 79
- 239000012453 solvate Substances 0.000 claims description 79
- 229940002612 prodrug Drugs 0.000 claims description 75
- 239000000651 prodrug Substances 0.000 claims description 75
- 230000002503 metabolic effect Effects 0.000 claims description 74
- 239000002243 precursor Substances 0.000 claims description 74
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 71
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 68
- 125000004429 atom Chemical group 0.000 claims description 63
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 61
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 60
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 60
- 239000001257 hydrogen Substances 0.000 claims description 59
- 125000002950 monocyclic group Chemical group 0.000 claims description 59
- 229910052799 carbon Inorganic materials 0.000 claims description 58
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 54
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 51
- 125000003282 alkyl amino group Chemical group 0.000 claims description 48
- 125000001188 haloalkyl group Chemical group 0.000 claims description 44
- 229910052770 Uranium Inorganic materials 0.000 claims description 39
- 125000002619 bicyclic group Chemical group 0.000 claims description 36
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 31
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims description 30
- 125000002252 acyl group Chemical group 0.000 claims description 27
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 26
- 125000004122 cyclic group Chemical group 0.000 claims description 23
- 125000005647 linker group Chemical group 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 208000018737 Parkinson disease Diseases 0.000 claims description 21
- 210000004558 lewy body Anatomy 0.000 claims description 21
- 201000002832 Lewy body dementia Diseases 0.000 claims description 16
- 230000002776 aggregation Effects 0.000 claims description 16
- 238000004220 aggregation Methods 0.000 claims description 16
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 15
- 125000002947 alkylene group Chemical group 0.000 claims description 15
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 14
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 11
- 239000001301 oxygen Chemical group 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 125000005549 heteroarylene group Chemical group 0.000 claims description 10
- 125000004419 alkynylene group Chemical group 0.000 claims description 9
- 125000004450 alkenylene group Chemical group 0.000 claims description 8
- 125000000732 arylene group Chemical group 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 6
- 229910052720 vanadium Inorganic materials 0.000 claims description 6
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 claims description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 5
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims description 4
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 claims description 4
- FGIVSGPRGVABAB-UHFFFAOYSA-N fluoren-9-ylmethyl hydrogen carbonate Chemical compound C1=CC=C2C(COC(=O)O)C3=CC=CC=C3C2=C1 FGIVSGPRGVABAB-UHFFFAOYSA-N 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- XKXIQBVKMABYQJ-UHFFFAOYSA-M tert-butyl carbonate Chemical compound CC(C)(C)OC([O-])=O XKXIQBVKMABYQJ-UHFFFAOYSA-M 0.000 claims description 4
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 claims description 4
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 3
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 25
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 6
- 230000004770 neurodegeneration Effects 0.000 abstract description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 327
- 239000000203 mixture Substances 0.000 description 185
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 165
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 156
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 155
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 124
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 123
- 239000000243 solution Substances 0.000 description 107
- 239000007787 solid Substances 0.000 description 102
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 96
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 82
- 238000004440 column chromatography Methods 0.000 description 70
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 67
- 239000012267 brine Substances 0.000 description 67
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 67
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 65
- 239000012044 organic layer Substances 0.000 description 57
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 56
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 56
- 229910052731 fluorine Inorganic materials 0.000 description 55
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 55
- 235000019439 ethyl acetate Nutrition 0.000 description 48
- 230000015572 biosynthetic process Effects 0.000 description 37
- 238000003786 synthesis reaction Methods 0.000 description 37
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 34
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 32
- 125000005825 oxyethoxy group Chemical group [H]C([H])(O[*:1])C([H])([H])O[*:2] 0.000 description 30
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 28
- VRZVPALEJCLXPR-UHFFFAOYSA-N ethyl 4-methylbenzenesulfonate Chemical compound CCOS(=O)(=O)C1=CC=C(C)C=C1 VRZVPALEJCLXPR-UHFFFAOYSA-N 0.000 description 27
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 23
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 22
- 201000010099 disease Diseases 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- 238000001914 filtration Methods 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 16
- 229910000027 potassium carbonate Inorganic materials 0.000 description 16
- 235000015320 potassium carbonate Nutrition 0.000 description 16
- 230000001575 pathological effect Effects 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- 229910052721 tungsten Inorganic materials 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- VYVPNTJBGPQTFA-UHFFFAOYSA-N 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCOCCOS(=O)(=O)C1=CC=C(C)C=C1 VYVPNTJBGPQTFA-UHFFFAOYSA-N 0.000 description 10
- 238000001556 precipitation Methods 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- LVQFHDAKZHGEAJ-UHFFFAOYSA-M 4-methylbenzenesulfonate Chemical compound [CH2]C1=CC=C(S([O-])(=O)=O)C=C1 LVQFHDAKZHGEAJ-UHFFFAOYSA-M 0.000 description 7
- 102100026882 Alpha-synuclein Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 125000003709 fluoroalkyl group Chemical group 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 239000011593 sulfur Chemical group 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
- JJUMFQGCQAUIFH-UHFFFAOYSA-N 3-(6-hydroxy-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1C2=CC(O)=CC=C2C(=O)N1C1CCC(=O)NC1=O JJUMFQGCQAUIFH-UHFFFAOYSA-N 0.000 description 6
- YCPULGHBTPQLRH-UHFFFAOYSA-N 3-aminopiperidine-2,6-dione;hydron;chloride Chemical compound Cl.NC1CCC(=O)NC1=O YCPULGHBTPQLRH-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 229940032147 starch Drugs 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 101000605835 Homo sapiens Serine/threonine-protein kinase PINK1, mitochondrial Proteins 0.000 description 5
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 5
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 5
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 5
- 102100038376 Serine/threonine-protein kinase PINK1, mitochondrial Human genes 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- ZIZXHPCBPDNLDD-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCOCCOCCOCCOCCOCCOS(=O)(=O)C1=CC=C(C)C=C1 ZIZXHPCBPDNLDD-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 4
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- NZNMILVWEHOGBB-UHFFFAOYSA-N NC(C(CCC(=O)O)N1C(C2=CC=C(C=C2C1)O)=O)=O Chemical compound NC(C(CCC(=O)O)N1C(C2=CC=C(C=C2C1)O)=O)=O NZNMILVWEHOGBB-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 208000018637 late onset Parkinson disease Diseases 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 102000045222 parkin Human genes 0.000 description 4
- KOUCTZDKTJGHSS-UHFFFAOYSA-N pentyl 4-methylbenzenesulfonate Chemical compound CCCCCOS(=O)(=O)C1=CC=C(C)C=C1 KOUCTZDKTJGHSS-UHFFFAOYSA-N 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- VPVJWIKIKYUVOX-UHFFFAOYSA-N 3-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]oxy]ethoxy]ethoxy]propanoic acid Chemical compound OC(CCOCCOCCOC(C=C1CN2C(CCC(N3)=O)C3=O)=CC=C1C2=O)=O VPVJWIKIKYUVOX-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000887201 Homo sapiens Polyamine-transporting ATPase 13A2 Proteins 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- 102100039917 Polyamine-transporting ATPase 13A2 Human genes 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 238000012754 cardiac puncture Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000105 evaporative light scattering detection Methods 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- XASWYPVFCVEQSU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;potassium Chemical compound [K].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O XASWYPVFCVEQSU-UHFFFAOYSA-N 0.000 description 2
- RNWRKOPOPSZBFZ-UHFFFAOYSA-N 2-[4-[6-[(2-methylpropan-2-yl)oxycarbonylamino]pyridin-3-yl]phenyl]pyrrolo[2,3-c]pyridine-1-carboxylic acid Chemical compound CC(C)(C)OC(NC(N=C1)=CC=C1C(C=C1)=CC=C1C1=CC2=CC=NC=C2N1C(O)=O)=O RNWRKOPOPSZBFZ-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- LPICBHMSLLEAQL-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCOCCOCCO[Si](C)(C)C(C)(C)C Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCOCCOCCO[Si](C)(C)C(C)(C)C LPICBHMSLLEAQL-UHFFFAOYSA-N 0.000 description 2
- VDWOJLHWBRGTHO-UHFFFAOYSA-N CN(C)C1=CC2=C(C=C1)N=C(S2)C3=CC=C(C=C3)C4=CN=C(C=C4)OC(=O)NCCOCCN5C(=O)CCC(C5=O)N6CC7=C(C6=O)C=CC(=C7)O Chemical compound CN(C)C1=CC2=C(C=C1)N=C(S2)C3=CC=C(C=C3)C4=CN=C(C=C4)OC(=O)NCCOCCN5C(=O)CCC(C5=O)N6CC7=C(C6=O)C=CC(=C7)O VDWOJLHWBRGTHO-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229910052684 Cerium Inorganic materials 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 102100039683 Cyclin-G-associated kinase Human genes 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 102100027346 GTP cyclohydrolase 1 Human genes 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 101000862581 Homo sapiens GTP cyclohydrolase 1 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 102100026918 Phospholipase A2 Human genes 0.000 description 2
- 101710096328 Phospholipase A2 Proteins 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000006736 behavioral deficit Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- JJXVDRYFBGDXOU-UHFFFAOYSA-N dimethyl 4-hydroxybenzene-1,2-dicarboxylate Chemical compound COC(=O)C1=CC=C(O)C=C1C(=O)OC JJXVDRYFBGDXOU-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003979 granulating agent Substances 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- FFQAITMDLOKTFE-UHFFFAOYSA-N methyl 5-amino-4-(6-hydroxy-3-oxo-1H-isoindol-2-yl)-5-oxopentanoate Chemical compound COC(CCC(C(N)=O)N(CC1=CC(O)=CC=C11)C1=O)=O FFQAITMDLOKTFE-UHFFFAOYSA-N 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- KCONMNWPRXAWKK-UHFFFAOYSA-N 2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCOCCOCCOS(=O)(=O)C1=CC=C(C)C=C1 KCONMNWPRXAWKK-UHFFFAOYSA-N 0.000 description 1
- SLAONPBUWDUSSO-UHFFFAOYSA-N 2-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCOCCOCCOCCOS(=O)(=O)C1=CC=C(C)C=C1 SLAONPBUWDUSSO-UHFFFAOYSA-N 0.000 description 1
- OHANZAJUTVTYPD-UHFFFAOYSA-N 2-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]oxy]acetic acid Chemical compound OC(=O)COC1=CC2=C(C=C1)C(=O)N(C2)C1CCC(=O)NC1=O OHANZAJUTVTYPD-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- AWBYNTHBIFCMFC-UHFFFAOYSA-N 2-azidoethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCN=[N+]=[N-])C=C1 AWBYNTHBIFCMFC-UHFFFAOYSA-N 0.000 description 1
- HGPRKOYQOBYISD-UHFFFAOYSA-N 3-(7-hydroxy-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1C=2C(O)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O HGPRKOYQOBYISD-UHFFFAOYSA-N 0.000 description 1
- YUNQZQREIHWDQT-UHFFFAOYSA-N 4-bromo-n-(6-methoxy-1,3-dimethyl-2-oxobenzimidazol-5-yl)-2-methylbenzenesulfonamide Chemical compound COC1=CC=2N(C)C(=O)N(C)C=2C=C1NS(=O)(=O)C1=CC=C(Br)C=C1C YUNQZQREIHWDQT-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- GMMNFKKJUMYAPM-UHFFFAOYSA-N 5-(4-methylphenyl)sulfonyloxypentyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCCCCOS(=O)(=O)C1=CC=C(C)C=C1 GMMNFKKJUMYAPM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102100037991 85/88 kDa calcium-independent phospholipase A2 Human genes 0.000 description 1
- 102100029824 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 Human genes 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 208000005685 Adult-onset dystonia-parkinsonism Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- JOGMLVNCICWNMJ-UHFFFAOYSA-N CC(C)(C)C1=C(C(C=C2)=CC=C2C2=CC=C(N(CCOCCOCCOCCOCCOCCOS(C3=CC=C(C)C=C3)(=O)=O)C(OC(C)(C)C)=O)N=C2)NC2=CN=CC=C12 Chemical compound CC(C)(C)C1=C(C(C=C2)=CC=C2C2=CC=C(N(CCOCCOCCOCCOCCOCCOS(C3=CC=C(C)C=C3)(=O)=O)C(OC(C)(C)C)=O)N=C2)NC2=CN=CC=C12 JOGMLVNCICWNMJ-UHFFFAOYSA-N 0.000 description 1
- IAUKDSDESQCJHN-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCOCCOCCOCCOC=1C=CC=2N(C=1)C=C(N=2)C1=CC=C(C=C1)C=1C(=NC(=CC=1)N(C)C)F Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCOCCOCCOCCOC=1C=CC=2N(C=1)C=C(N=2)C1=CC=C(C=C1)C=1C(=NC(=CC=1)N(C)C)F IAUKDSDESQCJHN-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 102100035180 Coiled-coil domain-containing protein 62 Human genes 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000012694 DDRGK1 Human genes 0.000 description 1
- 101150011286 DDRGK1 gene Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 102100030221 Diacylglycerol kinase theta Human genes 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 101710199743 F-box only protein 7 Proteins 0.000 description 1
- 102100029525 F-box only protein 7 Human genes 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100031361 Fibroblast growth factor 20 Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102100027778 GTP-binding protein Rit2 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 102100028640 HLA class II histocompatibility antigen, DR beta 5 chain Human genes 0.000 description 1
- 108010016996 HLA-DRB5 Chains Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101001095960 Homo sapiens 85/88 kDa calcium-independent phospholipase A2 Proteins 0.000 description 1
- 101000794082 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 Proteins 0.000 description 1
- 101000737082 Homo sapiens Coiled-coil domain-containing protein 62 Proteins 0.000 description 1
- 101000886209 Homo sapiens Cyclin-G-associated kinase Proteins 0.000 description 1
- 101000864574 Homo sapiens Diacylglycerol kinase theta Proteins 0.000 description 1
- 101000846532 Homo sapiens Fibroblast growth factor 20 Proteins 0.000 description 1
- 101001099051 Homo sapiens GPI inositol-deacylase Proteins 0.000 description 1
- 101000725879 Homo sapiens GTP-binding protein Rit2 Proteins 0.000 description 1
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 description 1
- 101001056160 Homo sapiens Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial Proteins 0.000 description 1
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 1
- 101001137535 Homo sapiens Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 Proteins 0.000 description 1
- 101000869523 Homo sapiens Phosphatidylinositide phosphatase SAC2 Proteins 0.000 description 1
- 101000882219 Homo sapiens Protein FAM47E Proteins 0.000 description 1
- 101000712725 Homo sapiens Ras-related protein Rab-7L1 Proteins 0.000 description 1
- 101000835998 Homo sapiens SRA stem-loop-interacting RNA-binding protein, mitochondrial Proteins 0.000 description 1
- 101000701497 Homo sapiens STE20/SPS1-related proline-alanine-rich protein kinase Proteins 0.000 description 1
- 101000654500 Homo sapiens Signal-induced proliferation-associated 1-like protein 2 Proteins 0.000 description 1
- 101000626379 Homo sapiens Synaptotagmin-11 Proteins 0.000 description 1
- 101000585079 Homo sapiens Syntaxin-1B Proteins 0.000 description 1
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 1
- 101000667104 Homo sapiens Vacuolar protein sorting-associated protein 13C Proteins 0.000 description 1
- 101000854862 Homo sapiens Vacuolar protein sorting-associated protein 35 Proteins 0.000 description 1
- 101000739853 Homo sapiens [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 1
- 102100020983 Lysosome membrane protein 2 Human genes 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100026552 Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229910003204 NH2 Inorganic materials 0.000 description 1
- 102100021007 Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 Human genes 0.000 description 1
- BURHAZLANYBZOZ-UHFFFAOYSA-N OC(=O)CCOCCOCCI Chemical compound OC(=O)CCOCCOCCI BURHAZLANYBZOZ-UHFFFAOYSA-N 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 102100032287 Phosphatidylinositide phosphatase SAC2 Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100038928 Protein FAM47E Human genes 0.000 description 1
- 208000009144 Pure autonomic failure Diseases 0.000 description 1
- 208000025535 REM sleep behavior disease Diseases 0.000 description 1
- 102100033100 Ras-related protein Rab-7L1 Human genes 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091005488 SCARB2 Proteins 0.000 description 1
- 108091006983 SLC41A1 Proteins 0.000 description 1
- 101150110423 SNCA gene Proteins 0.000 description 1
- 102100025491 SRA stem-loop-interacting RNA-binding protein, mitochondrial Human genes 0.000 description 1
- 102100030491 STE20/SPS1-related proline-alanine-rich protein kinase Human genes 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 102100031451 Signal-induced proliferation-associated 1-like protein 2 Human genes 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102100032013 Solute carrier family 41 member 1 Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004874 Synaptophysin Human genes 0.000 description 1
- 108090001076 Synaptophysin Proteins 0.000 description 1
- 102100024609 Synaptotagmin-11 Human genes 0.000 description 1
- 102100029931 Syntaxin-1B Human genes 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102100039112 Vacuolar protein sorting-associated protein 13C Human genes 0.000 description 1
- 102100020822 Vacuolar protein sorting-associated protein 35 Human genes 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 102100037607 [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial Human genes 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000005101 aryl methoxy carbonyl group Chemical group 0.000 description 1
- 125000005002 aryl methyl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 208000026030 autosomal recessive Parkinson disease 14 Diseases 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004638 bioanalytical method Methods 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000000806 fluorine-19 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000005154 hemibrain Anatomy 0.000 description 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- CUAUQBKUHAZSIJ-UHFFFAOYSA-N isoindole-1,3-dione Chemical compound C1=C=C[C]2C(=O)NC(=O)C2=C1 CUAUQBKUHAZSIJ-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000012006 liquid chromatography with tandem mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 108091031561 miR-4697 stem-loop Proteins 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000025220 protein targeting to vacuole Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- NPWMTBZSRRLQNJ-UHFFFAOYSA-N pyroglutamine Chemical compound NC1CCC(=O)NC1=O NPWMTBZSRRLQNJ-UHFFFAOYSA-N 0.000 description 1
- VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical compound NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200036624 rs104893875 Human genes 0.000 description 1
- 102200036626 rs104893877 Human genes 0.000 description 1
- 102200036620 rs104893878 Human genes 0.000 description 1
- 102200036623 rs201106962 Human genes 0.000 description 1
- 102220031971 rs431905511 Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000003755 striatonigral degeneration Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
Definitions
- Synucleinopathies are neurodegenerative diseases characterized by the abnormal accumulation of a-synuclein (a-Syn) aggregates in neurons and glial cells.
- ⁇ -Synuclein is a 140 amino acid protein preferentially expressed in neurons at pre-synaptic terminals where it is thought to play a role in regulating synaptic transmission (Bendor et al., Neuron 2013; 79:1044-66).
- a-Synuclein can form pathological aggregates in neurons known as Lewy bodies, which are characteristic of both Parkinson's Disease (PD) and dementia with Lewy bodies (DLB).
- the pathological aggregates consist of aggregated, insoluble accumulations of misfolded a-synuclein proteins in neurons, nerve fibers or glial cells and are a characteristic feature of synucleinopathies.
- Synucleinopathies include Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), the Lewy body variant of Alzheimer's disease (LBVAD), combined Parkinson's disease (PD) and Alzheimer's disease (AD), and neurodegeneration with brain iron accumulation type-1 (NBIA-1).
- PD and DLB a-Syn aggregates are in the neuronal cytoplasm and axonal processes into Lewy bodies and Lewy neurites, respectively, whereas a-Syn inclusions in oligodendroglia are the recognized neuropathologic hallmarks of MSA.
- the present disclosure stems from the recognition that a bispecific conjugate compound that includes an E3 ubiquitin ligase binding moiety that is based on an imide drug (e.g., lenalidomide, thalidomide, VHL ligand) and also includes a binder of a-synuclein may induce proteasome degradation of a-synuclein aggregates.
- an imide drug e.g., lenalidomide, thalidomide, VHL ligand
- the disclosure therefore provides compounds, compositions, and methods for the treatment of various neurodegenerative diseases associated with a-synuclein aggregates based on this discovery.
- the bispecific conjugate compounds described herein degrade the a-synuclein aggregates by removing a-synuclein aggregates or reducing the degree of a-synuclein aggregation to low levels in a cellular model and/or animal model, thereby possessing therapeutic potential in the treatment of patients with synucleinopathies including but not limited to Parkinson’s disease (PD), dementia with Lewy bodies (DLB), or multiple system atrophy (MSA).
- PD Parkinson’s disease
- DLB dementia with Lewy bodies
- MSA multiple system atrophy
- the present disclosure also provides methods to remove a-synuclein aggregation or reduce Lewy bodies or a-synuclein aggregate in a patient having Lewy body disease or risk of Lewy body disease, and methods to reduce dementia with Lewy bodies (DLB) or multiple system atrophy (MSA) or other synucleinopathies.
- DLB dementia with Lewy bodies
- MSA multiple system atrophy
- One aspect of the present disclosure is a compound of Formula A,
- EBM is an E3 ubiquitin ligase binding moiety
- L is a linker covalently attached to EBM and SBM; and SBM is an a-synuclein protein binding moiety of the formula: or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein covalently linked to L; and i .
- s a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
- Another aspect of the disclosure is a compound of any one of the Formula (I)-(VI): or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, or prodrugs thereof, wherein Li, L2, L3, X,
- composition comprising a compound of the disclosure, and a pharmaceutically acceptable excipient.
- Another aspect of the present disclosure is a method of treating, lessening the severity of, delaying the progression of, reducing the risk of developing, and/or delaying the onset of a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein, the method comprising administering to a subject in need thereof an effective amount of a compound or a composition of the present disclosure.
- Another aspect of the present disclosure is a method for synthesizing the compounds of the disclosure.
- Figure 1 shows the high content-based quantifications of aggregated a-synuclein species in combination with determination of nuclei count (% remaining cells) in differentiated ReNcell VM cells. Results showed that 24 hour treatment with test compounds 166362, 170357, 162640 and 180948, respectively, induced a concentration-dependent inhibition of MJFR14 immunoreactivity, indicative of decreased a-synuclein aggregation.
- Figures 2A-2D show the immunocytochemical images of cells treated with vehicle (0.1% DMSO) and test compounds 132168, 166362, and 170357, and immunostained with MJFR14, illustrating the reduction in a-synuclein expression following treatment with compounds 132168 and 166362.
- Figure 2A DMSO (0.1%)
- Figure 2B compound 132168 (3mM)
- Figure 2C compound 166362 (3mM)
- Figure 2D compound 170357 (10mM).
- Figure 3 shows the result of an in vivo a-synuclein degradation study. Upon treatment of compound 132168, insoluble a-synuclein fraction decreases 30% compared to DMSO vehicle control, indicating the reduction of insoluble a-synuclein aggregates.
- the present disclosure provides compounds, compositions, and methods useful for removing a-synuclein aggregates or reducing the degree of a-synuclein aggregation to low levels, thereby possessing therapeutic potential in the treatment of patients with synucleinopathies.
- bispecific conjugate compounds that can simultaneously bind a target protein (i.e., aggregated a-synuclein) and an E3 ubiquitin ligase.
- the bispecific conjugate compounds exhibit desirable functional properties including binding preferentially to a-synuclein aggregates, and allowing a-synuclein to be placed in proximity to the E3 ubiquitin ligase, thereby facilitating the selective ubiquitination and eventual proteasome-mediated degradation of a-synuclein aggregates.
- Methods described herein include the administration of a compound or a composition of the present disclosure to a subject to treat, alleviate or prevent a neurodegenerative disease or disorder characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein.
- One aspect of the present disclosure is a compound of Formula A,
- EBM is an E3 ubiquitin ligase binding moiety
- L is a linker covalently attached to EBM and SBM
- SBM is an a-synuclein protein binding moiety of the formula: or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein is covalently linked to L;
- (i) is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or
- (ii) is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and i .s a substi .tuted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
- the substituted or unsubstituted bicyclic fused aromatic ring is a substituted or unsubstituted bicyclic 5-6 system.
- Non-limiting examples include
- SBM is of Formula B or Formula C wherein
- Z is C or N; U is O, S or CH; V is N or NH;
- J is CR 6 or N;
- X is CR 6 or N;
- Y is CR 6 or N; where at least one of J, X and Y is N, but J and Y are not N at the same time, X and Y are not N at the same time;
- R 6 is independently selected from the group consisting of H, NH2, Ci-6 alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo; and in Formula B, V is N, where Z and U are not heteroatoms at the same time; and in Formula C, V is N or NH; T is CH or N; where up to two of U, Z, V and T contain heteroatoms.
- EBM is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- R 3 is H or Ci-6 alkyl; each occurrence of R 2 is independently selected from the group consisting of H,
- the compound is of any one of the Formula (I)-(VI):
- R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group
- L3 is a bond, - R-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group
- L2 is a substituted or unsubstituted Ci-50 hydrocarbon chain
- Z is C or N
- U is O, S or CH
- V is N, where Z and U are not heteroatoms at the same time
- K is CH or N
- Q is CH or N; where K and Q are not N at the same time
- each occurrence of R" is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3;
- each occurrence of R' is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl,
- T is CH or N; where up to two of U, Z, V and T contain heteroatoms; K is CH or N; Q is CH or N; where K and Q are not N at the same time; each occurrence of R" is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R 1 is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkyl, Ci-6 alkylamino, C3-6 cycloalkyl, C3-6 cycloalkylamino and C3-6 heterocycloalkyl; n is 0, 1 or 2; J is
- R al is independently hydrogen, substituted or unsubstituted Ci-6 alkyl (e.g., substituted or unsubstituted methyl or ethy
- the compound is of the structure of Formula I.
- the compound is of the structure of Formula II.
- the compound is of the structure of Formula III.
- the compound is of the structure of Formula IV.
- the compound is of the structure of Formula V.
- the compound is of the structure of Formula VI.
- the moiety in Formula (I), (II) and (III) is [0030] In certain embodiments, the moiety in Formula (IV), (V) and (VI) is [0031] In certain embodiments, the moiety in Formulae (I)-(VI) is
- LI is a bond
- L3 is a bond
- L3 is - H-, -0-, or -S-.
- At least one chain atom of the hydrocarbon chain of L2 is independently replaced with -0-
- the chain of L2 comprises up to 50 consecutive covalently bonded atoms in length, excluding hydrogen atoms and substituents.
- L2 comprises up to, for example 46, 45, 40, 35, 32, 30, 25, 23, 20, 15, 14, 12, 11, 10, 9, 8, 7, 6, 5, 3 consecutive covalently bonded atoms in length, excluding hydrogen atoms and substituents.
- any of the atoms in L2 can be substituted. In certain embodiments, none of the atoms in the linker L2 are substituted. In certain embodiments, none of the carbon atoms in the linker are substituted.
- L2 is a linker that contains an asymmetric carbon/stereocenter, i.e., an sp3 hybridized carbon atom bearing 4 different groups attached thereto.
- the compound comprising such an L2 group is enantiomerically enriched or substantially enantiomerically enriched.
- the compound comprising such an L2 group is enantiomerically pure.
- the compound comprising such an L2 group is racemic.
- L2 comprises substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroaryl ene, or substituted or unsubstituted heteroalkylene, or combinations thereof.
- L2 is substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroaryl ene, or substituted or unsubstituted heteroalkylene.
- L2 is a linker selected from the group consisting of substituted and unsubstituted alkylene, substituted and unsubstituted alkenylene, substituted and unsubstituted alkynylene, substituted and unsubstituted heteroalkylene, substituted and unsubstituted heteroalkenylene, substituted and unsubstituted heteroalkynylene, substituted and unsubstituted heterocyclylene, substituted and unsubstituted carbocyclylene, substituted and unsubstituted arylene, substituted and unsubstituted heteroaryl ene, and combinations thereof.
- L2 being a combination of at least two instances of the divalent moieties described herein refers to a linker consisting of at least one instance of a first divalent moiety and at least one instance of a second divalent moiety, wherein the first and second divalent moieties are the same or different and are within the scope of the divalent moieties described herein, and the instances of the first and second divalent moieties are consecutive covalently attached to each other.
- L2 is a combination of alkylene and heteroalkylene linkers
- -heteroalkylene-alkylene-heteroalkylene- are all within the scope of L2, wherein each instance of alkylene in any one of the linkers may be the same or different, and each instance of heteroalkylene in any one of the linkers may be the same or different.
- L2 comprises at least one instance of substituted or unsubstituted alkylene, e.g., substituted or unsubstituted Ci-6 alkylene, substituted or unsubstituted C1-2 alkylene, substituted or unsubstituted C1-3 alkylene, substituted or unsubstituted C3-4 alkylene, substituted or unsubstituted C4-5 alkylene, substituted or unsubstituted C5-6alkylene, substituted or unsubstituted C3-6alkylene, or substituted or unsubstituted C4-6alkylene.
- substituted or unsubstituted alkylene e.g., substituted or unsubstituted Ci-6 alkylene, substituted or unsubstituted C1-2 alkylene, substituted or unsubstituted C1-3 alkylene, substituted or unsubstituted C3-4 alkylene, substituted or unsubstituted C4-5 alkylene, substituted or unsubstitute
- alkylene groups include unsubstituted alkylene groups such as methylene (-CH2-), ethylene (-(CH2)2-), n-propylene (-(CH2)3-), n-butylene (- (CH2)4-), n-pentylene (-(Cl [2)5-), and n-hexylene (-(CH2)6-).
- L2 comprises at least one instance of substituted or unsubstituted alkenylene, e g., substituted or unsubstituted C2-6 alkenyl ene, substituted or unsubstituted C1-3 alkenylene, substituted or unsubstituted C3-4 alkenylene, substituted or unsubstituted C4-5 alkenylene or substituted or unsubstituted C5-6 alkenylene.
- substituted or unsubstituted alkenylene e g., substituted or unsubstituted C2-6 alkenyl ene, substituted or unsubstituted C1-3 alkenylene, substituted or unsubstituted C3-4 alkenylene, substituted or unsubstituted C4-5 alkenylene or substituted or unsubstituted C5-6 alkenylene.
- L2 comprises at least one instance of substituted or unsubstituted alkynylene, e.g., substituted or unsubstituted C2-6 alkynylene, substituted or unsubstituted C2-3 alkynylene, substituted or unsubstituted C3-4 alkynylene, substituted or unsubstituted C4-5 alkynylene or substituted or unsubstituted C5-6 alkynylene.
- substituted or unsubstituted alkynylene e.g., substituted or unsubstituted C2-6 alkynylene, substituted or unsubstituted C2-3 alkynylene, substituted or unsubstituted C3-4 alkynylene, substituted or unsubstituted C4-5 alkynylene or substituted or unsubstituted C5-6 alkynylene.
- L2 comprises at least one instance of substituted or unsubstituted heteroalkylene, e.g., substituted or unsubstituted heteroCi- 6 alkylene, substituted or unsubstituted heteroCi-2alkylene, substituted or unsubstituted heteroC2- 3alkylene, substituted or unsubstituted heteroC3-4alkylene, substituted or unsubstituted heteroC4- salkylene or substituted or unsubstituted heteroCs ⁇ alkylene.
- substituted or unsubstituted heteroalkylene e.g., substituted or unsubstituted heteroCi- 6 alkylene, substituted or unsubstituted heteroCi-2alkylene, substituted or unsubstituted heteroC2- 3alkylene, substituted or unsubstituted heteroC3-4alkylene, substituted or unsubstituted heteroC4- salkylene or substituted or unsubstituted heteroCs ⁇ alkylene
- L2 comprises at least one instance of substituted or unsubstituted heteroalkenylene, e.g., substituted or unsubstituted heteroC2-6alkenylene, substituted or unsubstituted heteroCi-3alkenylene, substituted or unsubstituted heteroC3- 4alkenylene, substituted or unsubstituted heteroC4-salkenylene, or substituted or unsubstituted heteroC ealkenylene.
- substituted or unsubstituted heteroalkenylene e.g., substituted or unsubstituted heteroC2-6alkenylene, substituted or unsubstituted heteroCi-3alkenylene, substituted or unsubstituted heteroC3- 4alkenylene, substituted or unsubstituted heteroC4-salkenylene, or substituted or unsubstituted heteroC ealkenylene.
- L2 comprises at least one instance of substituted or unsubstituted heteroalkynylene, e.g., substituted or unsubstituted heteroC2-6alkynylene, substituted or unsubstituted heteroC2-3alkynylene, substituted or unsubstituted heteroCb-4 alkynylene, substituted or unsubstituted heteroCr-salkynylene, or substituted or unsubstituted heteroC5-6alkynylene.
- substituted or unsubstituted heteroalkynylene e.g., substituted or unsubstituted heteroC2-6alkynylene, substituted or unsubstituted heteroC2-3alkynylene, substituted or unsubstituted heteroCb-4 alkynylene, substituted or unsubstituted heteroCr-salkynylene, or substituted or unsubstituted heteroC5-6alkynylene.
- L2 comprises at least one instance of substituted or unsubstituted carbocyclylene, e.g., substituted or unsubstituted C3- 6 carbocyclylene, substituted or unsubstituted Cb-icarbocyclylene, substituted or unsubstituted C4- scarbocyclylene, or substituted or unsubstituted C5-6 carbocyclylene.
- substituted or unsubstituted carbocyclylene e.g., substituted or unsubstituted C3- 6 carbocyclylene, substituted or unsubstituted Cb-icarbocyclylene, substituted or unsubstituted C4- scarbocyclylene, or substituted or unsubstituted C5-6 carbocyclylene.
- L2 comprises at least one instance of substituted or unsubstituted heterocyclylene, e g., substituted or un substituted 3-6 membered heterocyclylene, substituted or unsubstituted 3-4 membered heterocyclylene, substituted or unsubstituted 4-5 membered heterocyclylene, or substituted or unsubstituted 5-6 membered heterocyclylene.
- at least one chain atom of the hydrocarbon chain of L2 is independently replaced with a 5-8 membered heterocyclyl group with 1-4 ring heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur.
- At least one chain atom of the hydrocarbon chain of L2 is independently replaced with a 6-membered heterocyclyl group with 1-3 ring heteroatoms selected from the group consisting of nitrogen and oxygen. In certain embodiments, at least one chain atom of the hydrocarbon chain of L2 is independently replaced with piperidine, piperazine or morpholine.
- L2 comprises at least one instance of substituted or unsubstituted arylene, e.g., substituted or unsubstituted phenylene.
- at least one chain atom of the hydrocarbon chain of L2 is independently replaced with an optionally substituted phenyl group.
- L2 comprises at least one instance of substituted or unsubstituted heteroaryl ene, e.g., substituted or unsubstituted 5- to 6-membered heteroaryl ene.
- L2 is an unsubstituted hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -NR al - and each instance ofR al is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group, or optionally two instances of R al are taken together with their intervening atoms to form a substituted or unsubstituted heterocyclic or substituted or unsubstituted heteroaryl ring.
- at least one instance of R al is hydrogen.
- At least one instance of R al is substituted or unsubstituted Ci-6 alkyl (e.g., substituted or unsubstituted methyl or ethyl).
- at least one instance of R al is a nitrogen protecting group (e g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl or p-toluenesulfonamide (Ts)).
- L2 is an optionally substituted Ci-30 hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -O- or -NR al - In certain embodiments, L2 is an unsubstituted Ci-30 hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -O- or-NR al - In certain embodiments, L2 is an unsubstituted Ci-30 hydrocarbon chain, wherein at least one chain atom of the hydrocarbon chain is independently replaced with -0-.
- L2 is a substituted or unsubstituted C5-40 hydrocarbon chain.
- L2 is an unsubstituted Ci-26 hydrocarbon chain, wherein at least one chain atom of the hydrocarbon chain is independently replaced with - O — .
- the cyclic moiety herein refers to a cycloalkylene or a heterocycloalkylene, such as
- L2 is an all-carbon, substituted or unsubstituted Ci-45 hydrocarbon chain. In certain embodiments, L2 is an all-carbon, substituted or unsubstituted Ci-30 hydrocarbon chain. In certain embodiments, L2 is an all-carbon, substituted or unsubstituted Ci-26 hydrocarbon chain. In certain embodiments, L2 is an all-carbon, substituted or unsubstituted Ci-24 hydrocarbon chain. In certain embodiments, L2 is an all-carbon, substituted or unsubstituted Ci-20 hydrocarbon chain. In certain embodiments, L2 is an all-carbon, substituted or unsubstituted Ci-20 hydrocarbon chain.
- L2 is wherein g is 1, 2, 3, 4, 5, or 6. In certain embodiments, g is 1. In certain embodiments, g is 2. In certain embodiments, g is
- g is 4. In certain embodiments, g is 5. In certain embodiments, g is 6.
- L2 includes the moiety -NH-.
- L2 of the disclosure include, but are not limited to:
- L2 is of the formula:
- L2 is of the formula:
- L2 is of the formula: wherein g is 1, 2, 3, 4 or 5; h is 0, 1, 2, 3, 4 or 5; and f is 1, 2, 3, 4, 5, 6,
- L2 is of the formula:
- L2 is of the formula: wherein g is 1, 2, 3, 4, 5, 6, 7 or 8.
- L2 is of the formula:
- L2 is of the formula: herein g is 1, 2, 3, 4, 5, 6, 7 or 8; and f is 1, 2, 3, 4, 5, 6, 7 or 8.
- L2 is of the formula: , wherein g is 1, 2, 3, 4, 5, 6, 7 or 8.
- R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group
- L3 is a bond, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group
- L2 is a substituted or unsubstituted Ci-50 hydrocarbon chain
- Z is C orN
- U is O, S or CH; where Z and U are not heteroatoms at the same time
- Q is CH or N
- K is CH or N; where Q and K are not N at the same time
- each occurrence of R"' is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R' is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6
- the compound of Formula 1-1 is of the following:
- R' is H, Ci-3 haloalkyl or C1-3 alkoxy, preferably H, CF3, CCb, methoxy or ethoxy, more preferably H, CF3 or methoxy.
- An embodiment of the disclosure is the compound of Formula 1, wherein m is 0, 1, 2, 3 or 4, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 1, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino and C3-5 heterocycloalkyl, preferably H, F, Cl, NH2, methoxy, ethoxy, methylamino, dimethylamino, ethylamino, diethylamino, cyclopropyl, cyclobutyl or cyclopentyl, more preferably H, F, dimethylamino or cyclopropyl.
- An embodiment of the disclosure is the compound of Formula 1, wherein n is 0, 1 or 2, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 1, wherein R'" is H, OH or halogen, preferably H, OH, F or Cl, more preferably H.
- An embodiment of the disclosure is the compound of Formula 1, wherein k is 0, 1, 2 or 3, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 1, wherein R 1 is O,
- An embodiment of the disclosure is the compound of Formula 1, wherein A is O,
- An embodiment of the disclosure is the compound of Formula 1, wherein m2 is 2, 3, 4 or 6, preferably 2 or 6.
- An embodiment of the disclosure is the compound of Formula 1, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl, more preferably H.
- An embodiment of the disclosure is the compound of Formula 1 having the structure as shown in Formula 1-1, U is O, S or CH; Z is C or N; where U and Z are not heteroatoms at the same time; R 1 is H, Ci-3 haloalkyl or C1-3 alkoxy; R" is H, F, Cl, OH, NH2, C1-3 alkoxy, methylamino, dimethylamino, diethylamino or cyclopropylamino; n is 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 1-1, wherein m2 is 2, 3, 4 or 6, preferably 2 or 6.
- An embodiment of the disclosure is the compound of Formula 1-1, wherein R 3 is H or methyl.
- An embodiment of the disclosure is the compound of Formula 1-1, wherein A is O or
- An embodiment of the disclosure is the compound of Formula 1-1, wherein R 1 is
- An embodiment of the disclosure is the compound of Formula 1-1, wherein R 1 is O, NH,
- An embodiment of the disclosure is the compound of Formula 1-1, wherein Z is N,
- U is CH [0097]
- An embodiment of the disclosure is the compound of Formula 1-1, wherein Z is C, U is S or O.
- An embodiment of the disclosure is the compound of Formula 1-1, wherein R" is H, F, Cl, OF1, NH2, methoxy, methylamino, dimethylamino, diethylamino, cyclopropyl or cyclopropylamino, preferably H, F, methylamino, dimethylamino or cyclopropylamino.
- R' is H, F, Cl, OF1, NH2, methoxy, methylamino, dimethylamino, diethylamino, cyclopropyl or cyclopropylamino, preferably H, F, methylamino, dimethylamino or cyclopropylamino.
- R' is H, methoxy or CF3.
- An embodiment of the disclosure is the compound of Formula 5, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 5, wherein A is O, H
- An embodiment of the disclosure is the compound of
- An embodiment of the disclosure is the compound of Formula 5, wherein m4 is 0,
- An embodiment of the disclosure is the compound of Formula 5, wherein m5 is 0,
- An embodiment of the disclosure is the compound of Formula 5, wherein m3 is 1,
- An embodiment of the disclosure is the compound of Formula 5, wherein R 1 is O,
- An embodiment of the disclosure is the compound of Formula 5, wherein R 1 " is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably H.
- An embodiment of the disclosure is the compound of Formula 5, wherein k is 0, 1, 2 or 3, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 5, wherein Z is C, U is O or S.
- An embodiment of the disclosure is the compound of Formula 5, wherein Z is N,
- An embodiment of the disclosure is the compound of Formula 5, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCh, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 5, wherein m is 0, 1, 2 or 3, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 5, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, cyclopropyl or dimethylamino, more preferably H, F, CF3, cyclopropyl, cyclopropylamino or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 5, wherein n is 0, 1 or 2, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 5 having the structure as shown in Formula 5-1, are not heteroatoms at the same time;
- R'" is H, OH, C1-3 alkyl, C1-3 alkoxy or halogen;
- R' is H, halogen, OH, C1-3 alkyl, Ci-3haloalkyl or C1-3 alkoxy;
- R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino and C3-5 heterocycloalkyl;
- n is 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 5-1, wherein A is O.
- An embodiment of the disclosure is the compound of Formula 5-1, wherein m5 is 0 or 1.
- An embodiment of the disclosure is the compound of Formula 5-1, wherein m4 is 0 or 3.
- An embodiment of the disclosure is the compound of Formula 5-1, wherein m3 is 3, 5.
- An embodiment of the disclosure is the compound of Formula 5-1, wherein R 1 is
- An embodiment of the disclosure is the compound of Formula 5-1, wherein Z is C, U is O or S.
- An embodiment of the disclosure is the compound of Formula 5-1, wherein Z is N, U is CH.
- An embodiment of the disclosure is the compound of Formula 5-1, wherein R' is H, halogen, C1-3 alkyl, C1-3 fluoroalkyl or C1-3 alkoxy, preferably H, methyl, CF3, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 5-1, wherein R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, CF3, amino, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H, F, CF3, dimethylamino, cyclopropylamino or cyclopropyl.
- R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 6, wherein A is O, preferably O or NH.
- An embodiment of the disclosure is the compound of Formula 6, wherein m2 is 1, 2, 3, 4, 5, 6 or 7, preferably 2 or 6.
- An embodiment of the disclosure is the compound of Formula 6, wherein R 1 is O, , preferably O or NH.
- An embodiment of the disclosure is the compound of Formula 6, wherein Z is C or N, and U is O, S or CH, where Z and U are not heteroatoms at the same time; preferably Z is C and U is S.
- An embodiment of the disclosure is the compound of Formula 6, wherein R'" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably H.
- An embodiment of the disclosure is the compound of Formula 6, wherein R is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 6, wherein m is 0, 1, 2 or 3, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 6, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, cyclopropyl, cyclopropylamino or dimethylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 6, wherein n is 0 or
- An embodiment of the disclosure is the compound of Formula 6 having the structure as shown in Formula 6-1, R" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen; k is 0, 1, 2 or 3; Z is C or N; U is O, S or CH; where Z and U are not heteroatoms at the same time; R 1 is H, halogen, OH, C1-3 alkyl, Ci-3haloalkyl or C1-3 alkoxy; m is 0, 1, 2 or 3; R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; n is 0, 1 or 2.
- R 3 is H or C1-3 alkyl; Yi is CH2 or ; R" is H, OH, C1-3 alkyl, C1-3 alkoxy or halogen; k is 0, 1, 2 or 3; Z is C or N; U is O, S or CH; where Z and U are not heteroatoms at the same time; R 1 is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; m is 0, 1, 2 or 3; R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; n is 0, 1 or 2. [0138] An embodiment of the disclosure is the compound of Formula 6-1, wherein R 3 is H or methyl.
- An embodiment of the disclosure is the compound of Formula 6-1, wherein A is O or NI I.
- An embodiment of the disclosure is the compound of Formula 6-1, wherein m2 is 2 or 6.
- An embodiment of the disclosure is the compound of Formula 6-1, wherein R 1 is O, or NH.
- An embodiment of the disclosure is the compound of Formula 6-1, wherein R is
- An embodiment of the disclosure is the compound of Formula 6-1, wherein m is 0, 1, 2 or 3, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 6-1, wherein R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, CF3, methoxy, methyl, dimethylamino, cyclopropyl, cyclopropylamino or methylamino, more preferably H, CF3, F, dimethylamino, cyclopropyl or cyclopropylamino, most preferably H, dimethylamino, cyclopropyl or cyclopropylamino.
- An embodiment of the disclosure is the compound of Formula 6-1, wherein n is 0 or 1.
- An embodiment of the disclosure is the compound of Formula 6-1, wherein R" substitutes at the adjacent position to the N atom.
- An embodiment of the disclosure is the compound of Formula 8, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 8, wherein Yi is preferably CH2. [0149] An embodiment of the disclosure is the compound of Formula 8, wherein A is O,
- An embodiment of the disclosure is the compound of Formula 8, wherein m2 is 1, 2, 3 or 4, preferably 2.
- An embodiment of the disclosure is the compound of Formula 8, wherein R 1 is O, H, preferably O.
- An embodiment of the disclosure is the compound of Formula 8, wherein R'" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably
- An embodiment of the disclosure is the compound of Formula 8, wherein k is 0 or
- An embodiment of the disclosure is the compound of Formula 8, wherein Z is C or N; U is O, S or CH; where Z and U are not heteroatoms at the same time; preferably Z is N and U is CH; preferably Z is C and U is S.
- An embodiment of the disclosure is the compound of Formula 8, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 8, wherein m is 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 8, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 8, wherein n is 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 10, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 10, wherein Yi is , preferably CH2.
- An embodiment of the disclosure is the compound of Formula 10, wherein each A is independently ,
- An embodiment of the disclosure is the compound of Formula 10, wherein A is preferably
- An embodiment of the disclosure is the compound of Formula 10, wherein m5 is 0 or 1.
- An embodiment of the disclosure is the compound of Formula 10, wherein m4 is 0 or 1.
- An embodiment of the disclosure is the compound of Formula 10, wherein m3 is 1, 2, 3, 4 or 5, preferably 4.
- An embodiment of the disclosure is the compound of Formula 10, wherein R 1 is
- An embodiment of the disclosure is the compound of Formula 10, wherein R" is H, OH, C1-3 alkyl, C1-3 alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably H.
- An embodiment of the disclosure is the compound of Formula 10, wherein k is 0 or 1.
- An embodiment of the disclosure is the compound of Formula 10, wherein Z is C,
- U is S or O.
- An embodiment of the disclosure is the compound of Formula 10, wherein Z is N,
- An embodiment of the disclosure is the compound of Formula 10, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 10, wherein m is 0 or 1.
- An embodiment of the disclosure is the compound of Formula 10, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, cyclopropyl, cyclopropylamino or dimethylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 10, wherein n is 0 or 1.
- An embodiment of the disclosure is the compound of Formula 13, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 13, wherein Yi is preferably CH2.
- An embodiment of the disclosure is the compound of Formula 13, wherein A is O,
- An embodiment of the disclosure is the compound of Formula 13, wherein m2 is 1, 2, 3 or 4, preferably 1.
- An embodiment of the disclosure is the compound of Formula 13, wherein R 1 is
- An embodiment of the disclosure is the compound of Formula 13, wherein R"' is
- H OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably H.
- An embodiment of the disclosure is the compound of Formula 13, wherein k is 0,
- An embodiment of the disclosure is the compound of Formula 13, wherein Z is C, U is S or O.
- An embodiment of the disclosure is the compound of Formula 13, wherein Z is N, U is CH
- An embodiment of the disclosure is the compound of Formula 13, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 13, wherein m is 0, 1, 2 or 3, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 13, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, cyclopropyl, cyclopropylamino or dimethylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 13, wherein n is 0,
- An embodiment of the compound of Formula II-l is of the following Formula 3, wherein R 1 is O, NH,
- An embodiment of the disclosure is the compound of Formula 3, wherein R 2 is H, OH, Ci-3 alkyl, C1-3 alkoxy, C1-3 alkylamino or NH2, preferably H, OH orML ⁇ .
- An embodiment of the disclosure is the compound of Formula 3, wherein m6 is 0,
- An embodiment of the disclosure is the compound of Formula 3, wherein R 1 is O or NH.
- An embodiment of the disclosure is the compound of Formula 3, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, halogen or C1-3 fluoroalkyl, more preferably H or F.
- An embodiment of the disclosure is the compound of Formula 3, wherein m is 0, 1,
- An embodiment of the disclosure is the compound of Formula 3, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino, preferably H, halo, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, more preferably H, F or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 3, wherein n is 0, 1, 2 or 3, preferably 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 3, wherein Z is C,
- U is O or S.
- An embodiment of the disclosure is the compound of Formula 3, wherein Z is N,
- An embodiment of the disclosure is the compound of Formula 3, wherein R'" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, F, methyl or methoxy, more preferably H.
- An embodiment of the disclosure is the compound of Formula 3 having the structure as shown in Formula 3-1, wherein R 2 is H, OH, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylamino or H2; m6 is 0, 1, 2 or 3; Yi
- R" is H, halo, OH, NH2, C1-3 alkoxy, C1-3 haloalkyl, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino; n is 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 3-1, wherein R 2 is H, NH2 or OH.
- An embodiment of the disclosure is the compound of Formula 3-1, wherein m6 is 0 or 1.
- An embodiment of the disclosure is the compound of Formula 3-1, wherein when substituted at the following position in the phenyl:
- An embodiment of the disclosure is the compound of Formula 3-1, wherein R 1 is O or NH.
- An embodiment of the disclosure is the compound of Formula 3-1, wherein R" is F, dimethylamino, methylamino, cyclopropyl or cyclopropylamino.
- An embodiment of the disclosure is the compound of Formula 3-1, wherein n is 0, 1, or 2.
- An embodiment of the disclosure is the compound of Formula 15, wherein R 1 is , preferably O or NH.
- An embodiment of the disclosure is the compound of Formula 15, wherein R" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, F, methyl or methoxy, more preferably H.
- An embodiment of the disclosure is the compound of Formula 15, wherein Z is C, U is O or S.
- An embodiment of the disclosure is the compound of Formula 15, wherein Z is N,
- An embodiment of the disclosure is the compound of Formula 15, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, halogen or C1-3 fluoroalkyl, more preferably H, CF3 or F.
- An embodiment of the disclosure is the compound of Formula 15, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 15, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino, preferably H, halo, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, more preferably H, F, methylamino, cyclopropylamino or dimethylamino, most preferably H or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 15, wherein n is 0,
- An embodiment of the compound of Formula IV-1 is of the following Formula 2, 7, 9, 11, 12 or 14,
- An embodiment of the disclosure is the compound of Formula 2, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 2, wherein Yi is [0219]
- An embodiment of the disclosure is the compound of Formula 2, wherein m2 is 2, 3, 4, 5 or 6, preferably 2 or 6.
- An embodiment of the disclosure is the compound of Formula 2, wherein R 1 is O, preferably NH.
- An embodiment of the disclosure is the compound of Formula 2, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, H2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 2, wherein n is 0, 1 or 2, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 2, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 2, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 2, wherein Z is C,
- U is O or S
- W is CH
- An embodiment of the disclosure is the compound of Formula 2, wherein Z is N,
- An embodiment of the disclosure is the compound of Formula 2, wherein Z is C, W is N, U is CH.
- An embodiment of the disclosure is the compound of Formula 2, wherein R'" is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 2, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 7, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 7, wherein Yi is
- An embodiment of the disclosure is the compound of Formula 7, wherein A is O,
- An embodiment of the disclosure is the compound of Formula 7, wherein m2 is 2, 3, 4, 5 or 6, preferably 2 or 3.
- An embodiment of the disclosure is the compound of Formula 7, wherein R 1 is O,
- NH preferably NH.
- An embodiment of the disclosure is the compound of Formula 7, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 7, wherein n is 0, 1, or 2, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 7, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 7, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 7, wherein Z is C,
- U is O or S, W is CH.
- An embodiment of the disclosure is the compound of Formula 7, wherein Z is N, U is CH, W is CH.
- An embodiment of the disclosure is the compound of Formula 7, wherein Z is C, W is N, U is CH.
- An embodiment of the disclosure is the compound of Formula 7, wherein R'" is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 7, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 9, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 9, wherein Yi is
- An embodiment of the disclosure is the compound of Formula 9, wherein A is O,
- An embodiment of the disclosure is the compound of Formula 9, wherein m2 is 2, 3, 4, 5 or 6, preferably 2 or 3.
- An embodiment of the disclosure is the compound of Formula 9, wherein R 1 is O, , preferably NH.
- An embodiment of the disclosure is the compound of Formula 9, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H, F, CF3, cyclopropyl or cyclopropylamino.
- An embodiment of the disclosure is the compound of Formula 9, wherein n is 0, 1, or 2, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 9, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 9, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 9, wherein Z is C,
- U is O or S
- W is CH
- An embodiment of the disclosure is the compound of Formula 9, wherein Z is N,
- An embodiment of the disclosure is the compound of Formula 9, wherein Z is C, W is N, U is CH.
- An embodiment of the disclosure is the compound of Formula 9, wherein R'" is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 9, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 11, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 11, wherein Yi is
- An embodiment of the disclosure is the compound of Formula 11, wherein A is O,
- An embodiment of the disclosure is the compound of Formula 11, wherein m2 is 2, 3, 4, 5 or 6, preferably 2 or 3.
- An embodiment of the disclosure is the compound of Formula 11, wherein R 1 is
- An embodiment of the disclosure is the compound of Formula 11, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 11, wherein n is 0,
- An embodiment of the disclosure is the compound of Formula 11, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 11, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 11, wherein Z is C, U is O or S, W is CH.
- An embodiment of the disclosure is the compound of Formula 11, wherein Z is N, U is CH, W is CH
- An embodiment of the disclosure is the compound of Formula 11, wherein Z is C, W is N, U is CH.
- An embodiment of the disclosure is the compound of Formula 11, wherein R" is
- An embodiment of the disclosure is the compound of Formula 11, wherein k is 0,
- An embodiment of the disclosure is the compound of Formula 12, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl. [0273] An embodiment of the disclosure is the compound of Formula 12, wherein Yi is , preferably CH2.
- An embodiment of the disclosure is the compound of Formula 12, wherein each A is independently O, NH, An embodiment of the disclosure is the compound of Formula 12, wherein A is O, NH, , preferably O.
- An embodiment of the disclosure is the compound of Formula 12, wherein m3 is 1, 2, 3, 4, 5 or 6, preferably 2 or 3.
- An embodiment of the disclosure is the compound of Formula 12, wherein m4 is 0 or 1, 2 or 3, preferably 0 or 3.
- An embodiment of the disclosure is the compound of Formula 12, wherein m5 is 0 or 1, 2 or 3, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 12, wherein R 1 is
- An embodiment of the disclosure is the compound of Formula 12, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 12, wherein n is 0,
- An embodiment of the disclosure is the compound of Formula 12, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 12, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 12, wherein Z is C, U is O or S, W is CH.
- An embodiment of the disclosure is the compound of Formula 12, wherein Z is N, U is CH, W is CH
- An embodiment of the disclosure is the compound of Formula 12, wherein Z is C, W is N, U is CH.
- An embodiment of the disclosure is the compound of Formula 12, wherein R"' is
- An embodiment of the disclosure is the compound of Formula 12, wherein k is 0,
- An embodiment of the disclosure is the compound of Formula 14, wherein R 3 is H or C1-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 14, wherein Yi is , preferably CH2.
- An embodiment of the disclosure is the compound of Formula 14, wherein each A is independently O, NH, An embodiment of the disclosure is the compound of Formula 14, wherein A is O, NH , preferably O.
- An embodiment of the disclosure is the compound of Formula 14, wherein m3 is 1, 2, 3, 4, 5 or 6, preferably 2, 3 or 4.
- An embodiment of the disclosure is the compound of Formula 14, wherein m4 is 0 , 1, 2, 3 or 4, preferably 0 or 3.
- An embodiment of the disclosure is the compound of Formula 14, wherein m5 is 0 or 1, 2 or 3, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 14, wherein R 1 is
- An embodiment of the disclosure is the compound of Formula 14, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1.3 haloalkyl, C1.3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, H2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 14, wherein n is 0,
- An embodiment of the disclosure is the compound of Formula 14, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 14, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 14, wherein Z is C, U is O or S, W is CH.
- An embodiment of the disclosure is the compound of Formula 14, wherein Z is N, U is CH, W is CH
- An embodiment of the disclosure is the compound of Formula 14, wherein Z is C, W is N, U is CH.
- An embodiment of the disclosure is the compound of Formula 14, wherein R" is
- An embodiment of the disclosure is the compound of Formula 14, wherein k is 0,
- An embodiment of the disclosure is the compound of Formula 4, wherein R 2 is H, OH, Ci-3 alkyl, C1-3 alkoxy, C1-3 alkylamino or NH2, preferably H, OH orML ⁇ .
- An embodiment of the disclosure is the compound of Formula 4, wherein m6 is 0,
- An embodiment of the disclosure is the compound of Formula 4, wherein R 1 is O,
- NH preferably O or NH.
- An embodiment of the disclosure is the compound of Formula 4, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, halogen or C1-3 fluoroalkyl, more preferably H or F.
- An embodiment of the disclosure is the compound of Formula 4, wherein m is 0, 1,
- An embodiment of the disclosure is the compound of Formula 4, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino, preferably H, halo, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, more preferably H, F or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 4, wherein n is 0, 1, or 2, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 4, wherein Z is C,
- U is O or S, W is CH [0313]
- An embodiment of the disclosure is the compound of Formula 4, wherein Z is N, U is CH, W is CH
- An embodiment of the disclosure is the compound of Formula 4, wherein Z is C, U is CH, W is N.
- An embodiment of the disclosure is the compound of Formula 4, wherein R'" is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 4, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 4 having the structure as shown in Formula 4-1, alkoxy, C1-3 haloalkyl, C1-3 alkylamino or C3-5 heterocycloalkyl; n is 0, 1 or 2; R is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; m is n is 0, 1 or 2; U is O or S; R 1 " is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen; k is 0, 1, 2, 3 or 4.
- An embodiment of the disclosure is the compound of Formula 4-1, wherein R 1 is NH.
- An embodiment of the disclosure is the compound of Formula 4-1, wherein R" is H.
- An embodiment of the disclosure is the compound of Formula 4-1, wherein R' is H.
- An embodiment of the disclosure is the compound of Formula 4-1, wherein R 2 is
- An embodiment of the disclosure is the compound of Formula 4-1, wherein R'" is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 4, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 4, wherein U is S.
- An embodiment of the compound of Formula VI-1 is of the following Formula 16 or 17,
- An embodiment of the disclosure is the compound of Formula 16, wherein m2 is 1,
- An embodiment of the disclosure is the compound of Formula 16, wherein R 1 is [0329]
- An embodiment of the disclosure is the compound of Formula 16, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, halogen or C1-3 fluoroalkyl, more preferably H or F.
- An embodiment of the disclosure is the compound of Formula 16, wherein m is 0,
- An embodiment of the disclosure is the compound of Formula 16, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino, preferably H, halo, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, more preferably H, F or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 16, wherein n is 0,
- An embodiment of the disclosure is the compound of Formula 16, wherein Z is C, U is O or S, W is CH.
- An embodiment of the disclosure is the compound of Formula 16, wherein Z is N, U is CH, W is CH
- An embodiment of the disclosure is the compound of Formula 16, wherein Z is C, U is CH, W is N.
- An embodiment of the disclosure is the compound of Formula 16, wherein R" is
- An embodiment of the disclosure is the compound of Formula 16, wherein k is 0,
- An embodiment of the disclosure is the compound of Formula 17, wherein m2 is 1, 2, 3, 4, 5 or 6, preferably 2 or 5.
- An embodiment of the disclosure is the compound of Formula 17, wherein R 1 is preferably NH.
- An embodiment of the disclosure is the compound of Formula 17, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, halogen or C1-3 fluoroalkyl, more preferably H or F.
- An embodiment of the disclosure is the compound of Formula 17, wherein m is 0,
- An embodiment of the disclosure is the compound of Formula 17, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino, preferably H, halo, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, more preferably H, F or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 17, wherein n is 0,
- An embodiment of the disclosure is the compound of Formula 17, wherein Z is C, U is O or S, W is CH.
- An embodiment of the disclosure is the compound of Formula 17, wherein Z is N, U is CH, W is CH
- An embodiment of the disclosure is the compound of Formula 17, wherein Z is C, U is CH, W is N.
- An embodiment of the disclosure is the compound of Formula 17, wherein R" is
- An embodiment of the disclosure is the compound of Formula 17, wherein k is 0,
- Some embodiments of the disclosure are the compounds having a structure depicted in Table 2, or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof.
- solvate, hydrate, salt, or ester of a compound of the present disclosure is provided herein.
- An aspect of the disclosure is a composition, comprising a compound disclosed herein and at least one pharmaceutically acceptable excipient.
- Ci-6 is intended to encompass Ci, C2, C3, C4, Cs, Ce, Ci-6, C1-5, C1-4, C1-3, C1-2, C2-6, C2-5, C2-4, C2-3, C3-6, C3-5, C3-4, C4-6, C4-5, and C5-6.
- Alkyl refers to a radical of a straight-chain or branched saturated hydrocarbon group having indicated number of carbon atoms.
- an alkyl group has 1 to 6 carbon atoms (“Ci-6 alkyl”).
- an alkyl group has 1 to 5 carbon atoms (“Ci-5 alkyl”).
- an alkyl group has 1 to 4 carbon atoms (“C1-4 alkyl”).
- an alkyl group has 1 to 3 carbon atoms (“C1-3 alkyl”).
- an alkyl group has 1 to 2 carbon atoms (“C1-2 alkyl”).
- an alkyl group has 1 carbon atom (“Ci alkyl”).
- an alkyl group has 2 to 6 carbon atoms (“C2-6 alkyl”).
- Ci-6 alkyl groups include methyl (Ci), ethyl (C2), «-propyl (C3), Ao-propyl (C3), «-butyl (C4), tert- butyl (C4), sec-butyl (C4), /.so-butyl (C4), «-pentyl (Cs), 3-pentyl (Cs), amyl (C5), neopentyl (Cs), 3 -methy 1-2-butyl (C5), tertiary amyl (C5), and «-hexyl (C6).
- alkenyl refers to an alkyl group with one or more carbon-carbon double bonds at any position of the chain, which can be monosub stituted or poly substituted, and can be monovalent, divalent or multivalent.
- alkenyl group include a vinyl group, a propenyl group, a butenyl group, a pentenyl group, a hexenyl group, a butadienyl group, a pentadienyl group, a hexadienyl group, etc.
- Alkynyl refers to an alkyl group with one or more carbon-carbon triple bonds at any position of the chain, which can be monosub stituted or poly sub stituted, and can be monovalent, divalent or multivalent.
- alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, etc.
- Cycloalkyl includes any stable cyclic or polycyclic hydrocarbon group and any carbon atom which is saturated, which can be monosub stituted or polysubstituted, and can be monovalent, divalent or multivalent.
- Examples of such cycloalkyl groups include, but are not limited to, cyclopropyl, norbornyl, [2.2.2]bicyclooctane, [4.4.0]bicyclononane, etc.
- Substituted means that any one or more hydrogen atoms on a particular atom are replaced with substituents, including deuterium and hydrogen variants, as long as the valence of a particular atom is normal and the substituted compound is stable.
- substituents including deuterium and hydrogen variants, as long as the valence of a particular atom is normal and the substituted compound is stable.
- Ketone substitution does not occur on aromatic groups.
- optionally substituted means that it may or may not be substituted. Unless otherwise specified, the type and number of substituents may be arbitrary on the basis of being chemically achievable.
- any variable e.g., R
- its definition at each occurrence is independent of its definition at every other occurrence.
- R e.g., R
- said group may optionally be substituted by up to two R groups and R at each occurrence is selected independently from the definition of R.
- substituents and/or variables are permissible only if such combinations result in stable compounds.
- Alkoxy refers to refers to said alkyl group with a specified number of carbon atoms attached through an oxygen bridge. Unless otherwise specified, Ci-6 alkoxy includes Ci, Ci, Ci, C4, Cs and Ce alkoxy group. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentyloxy and S- pentyloxy.
- Aryl refers to a polyunsaturated, aromatic hydrocarbon substituent which can be monosub stituted or polysubstituted, and can be monovalent, divalent or polyvalent, and can be monocyclic or polycyclic (e.g., 1 to 3 rings; at least one of which is aromatic). They are fused together or covalently linked.
- Halo or "halogen” by itself or as part of another substituent refers to a fluorine, chlorine, bromine or iodine atom.
- Haloalkyl includes both monohaloalkyl and polyhaloalkyl.
- halo(Ci-4)alkyl includes, but is not limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, etc.
- examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl.
- Heterocyclo refers to a radical of a 3 - to 10-membered non-aromatic ring or aromatic ring system having indicated ring carbon atoms (such as 2 to 6 ring carbon atoms) and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“C2-6 heterocyclo”).
- C2-6 heterocyclo nitrogen, oxygen and sulfur
- a heterocyclo group can either be monocyclic (“monocyclic heterocyclo”) or a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclo”), and can be saturated or partially unsaturated.
- Heterocyclo bicyclic ring systems can include one or more heteroatoms in one or both rings.
- “Heterocyclo” also includes ring systems wherein the heterocyclic ring, as defined above, is fused with one or more carbocyclic groups wherein the point of attachment is either on the carbocyclic or heterocyclic ring, or ring systems wherein the heterocyclic ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclic ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclic ring system.
- Nitrogen protecting group refers to a protecting group for preventing side reactions at the amino nitrogen position.
- Representative amino protecting groups include, but are not limited to formyl; acyl, such as alkanoyl (e.g., acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, such as tert-butoxycarbonyl (Boc); Arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1, 1-di -(4'-methoxyphenyl)methyl; silyl groups such as trimethyl silyl (TMS) and tert-butyldimethylsilyl (TBS), etc..
- acyl such as alkanoyl (e.g., acetyl,
- a heterocyclo group is a 5-10 membered non-aromatic ring system or aromatic ring system having indicated ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur.
- a heterocyclo group is a 5-6 membered non-aromatic ring system or aromatic ring system having indicated ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heterocyclo”).
- the 5-6 membered heterocyclo has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5-6 membered heterocyclo has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5-6 membered heterocyclo has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
- Exemplary 3-membered heterocyclo groups containing one heteroatom include, without limitation, azirdinyl, oxiranyl, and thiorenyl.
- Exemplary 4-membered heterocyclo groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl, and thietanyl.
- Exemplary 5-membered heterocyclo groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione.
- 5-membered heterocyclo groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one.
- Exemplary 5-membered heterocyclo groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl.
- Exemplary 6-membered heterocyclo groups containing one heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl.
- Exemplary 6-membered heterocyclo groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, and dioxanyl.
- 6-membered heterocyclo groups containing two heteroatoms include, without limitation, triazinanyl.
- Exemplary 7-membered heterocyclo groups containing one heteroatom include, without limitation, azepanyl, oxepanyl, and thiepanyl.
- Exemplary 8-membered heterocyclo groups containing one heteroatom include, without limitation, azocanyl, oxecanyl, and thiocanyl.
- Exemplary 5-membered heterocyclo groups fused to a Cr, aryl ring include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like.
- Exemplary 6-membered heterocyclo groups fused to an aryl ring include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
- pharmaceutically acceptable salt means a salt that is not harmful to mammals, especially humans.
- Pharmaceutically acceptable salts can be formed using non-toxic acids or bases, including mineral acids or inorganic bases, or organic acids or organic bases.
- examples of pharmaceutically acceptable salts include metal salts formed with aluminum, calcium, lithium, magnesium, potassium, sodium, zinc and so on, and organic salts formed with lysine, N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), procaine and so on.
- pharmaceutically acceptable salts contain acid-addition salts and base-addition salts.
- solvate means a solvent-containing compound that is formed by association of one or a plurality of solvent molecules to the compounds of the present disclosure.
- Solvates include, for example, monosolvates, disolvates, trisolvates, and tetrasolvates.
- solvates include hydrates.
- hydrate means a compound further containing a stoichiometric or a non-stoichiometric amount of water constrained by non-covalent bonding intermolecular force, or a salt thereof. Hydrates include monohydrates, dihydrates, trihydrates, tetrahydrates, and the like.
- a “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult, or senior adult)) and/or other non-human animals, for example, mammals (e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or dogs) and birds (e.g., commercially relevant birds such as chickens, ducks, geese, and/or turkeys).
- the animal is a mammal.
- the animal may be a male or female and at any stage of development.
- a non-human animal may be a transgenic animal.
- administer refers to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing an inventive compound, or a pharmaceutical composition thereof.
- treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a “pathological condition” (e.g., a disease, disorder, or condition, or one or more signs or symptoms thereof) described herein.
- pathological condition e.g., a disease, disorder, or condition, or one or more signs or symptoms thereof
- treatment may be administered after one or more signs or symptoms of the disease have developed or have been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of the disease or condition.
- treatment may be administered to a susceptible subj ect prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence.
- an “effective amount” of a compound or a composition refers to an amount sufficient to elicit the desired biological response, i.e., treating the condition.
- the effective amount of a compound or a composition may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject.
- An effective amount encompasses therapeutic and prophylactic treatment.
- a “therapeutically effective amount” of a compound or a composition is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to delay or minimize one or more symptoms associated with the condition.
- a therapeutically effective amount of a compound or a composition means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the condition.
- the term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces, or avoids symptoms or causes of the condition, or enhances the therapeutic efficacy of another therapeutic agent.
- alpha-synuclein refers to a 140 amino acid polypeptide with the following amino acid sequence (wild-type human a-synuclein).
- binder refers to a compound that binds to a protein.
- the binder binds to a protein with a Kd of less than 50,000 nM, less than 20,000 nM, less than 10,000 nM, less than 5,000 nM, less than 2,500 nM, less than 1,000 nM, less than 900 nM, less than 800 nM, less than 700 nM, less than 600 nM, less than 500 nM, less than 400 nM, less than 300 nM, less than 200 nM, less than 100 nM, less than 90 nM, less than 80 nM, less than 70 nM, less than 60 nM, less than 50 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, or less than 1 nM.
- proteasome refers to a protease complex for carrying out degradation of proteins.
- the proteasome is a multisubunit enzyme complex, which can also play a key role regulating proteins that control cell-cycle progression and apoptosis.
- the proteasome conducts proteolysis of selected proteins.
- pharmaceutically acceptable excipient means pharmaceutically acceptable materials, compositions, or vehicles such as physiological saline solutions, liquid or solid fillers, diluents, solvents, or encapsulants.
- pharmaceutically acceptable excipients include water, saline water, physiological saline water or phosphate buffered saline water (PBS), sodium chloride injection solution, Ringer’s injection solution, isotonic dextrose injection solution, sterile water injection solution, dextrose, and lactated Ringer’s injection solution.
- Another aspect of the present disclosure is a method for aiding in the treatment of a synucleinopathy in a subject, the method comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound as disclosed herein, or a composition as disclosed herein.
- Another aspect of the present disclosure is a method of treating a subject (e.g., a human) suffering from a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein, the method comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound as disclosed herein or a composition as disclosed herein.
- a subject e.g., a human
- Another aspect of the present disclosure is a method for prophylaxis of a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject, the method comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound or a composition as disclosed herein.
- kits for treating a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound or a pharmaceutical composition described herein.
- kits for lessening the severity of a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound or a pharmaceutical composition described herein.
- kits for delaying the progression of a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound or a pharmaceutical composition described herein.
- kits for reducing the risk of developing a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject comprising, consisting essentially of, or consisting of administering to the subject at risk of developing the disease an effective amount of a compound or a pharmaceutical composition described herein.
- kits for delaying the onset of a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject at risk of developing the disease comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound or a pharmaceutical composition described herein.
- the subject to be treated exhibits one or more symptoms (signs) of synucleinopathies, such as neuropsychiatric manifestations (depression, dementia, hallucinations, anxiety, apathy, anhedonia), autonomic changes (orthostatic hypotension, bladder disturbances, constipation, fecal incontinence, sialorrhea, dysphagia, sexual dysfunction, changes in cerebral blood flow), sensory changes (olfactory, pain, color discrimination abnormal sensations), sleep disorders (REM sleep behavior disorder (RBD), restless legs syndrome/periodic extremity movements, hypersomnia, insomnia), or other signs and symptoms (fatigue, diplopia, blurred vision, seborrhea, weight loss/gain).
- neuropsychiatric manifestations depression, dementia, hallucinations, anxiety, apathy, anhedonia
- autonomic changes orthostatic hypotension, bladder disturbances, constipation, fecal incontinence, sialorrhea, dysphagia, sexual dysfunction, changes in
- the subject to be treated does not exhibit one or more symptoms of a synucleinopathy, but is known to have a genetic risk for developing a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in the brain.
- a genetic risk for developing a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in the brain.
- such an individual may have one or more relatives with the disease, or their risk is determined by analysis of genetic or biochemical markers.
- mutations in SNCA PARK1, encoding a-synuclein
- A30P, E46K, H50Q, G51D, and A53T mutations in SNCA (PARK1, encoding a-synuclein), including A30P, E46K, H50Q, G51D, and A53T, as well as duplications and triplications of the entire SNCA gene cause autosomal dominant forms of PD.
- PINK1 PARK6, PTEN-induced kinase 1
- DJ-1 PARK7
- Parkin PARK2
- ATP13A2 PARK9, ATPase type 13A2
- FBX07 PARK 15, F-box only protein 7
- PLA2 GB PARK14, phospholipase A2, group VI
- 28 different genetic risk loci associated with PD and related synucleinopathies have been identified including SNCA, LRRK2, GBA/SYT11, MAPT, HLA-DRB5, GAK, GCH1, NUCKS1/RAB7L1, SLC41A1, BST1, SIPA1L2,
- ACM SD/TMEM 163, STK39, MCCC1, TMEM 175/GAK/DGKQ, FAM47E/SCARB2, GPNMB, FGF20, INPP5F, MIR4697, CCDC62, GCH1, VPS13C, BCKDK/STX1B, SREBF/RAIl, RIT2 and DDRGK1 (Nails et al. (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nature Genetics 46(9): 989-993).
- the antibodies described herein, or pharmaceutical compositions comprising the same are administered to a patient susceptible to, or otherwise at risk of the disease in a regime (dose, frequency and route of administration) effective to reduce the risk, lessen the severity, or delay the onset of at least one sign or symptom of the disease.
- a regime dose, frequency and route of administration
- the regime is effective to inhibit or delay accumulation of a-synuclein in the brain, and/or inhibit or delay its toxic effects and/or inhibit or delay development of behavioral deficits in the patient.
- the methods described above generate a beneficial therapeutic response in a patient (e.g., reduction of a-synuclein aggregates in the brain, improved cognitive function, and/or reversing, treating or preventing cognitive decline) in the subject.
- the compounds or the pharmaceutical compositions described herein are administered to a patient suspected of, or already suffering from a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a regime (dose, frequency and route of administration) effective to ameliorate or at least inhibit further deterioration of at least one sign or symptom of the disease.
- the regime is effective to reduce or at least inhibit further increase of levels of a-synuclein, associated toxicities, and/or behavioral deficits.
- the treatments can result in, e.g., a reduction of a-synuclein aggregates in the brain by 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more, relative to before initiating treatment or as compared to a population of untreated control patients.
- the disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in the brain is Parkinson's disease (including idiopathic Parkinson's disease), DLB, DLBD, LBVAD, pure autonomic failure, Lewy body dysphagia, incidental LBD, inherited LBD (e.g., mutations of SNCA (PARKl), LRRK2 (PARK8), VP S35 (PARK 17), PINK1 (PARK6), DJ-1 (PARK7), Parkin (PARK2), ATP13A2 (PARK9), FBX07 (PARK 15) and PLA2 GB (PARK 14)), or multiple system atrophy (MSA; e.g., olivopontocerebellar atrophy, striatonigral degeneration and Shy-Drageri syndrome).
- MSA multiple system atrophy
- compositions of the present disclosure can be administered to humans and other animals orally, parenterally, intracisternally, intraperitoneally, intrathecally, intraventricularly, topically, bucally, or the like, depending on the disease or condition being treated.
- a pharmaceutical composition comprising a compound of the disclosure is administered orally or parenterally, at dosage levels sufficient to deliver from about 0.001 mg/kg to about 200 mg/kg in one or more doses for one or several days.
- the effective amount per dose varies from about 0.001 mg/kg to about 200 mg/kg, about 0.001 mg/kg to about 100 mg/kg, about 0.01 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, from about 0.1 mg/kg to about 40 mg/kg, from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic and/or prophylactic effect.
- the compounds described herein are at dosages sufficient to deliver from about 0.001 mg/kg to about 200 mg/kg, from about 0.001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, from about 0.1 mg/kg to about 40 mg/kg, from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, or from about 1 mg/kg to about 25 mg/kg, of subj ect body weight per day, one or more times a day, to obtain the desired therapeutic and/or prophylactic effect.
- the desired dosage may be delivered three times a day, twice a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks.
- the dosage is delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).
- the composition described herein is administered at a dose that is below the dose at which the agent causes non-specific effects.
- compositions described herein can be prepared by methods generally known in the art of pharmacology. In general, such methods include the steps of combining the compound of the disclosure with a carrier and/or one or more other accessory ingredients, and then shaping and/or packaging the product into a desired single- or multi-dose unit.
- compositions can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses.
- a “unit dose” is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient.
- the amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage, such as, for example, one-half or one-third of such a dosage.
- compositions include inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, stabilizers, buffering agents, lubricating agents, and/or oils. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents may also be present in the composition.
- Suitable diluents include calcium carbonate, sodium carbonate, calcium phosphate, calcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, and mixtures thereof.
- Suitable granulating and/or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose, and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate
- LCMS measurement was run on an Agilent 1200 HPLC/6100 SQ System using the following conditions: Method A: Mobile Phase: A: Water (0.01% TFA) B: CAN (0.01% TFA); Gradient Phase: 5%B increasing to 95%B within 1.4 min, 95%B with 1.6 min (total runtime: 3 min); Flow Rate: 2.3 mL/min; Column: SunFire C18, 4.6*50 mm, 3.5 pm; Column Temperature: 50°C. Detectors: ADC ELSD, DAD (214 nm and 254 nm), ES-API.
- Method B Mobile Phase: A: Water (10 mMNFEHCCri) B: Acetonitrile; Gradient Phase: 5% to 95%B within 1.5 min, 95%B with 1.5 min (total runtime: 3 min); Flow Rate: 2.0 mL/min; Column: XBridge C18, 4.6*50 mm, 3.5 pm; Column Temperature: 40°C. Detectors: ADC ELSD, DAD (214 nm and 254 nm), MSD (ES-API).
- Method C Mobile Phase: A: Water (10 mM H4HC03)B: Acetonitrile; Gradient Phase: 5% to 95%B within 1.5 min, 95%B with 1.5 min (total runtime: 3 min); Flow Rate: 2.0 mL/min; Column: XBridge C18, 4.6*50mm, 3.5 pm; Column Temperature: 40°C. Detectors: ADC ELSD, DAD (214 nm and 254 nm), MSD (ES-API).
- N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]carbamate 500 mg, 1.12 mmol
- DMF 10 mL
- NaFI 107.49 mg, 4.48 mmol
- Compound 161409 could be synthesized by method similar to example 19.
- Compound 164263 A mixture of tert-butyl N-(2-bromanyl-l,3-benzothiazol-6-yl)carbamate (1100 mg, 3.34 mmol), N,N-dimethyl-5-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl )phenyl]pyridin-2-amine (1704 mg, 4.34 mmol), Pd(dppf)Ch (247 mg, 0.33 mmol) and 2M Na2CC>3(aq) solution (5 mL, 10.02 mmol) in dioxane (35 mL) was heated at 80°C for 16 h under argon.
- N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6-yl] carbamate (1056 mg, 2.05 mmol) in DMF (20 mL) was added NaH (148 mg, 6.16 mmol) at 0°C and stirred at 25°C for 1 h.
- 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate (2.55 g, 6.16 mmol) in DMF (20 mL) was added to the reaction mixture and stirred at room temperature for 14 h.
- N-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-yl]carbamate (1.52 g, 4.75 mmol)
- 2-(4-bromophenyl)-6-methoxy-imidazo[l,2-a]pyridine 1.2 g, 3.96 mmol
- triphenylphosphine (34.6 mg, 0.13 mmol) in EtOH (4 mL) and toluene (2.8 mL) was purged with argon and then added with K2CO3 solution (1.75M, 7.92 mL, 13.85 mmol) dropwise.
- N-[2-[2-(2-iodanylethoxy)ethoxy]ethyl]-N-[4-[4-(6-methoxyimidazo[l,2-a]pyri din-2 -yl)phe nyl]pyridin-2-yl]carbamate 100 mg, 0.15 mmol
- K2CO3 63 mg, 0.46 mmol
- methyl 5-azanyl-5-oxidanylidene-4-(6-oxidanyl-3-oxidanylidene-lH-isoindol-2-yl)pentanoate 49 mg, 0.17 mmol
- DMF 5 mL
- N-methyl-N-[5-[4-[6-[(2-methylpropan-2-yl)oxycarbonylamino]-l,3-benzothiazol-2-yl]-3-(t rifluoromethyl)phenyl]pyridin-2-yl]carbamate 200 mg, 0.33 mmol
- dry DMF 5 mL
- NaH 40 mg, 1.00 mmol
- N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6-yl] carbamate (447 mg, 0.87 mmol) in DMF (8 mL) was added NaH (63 mg, 2.61 mmol) at 0°C, stirred at room temperature for 1 h and then added 5-(4-methylphenyl)sulfonyloxypentyl
- N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6-yl] carbamate 300 mg, 0.58 mmol) in DMF (5 mL) was cooled to 0°C and added NaH (56 mg, 2.33 mmol). The mixture was stirred at room temperature for 1 h, added 2-azidoethyl 4-methylbenzenesulfonate (281 mg, 1.17 mmol) in DMF (5 mL) and heated at 50°C for 20 h. The mixture was cooled to 0°C and added water (5 mL).
- N-(2-azidoethyl)-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-b enzothiazol-6-yl]carbamate (341 mg, 0.58 mmol) in THF (5mL)/EtOH (5mL) was added Pd(OH)2 (1701 mg, 1.61 mmol) and stirred under 1 atmosphere of Lb for 4 h. The mixture was filtered through a Celite pad and the filtrate was concentrated to dryness.
- the supernatant was then boiled at 95 °C for 15 min with manual agitation by every 5 minutes, followed by centrifugation (6000 g, 30 min, 4 °C).
- Supernatant was dialyzed with (10 mM Tris, 1 mM EGTA, 50 mMNaCl, pH 7.5) buffer and concentrated with concentrator.
- the collected sample was loaded onto a Superdex200 column, the flow-through fraction was then loaded onto a Q-HP column. Collected fractions with a-synuclein eluates were pooled, concentrated and stored at -80 °C.
- ReNcell VM a-synuclein aggregation assay was conducted at Charles River Laboratories (CRL).
- ReNcell VM is an immortalized human neural progenitor cell line derived from the ventral mesencephalon region of the brain.
- ReNcell VM cells were selected as in vitro cellular model for the a-synuclein aggregation assay, based on their growth features, differentiation potential into terminally differentiated neurons and amenability to adenoviral transduction. Aggregated human wild type a-synuclein was overexpressed through adenoviral delivery.
- Aggregated a-synuclein was detected with the aggregate-selective anti-a-synuclein antibody MJFR14 using immunocytochemistry; total a-synuclein levels were detected with Syn205 (a/b-synuclein-specific antibody).
- the ReNcell VM a-synuclein aggregation assay was applied for compound screening to identify compounds capable of degrading a-synuclein aggregates. Specifically, adenovirally transduced ReNcell VM cells were treated with test compounds (serially diluted) for 24 hours, followed by fixation, and then processed for ReNcell immunocytochemistry by staining with Syn205 and MJFR14.
- Immunoreactivity toward aggregated (MJFR14) and total a-synuclein (Syn205) was quantified using high content-based segmentation of immunoactive areas in immunocytochemical images (performed with the IN Cell 2200 (GE Healthcare)), followed by quantification of immunofluorescent intensity (performed by CRL’s developed algorithm using IN Cell Developer Toolbox software).
- FIG. 1 shows the high content-based quantifications of aggregated a-synuclein species in combination with determination of nuclei count (% remaining cells) in differentiated ReNcell VM cells. Results showed that 24 hour treatment with test compounds 166362, 170357, 162640 and 180948, respectively, induced a concentration-dependent inhibition of MJFR14 immunoreactivity, indicative of decreased a-synuclein aggregation. Each panel of graph displays normalized data for percentage effect (PE) and remaining cells (%).
- Percentage effect (PE) Inhibition in comparison to BLANK (0.1% DMSO).
- PE 100 - (signal of compound/average signal BLANK) x 100 [0561] Compound-induced cytotoxicity (% remaining cells)
- % remaining cells (nuclei count of compound/average nuclei count of BLANK) x 100
- FIGS 2A-2D show the representative immunocytochemical images of cells treated with vehicle (0.1% DMSO) and test compounds 132168, 166362, and 170357, and immunostained with MJFR14, illustrating the reduction in a-synuclein expression following treatment with compounds 132168 and 166362.
- DC50 indicates the concentration at which 50% of a-synuclein aggregates has been degraded.
- Example 40 In Vivo Assay For Degrading a-Synuclein Ag2regates
- mice Male transgenic Line61 mice at age of three-month-old were used for the study. Mice were treated once via intravenous injection with the compound 132168 (25 mpk). Plasma and brain samples were collected at 0.25, 0.5, 1, 2, 4, 8 and 24 h post treatment. Blood samples were collected via cardiac puncture into MiniCollect® 0.5 mL K2EDTA (Potassium ethylenediaminetetraacetic acid) tubes. The blood samples were centrifuged at 3000 x g for 10 minutes at room temperature (22°C). Plasma was transferred to a pre-labeled 1.5 ml LoBind Eppendorf tube (2 aliquot, each ⁇ 75 m ⁇ ), frozen on dry ice and stored at -80°C until analysis.
- K2EDTA Paratassium ethylenediaminetetraacetic acid
- example compound 132168 was administered to mice in a pharmacokinetic study (10 and 25 mg/kg, intravenous).
- Animal Husbandry Mice were housed at animal room environment with ventilation 15 times/hour, lighting 12 hours/day, temperature 20 °C to 24 °C and humidity 40 % to 70 %. The study rooms were disinfected and cleaned prior to the start of the study and the operation area was cleaned after each dosing or sampling during the study conduct. All animals had free access to food and water during the study. The animals had access to Certified Rodent Diet and water ad libitum. The nutritional composition and levels of contaminants of the diet and impurities and contaminants of the water were monitored by third organization. The health status of the animals was evaluated in accordance with accepted animal husbandry procedures and deemed suitable for experimental use.
- Sample Collection & Processing Approximately 110 pL of whole blood were collected from all animals via facial or cardiac puncture under anesthesia with Isoflurane into test tubes containing potassium ethylenediaminetetraacetate (K2EDTA) at 0.25, 0.5, 1, 2, 4, 8 and 24 hr post dose. Brian samples were collected at 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose. A perfusion with pre-cold saline will be conducted via cardiac puncture before brain collection. Blood samples were centrifuged at 2000g at 4°C for 5 minutes to obtain plasma samples by transferring the supernatants into new tubes. All plasma and brain samples were stored at approximately -70 °C until analysis.
- K2EDTA potassium ethylenediaminetetraacetate
- Bioanalytical Method Development The concentrations of compound in plasma and brain samples were determined using a liquid chromatography with tandem mass spectrometry (LC-MS/MS) based method.
- Embodiment 1 A method to treat synucleinopathy in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula A,
- EBM is an E3 ubiquitin ligase binding moiety
- L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula: or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein is covalently linked to L; and is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S,
- Embodiment 2 A method to reduce a-synuclein aggregation in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula A,
- EBM is an E3 ubiquitin ligase binding moiety
- L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula: or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein is covalently linked to L; and is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S,
- Embodiment 3 A method to reduce Lewy bodies in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula A,
- EBM is an E3 ubiquitin ligase binding moiety
- L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula: or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein is covalently linked to L; and is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S,
- Embodiment 4 Use of a compound of Formula A:
- EBM-L-SBM (Formula A) or a pharmaceutical acceptable salt, a enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug thereof, in the manufacture of a medicament for treating synucleinopathy, wherein
- EBM is an E3 ubiquitin ligase binding moiety
- L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula: wherein covalently linked to L, and is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted mono
- Embodiment 5 Use of a compound of Formula A:
- EBM-L-SBM (Formula A) or a pharmaceutical acceptable salt, a enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug thereof, in the manufacture of a medicament for reducing a-synuclein aggregation, wherein
- EBM is an E3 ubiquitin ligase binding moiety
- L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula: wherein is covalently linked to L; and is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted
- Embodiment 6 Use of a compound of Formula A:
- EBM-L-SBM (Formula A) or a pharmaceutical acceptable salt, a enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug thereof, in the manufacture of a medicament for reducing Lewy bodies, wherein
- EBM is an E3 ubiquitin ligase binding moiety
- L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula: wherein is covalently linked to L; and is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted
- Embodiment 7 The method of Embodiment 1 or the use of Embodiment 4, wherein the synucleinopathy is Parkinson’s Disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), or a combination of two or more thereof
- Embodiment 8 The method or use of any one of Embodiments 1-7, wherein the substituted or unsubstituted bicyclic fused aromatic ring is a substituted or unsubstituted bicyclic 5-6 system.
- Embodiment 9 The method or use of any one of Embodiments 1-8, wherein SBM is of Formula B or Formula C wherein
- Z is C or N; U is O, S or CH; V is N or Mi;
- Embodiment 10 The method or use of any one of Embodiments 1-9, wherein EBM is wherein
- R 3 is H or Ci-6 alkyl; each occurrence of R 2 is independently selected from the group consisting of H, OH, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkylamino andMB; m6 is 0, 1, 2, 3 or 4; and
- Embodiment 11 The method or use of any one of Embodiments 1-10, wherein the compound is of any one of Formula I to Formula YI,
- Z is C or N; U is O, S or CH;
- J is CR 6 or N;
- X is CR 6 or N;
- Y is CR 6 or N; where at least one of J, X and Y is N, but J and Y are not N at the same time, X and Y are not N at the same time;
- R 6 is independently selected from the group consisting of H, NH2, Ci-6 alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo; in Formula I, L3 is a bond, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; R 3 is H or Ci- 6 alkyl; Yi is CH2 or V is N, where Z and U are not heteroatoms at the same time; in Formula II, each occurrence of R 2 is independently selected from the group consisting of H, OH, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkylamino and NH2; m6 is 0, 1, 2, 3 or 4;
- Yi is CH2 or V is N, where Z and U are not heteroatoms at the same time; in Formula III, V is N, where Z and U are not heteroatoms at the same time; in Formula IV, L3 is a bond, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; R 3 is H or Ci-6 alkyl; two of U, Z, V and T contain heteroatoms; in Formula V, each occurrence of R 2 is independently selected from the group consisting of H, OH, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkylamino and NH2; m6 is 0, 1, 2, 3 or 4; two of U, Z, V and T contain heteroatoms; in Formula VI, V is N; T is CH or N; where up to two of U, Z, V and T contain heteroatoms.
- Embodiment 14 The method or use of Embodiment 11, wherein L2 is selected from the group consisting of substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroaryl ene, or substituted or unsubstituted heteroalkylene, and combinations thereof; preferably, L2 is selected from the group consisting of substituted and unsubstituted alkylene, substituted and unsubstituted alkenylene, substituted and unsubstituted alkynylene, substituted and unsubstituted heteroalkylene, substituted and unsubstituted heteroalkenylene, substituted and unsubstituted heteroalkynylene, substituted and unsubstituted heterocyclylene, substituted and unsubstituted carbocyclylene, substituted and unsubstituted arylene, substituted and unsubstitute
- Embodiment 16 The method or use of Embodiment 14, wherein L2 comprises at least one instance selected from the group consisting of substituted or unsubstituted Ci-6 alkylene, substituted or unsubstituted C2-6 alkenylene, substituted or unsubstituted C2-6 alkynylene, substituted or unsubstituted heteroCi-6alkylene, substituted or unsubstituted heteroC2-6alkenylene, substituted or unsubstituted heteroC2-6alkynylene, substituted or unsubstituted C3-6carbocyclylene, substituted or unsubstituted 3-6 membered heterocyclylene, substituted or unsubstituted phenylene, and substituted or unsubstituted 5- to 6-membered heteroarylene.
- L2 comprises at least one instance selected from the group consisting of substituted or unsubstituted Ci-6 alkylene, substituted or unsubstituted C2-6 alkenylene,
- Embodiment 17 The method or use of Embodiment 14, wherein L2 comprises at least one instance selected from the group consisting of substituted or unsubstituted methylene, ethylene, n-propylene, n-butylene, n-pentylene, n-hexylene, -
- Embodiment 18 The method or use of Embodiment 14, wherein at least one chain atom of the hydrocarbon chain of L2 is independently replaced with a 6-membered heterocyclyl group with 1-3 ring heteroatoms selected from the group consisting of nitrogen and oxygen; preferably, at least one chain atom of the hydrocarbon chain of L2 is independently replaced with piperidine, piperazine or morpholine; preferably, at least one chain atom of the hydrocarbon chain of L2 is independently replaced with an optionally substituted phenyl group.
- Embodiment 19 Embodiment 19.
- Embodiment 14 wherein L2 is an unsubstituted hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -NR a1 -, and each instance of R al is independently hydrogen, substituted or unsubstituted Ci-e alkyl or a nitrogen protecting group, or optionally two instances of R al are taken together with their intervening atoms to form a substituted or unsubstituted heterocyclic or substituted or unsubstituted heteroaryl ring.
- Embodiment 20 The method or use of Embodiment 19, wherein at least one instance of R al is hydrogen, substituted or unsubstituted Ci-6 alkyl (e.g., substituted or unsubstituted methyl or ethyl), or a nitrogen protecting group (e.g., benzyl, t-butyl carbonate, benzyl carbamate, 9-fluorenylmethyl carbonate, trifluoroacetyl, triphenylmethyl, acetyl or p-toluenesulfonamide).
- a nitrogen protecting group e.g., benzyl, t-butyl carbonate, benzyl carbamate, 9-fluorenylmethyl carbonate, trifluoroacetyl, triphenylmethyl, acetyl or p-toluenesulfonamide.
- Embodiment 21 The method or use of Embodiment 11, wherein Li i iss wherein g is 1, 2, 3, 4, 5, or 6.
- Embodiment 22 The method or use of Embodiment 11, wherein L2 includes the moiety
- Embodiment 23 The method or use of Embodiment 11, wherein L2 is selected from the group consisting of
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Treating Waste Gases (AREA)
Abstract
The present disclosure provides compounds comprising an E3 ubiquitin ligase binding moiety and an alpha-synuclein protein binding moiety for use in the treatment of neurodegenerative diseases, in particular synucleinopathies.
Description
COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES
AND USES THEREOF
BACKGROUND
[0001] Neurodegenerative diseases affect an estimated 50 million Americans each year, exacting an incalculable personal toll and an annual economic cost of hundreds of billions of dollars in medical expenses and lost productivity. Synucleinopathies are neurodegenerative diseases characterized by the abnormal accumulation of a-synuclein (a-Syn) aggregates in neurons and glial cells.
[0002] α-Synuclein is a 140 amino acid protein preferentially expressed in neurons at pre-synaptic terminals where it is thought to play a role in regulating synaptic transmission (Bendor et al., Neuron 2013; 79:1044-66). a-Synuclein can form pathological aggregates in neurons known as Lewy bodies, which are characteristic of both Parkinson's Disease (PD) and dementia with Lewy bodies (DLB). The pathological aggregates consist of aggregated, insoluble accumulations of misfolded a-synuclein proteins in neurons, nerve fibers or glial cells and are a characteristic feature of synucleinopathies. Synucleinopathies include Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), the Lewy body variant of Alzheimer's disease (LBVAD), combined Parkinson's disease (PD) and Alzheimer's disease (AD), and neurodegeneration with brain iron accumulation type-1 (NBIA-1). In PD and DLB, a-Syn aggregates are in the neuronal cytoplasm and axonal processes into Lewy bodies and Lewy neurites, respectively, whereas a-Syn inclusions in oligodendroglia are the recognized neuropathologic hallmarks of MSA. [0003] There is currently a lack of therapeutics that target synucleinopathies from the perspective of a-synuclein aggregation. Strategies aimed at reducing a-synuclein aggregation possess therapeutic potential in the treatment of patients with synucleinopathies.
SUMMARY
[0004] The present disclosure stems from the recognition that a bispecific conjugate compound that includes an E3 ubiquitin ligase binding moiety that is based on an imide drug
(e.g., lenalidomide, thalidomide, VHL ligand) and also includes a binder of a-synuclein may induce proteasome degradation of a-synuclein aggregates. The disclosure therefore provides compounds, compositions, and methods for the treatment of various neurodegenerative diseases associated with a-synuclein aggregates based on this discovery. The bispecific conjugate compounds described herein degrade the a-synuclein aggregates by removing a-synuclein aggregates or reducing the degree of a-synuclein aggregation to low levels in a cellular model and/or animal model, thereby possessing therapeutic potential in the treatment of patients with synucleinopathies including but not limited to Parkinson’s disease (PD), dementia with Lewy bodies (DLB), or multiple system atrophy (MSA).
[0005] The present disclosure also provides methods to remove a-synuclein aggregation or reduce Lewy bodies or a-synuclein aggregate in a patient having Lewy body disease or risk of Lewy body disease, and methods to reduce dementia with Lewy bodies (DLB) or multiple system atrophy (MSA) or other synucleinopathies.
[0006] One aspect of the present disclosure is a compound of Formula A,
EBM-L-SBM (Formula A) wherein
EBM is an E3 ubiquitin ligase binding moiety;
L is a linker covalently attached to EBM and SBM; and SBM is an a-synuclein protein binding moiety of the formula:
or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein covalently linked to L; and
i . s a substituted or unsubstituted bicyclic fused aromatic ring containing
at least 1 ring heteroatom selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
[0007] Another aspect of the disclosure is a compound of any one of the Formula (I)-(VI):
or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, or prodrugs thereof, wherein Li, L2, L3, X,
Y, J, Q, K, T, U, V, Z, Yi, R', R", R'", R2 , R3 , n, m, k and m6 are as defined herein.
[0008] Another aspect of the present disclosure is a composition comprising a compound of the disclosure, and a pharmaceutically acceptable excipient.
[0009] Another aspect of the present disclosure is a method of treating, lessening the severity of, delaying the progression of, reducing the risk of developing, and/or delaying the onset of a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein, the method comprising administering to a subject in need thereof an effective amount of a compound or a composition of the present disclosure.
[0010] Another aspect of the present disclosure is a method for synthesizing the compounds of the disclosure.
[0011] The foregoing summary is illustrative only and is not intended to be in any way limiting. In addition to the illustrative embodiments and features described herein, further aspects, embodiments, objects and features of the disclosure will become fully apparent from the drawings and the detailed description and the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 shows the high content-based quantifications of aggregated a-synuclein species in combination with determination of nuclei count (% remaining cells) in differentiated ReNcell VM cells. Results showed that 24 hour treatment with test compounds 166362, 170357, 162640 and 180948, respectively, induced a concentration-dependent inhibition of MJFR14 immunoreactivity, indicative of decreased a-synuclein aggregation. [0013] Figures 2A-2D show the immunocytochemical images of cells treated with vehicle (0.1% DMSO) and test compounds 132168, 166362, and 170357, and immunostained with MJFR14, illustrating the reduction in a-synuclein expression following treatment with compounds 132168 and 166362. Figure 2A: DMSO (0.1%); Figure 2B: compound 132168 (3mM); Figure 2C: compound 166362 (3mM); and Figure 2D: compound 170357 (10mM).
[0014] Figure 3 shows the result of an in vivo a-synuclein degradation study. Upon treatment of compound 132168, insoluble a-synuclein fraction decreases 30% compared to DMSO vehicle control, indicating the reduction of insoluble a-synuclein aggregates.
DETAILED DESCRIPTION OF THE DISCLOSURE [0015] The present disclosure provides compounds, compositions, and methods useful for removing a-synuclein aggregates or reducing the degree of a-synuclein aggregation to low levels, thereby possessing therapeutic potential in the treatment of patients with synucleinopathies.
[0016] Provided herein are bispecific conjugate compounds that can simultaneously bind a target protein (i.e., aggregated a-synuclein) and an E3 ubiquitin ligase. The bispecific conjugate compounds exhibit desirable functional properties including binding preferentially to a-synuclein aggregates, and allowing a-synuclein to be placed in proximity to the E3 ubiquitin ligase, thereby facilitating the selective ubiquitination and eventual proteasome-mediated degradation of a-synuclein aggregates.
[0017] Methods described herein include the administration of a compound or a composition of the present disclosure to a subject to treat, alleviate or prevent a
neurodegenerative disease or disorder characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein.
Compounds
[0018] One aspect of the present disclosure is a compound of Formula A,
EBM-L-SBM (Formula A) wherein
EBM is an E3 ubiquitin ligase binding moiety;
L is a linker covalently attached to EBM and SBM, and SBM is an a-synuclein protein binding moiety of the formula:
or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein
is covalently linked to L; and
(i)
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or
(ii)
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
i .s a substi .tuted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
[0019] In some embodiments, the substituted or unsubstituted bicyclic fused aromatic ring is a substituted or unsubstituted bicyclic 5-6 system. Non-limiting examples include
[0020] In some embodiments, SBM is of Formula B or Formula C
wherein
Z is C or N; U is O, S or CH; V is N or NH;
K is CH or N; Q is CH or N; where K and Q are not N at the same time; each occurrence of R'" is independently selected from the group consisting of H, OH, NFh, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R' is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkyl, Ci-6 alkylamino, C3-6 cycloalkylamino, C3-6 cycloalkyl and C3-6 heterocycloalkyl; n is 0, 1 or 2;
J is CR6 or N; X is CR6 or N; Y is CR6 or N; where at least one of J, X and Y is N, but J and Y are not N at the same time, X and Y are not N at the same time;
R6 is independently selected from the group consisting of H, NH2, Ci-6 alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo; and in Formula B, V is N, where Z and U are not heteroatoms at the same time; and
in Formula C, V is N or NH; T is CH or N; where up to two of U, Z, V and T contain heteroatoms.
[0021] In some embodiments, EBM is
R3 is H or Ci-6 alkyl; each occurrence of R2 is independently selected from the group consisting of H,
OH, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkylamino andMH; m6 is 0, 1, 2, 3 or 4; and
[0022] In some embodiments, the compound is of any one of the Formula (I)-(VI):
wh
erein, in Formula I, R3 is H or Ci-6 alkyl; Yi is CH2 or LI is a bond, -C(=0)-,
-NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L3 is a bond, - R-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L2 is a substituted or unsubstituted Ci-50 hydrocarbon chain; Z is C or N; U is O, S or CH; V is N, where Z and U are not heteroatoms at the same time; K is CH or N; Q is CH or N; where K and Q are not N at the same time; each occurrence of R" is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0,
1, 2 or 3; each occurrence of R' is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-e haloalkyl, Ci-e alkylamino, C3-6 cycloalkylamino, C3-6 cycloalkyl and C3-6 heterocycloalkyl; n is 0, 1 or 2; J is CR6 or N; X is CR6 or N; Y is CR6 or N; where at least one of J, X and Y is N, but J and Y are not N at the same time, X and Y are not N at the same time; R6 is independently selected from the group consisting of H, NH2, Ci-6 alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo; in Formula P, each occurrence of R2 is independently selected from the group consisting of
H, OH, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkylamino and NH2; m6 is 0, 1, 2, 3 or 4; Yi is CH2 or
; Li is a bond, -C(=0)-, -NR-, -O-, or -S-, wherein R is hydrogen, optionally
substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L2 is a substituted or unsubstituted Ci-50 hydrocarbon chain; Z is C or N; U is O, S or CH; V is N, where Z and U are not heteroatoms at the same time; K is CH or N; Q is CH or N; where K and Q are not N at the same time; each occurrence of R"1 is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0,
I, 2 or 3; each occurrence of R' is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkyl, Ci-6 alkylamino, C3-6 cycloalkyl and C3-6 heterocycloalkyl; n is 0, 1 or 2; J is CR6 or N; X is CR6 or N; Y is CR6 or N; where at least one of J, X and Y is N, but J and Y are not N at the same time, X and Y are not N at the same time; R6 is independently selected from the group consisting of H, NH2, Ci-e alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo; in Formula PI, Li is a bond, -C(=0)-, -NR-, -O-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L2 is a
substituted or unsubstituted Ci-50 hydrocarbon chain; Z is C or N; U is O, S or CH; V is N, where Z and U are not heteroatoms at the same time; K is CH or N; Q is CH or N; where K and Q are not N at the same time; each occurrence of R"1 is independently selected from the group consisting of H, OH, NH2, Ci-e alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R' is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkyl, Ci-6 alkylamino, C3-6 cycloalkyl, C3-6 cycloalkylamino and C3-6 heterocycloalkyl; n is 0, 1 or 2; J is CR6 or N; X is CR6 or N; Y is CR6 or N; where at least one of J, X and Y is N, but J and Y are not N at the same time, X and Y are not N at the same time; R6 is independently selected from the group consisting of H, NH2, Ci-6 alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo; in Formula IV, R3 is H or Ci-6 alkyl;
bond, -C(=0)-, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L3 is a bond, -NR-, -O-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L2 is a substituted or unsubstituted Ci-50 hydrocarbon chain; Z is C or N; U is O, S or CH; V is N or NH; T is CH or N; where up to two of U, Z, V and T contain heteroatoms; K is CH or N; Q is CH or N; where K and Q are not N at the same time; each occurrence of R1" is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkyl, Ci-6 alkylamino, C3-6 cycloalkyl, C3-6 cycloalkylamino, and C3-6 heterocycloalkyl; n is 0, 1 or 2; J is CR6 or N; X is CR6 or N; Y is CR6 or N; where at least one of J, X and Y is N, but J and Y are not N at the same time, X and Y are not N at the same time; R6 is
independently selected from the group consisting of H, NH2, Ci-6 alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo; in Formula V, each occurrence of R2 is independently selected from the group consisting of
H, OH, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkylamino and NH2; m6 is 0, 1, 2, 3 or 4; Yi is CH2 or
Li is a bond, -C(=0)-, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L2 is a substituted or unsubstituted Ci-50 hydrocarbon chain; Z is C or N; U is O, S or CH; V is N or NH; T is CH or N; where up to two of U, Z, V and T contain heteroatoms; K is CH or N; Q is CH or N; where K and Q are not N at the same time; each occurrence of R1" is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R1 is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-e haloalkyl, Ci-e alkylamino, C3-6 cycloalkyl, C3-6 cycloalkylamino and C3-6 heterocycloalkyl; n is 0, 1 or 2; J is CR6 or N; X is CR6 or N; Y is CR6 or N; where at least one of J, X and Y is N, but J and Y are not N at the same time, X and Y are not N at the same time; R6 is independently selected from the group consisting of H, NH2, Ci-6 alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo; in Formula YI, Li is a bond, -C(=0)-, -NR-, -O-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L2 is a substituted or unsubstituted Ci-50 hydrocarbon chain; Z is C or N; U is O, S or CH; V is N;
T is CH or N; where up to two of U, Z, V and T contain heteroatoms; K is CH or N; Q is CH or N; where K and Q are not N at the same time; each occurrence of R" is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R1 is
independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkyl, Ci-6 alkylamino, C3-6 cycloalkyl, C3-6 cycloalkylamino and C3-6 heterocycloalkyl; n is 0, 1 or 2; J is CR6 or N; X is CR6 or N; Y is CR6 or N; where at least one of J, X and Y is N, but J and Y are not N at the same time, X and Y are not N at the same time; R6 is independently selected from the group consisting of H, NH2, Ci-6 alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo. Optionally, one or more chain atoms of the substituted or unsubstituted Ci-50 hydrocarbon chain are independently replaced with -C(=0)-, -0-, - NRa1-, -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl (e.g., substituted or unsubstituted methyl or ethyl), or a nitrogen protecting group (e g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl or p-toluenesulfonamide (Ts)).
[0023] In certain embodiments, the compound is of the structure of Formula I.
[0024] In certain embodiments, the compound is of the structure of Formula II.
[0025] In certain embodiments, the compound is of the structure of Formula III.
[0026] In certain embodiments, the compound is of the structure of Formula IV.
[0027] In certain embodiments, the compound is of the structure of Formula V.
[0028] In certain embodiments, the compound is of the structure of Formula VI.
[0029] In certain embodiments, the moiety
in Formula (I), (II) and (III) is
[0030] In certain embodiments, the moiety in Formula (IV), (V) and (VI) is
[0031] In certain embodiments, the moiety in Formulae (I)-(VI) is
[0034] In one embodiment of the disclosure, LI is a bond.
[0035] In one embodiment of the disclosure, LI is -C(=0)-, -NH-, -0-, or -S-.
[0036] In one embodiment of the disclosure, L3 is a bond.
[0037] In one embodiment of the disclosure, L3 is - H-, -0-, or -S-.
[0038] In one embodiment of the disclosure, L2 is a substituted or unsubstituted Ci-30 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -0-, -NRa1-, -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group.
[0039] In certain embodiments, L2 is an unsubstituted Ci-30 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -0-, -NRal- -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group.
[0040] In certain embodiments, L2 is a substituted or unsubstituted Ci-24 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -0-, -NRa1-, -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group.
[0041] In certain embodiments, L2 is an unsubstituted Ci-24 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with
— C(=0) — , -0-, - Ral- , -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group.
[0042] In certain embodiments, L2 is a substituted or unsubstituted Ci-20 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -0-, -NRal- -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group.
[0043] In certain embodiments, L2 is an unsubstituted Ci-20 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with — C(=0) — , -0-, -NRa1-, -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group.
[0044] In certain embodiments, at least one chain atom of the hydrocarbon chain of L2 is independently replaced with -0-
[0045] In certain embodiments, the chain of L2 comprises up to 50 consecutive covalently bonded atoms in length, excluding hydrogen atoms and substituents.
[0046] In certain embodiments, L2 comprises up to, for example 46, 45, 40, 35, 32, 30, 25, 23, 20, 15, 14, 12, 11, 10, 9, 8, 7, 6, 5, 3 consecutive covalently bonded atoms in length, excluding hydrogen atoms and substituents.
[0047] In certain embodiments, any of the atoms in L2 can be substituted. In certain embodiments, none of the atoms in the linker L2 are substituted. In certain embodiments, none of the carbon atoms in the linker are substituted.
[0048] In certain embodiments, L2 is a linker that contains an asymmetric carbon/stereocenter, i.e., an sp3 hybridized carbon atom bearing 4 different groups attached thereto. In certain embodiments, the compound comprising such an L2 group is enantiomerically enriched or substantially enantiomerically enriched. In certain embodiments, the compound comprising such an L2 group is enantiomerically pure. In certain embodiments, the compound comprising such an L2 group is racemic.
[0049] In certain embodiments, L2 comprises substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroaryl ene, or substituted or unsubstituted heteroalkylene, or combinations thereof. In certain embodiments, L2 is substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroaryl ene, or substituted or unsubstituted heteroalkylene. In certain embodiments, L2 is a linker selected from the group consisting of substituted and unsubstituted alkylene, substituted and unsubstituted alkenylene, substituted and unsubstituted alkynylene, substituted and unsubstituted heteroalkylene, substituted and unsubstituted heteroalkenylene, substituted and unsubstituted heteroalkynylene, substituted and unsubstituted heterocyclylene, substituted and unsubstituted carbocyclylene, substituted and unsubstituted arylene, substituted and unsubstituted heteroaryl ene, and combinations thereof.
[0050] Reference to L2 being a combination of at least two instances of the divalent moieties described herein refers to a linker consisting of at least one instance of a first divalent moiety and at least one instance of a second divalent moiety, wherein the first and second divalent moieties are the same or different and are within the scope of the divalent moieties described herein, and the instances of the first and second divalent moieties are consecutive covalently attached to each other. For example, when L2 is a combination of alkylene and heteroalkylene linkers, -alkylene-heteroalkylene-, -alkylene- (heteroalkylene)2-, and -heteroalkylene-alkylene-heteroalkylene- are all within the scope of L2, wherein each instance of alkylene in any one of the linkers may be the same or different, and each instance of heteroalkylene in any one of the linkers may be the same or different.
[0051] In certain embodiments, L2 comprises at least one instance of substituted or unsubstituted alkylene, e.g., substituted or unsubstituted Ci-6 alkylene, substituted or unsubstituted C1-2 alkylene, substituted or unsubstituted C1-3 alkylene, substituted or unsubstituted C3-4 alkylene, substituted or unsubstituted C4-5 alkylene, substituted or
unsubstituted C5-6alkylene, substituted or unsubstituted C3-6alkylene, or substituted or unsubstituted C4-6alkylene. Exemplary alkylene groups include unsubstituted alkylene groups such as methylene (-CH2-), ethylene (-(CH2)2-), n-propylene (-(CH2)3-), n-butylene (- (CH2)4-), n-pentylene (-(Cl [2)5-), and n-hexylene (-(CH2)6-).
[0052] In certain embodiments, L2 comprises at least one instance of substituted or unsubstituted alkenylene, e g., substituted or unsubstituted C2-6 alkenyl ene, substituted or unsubstituted C1-3 alkenylene, substituted or unsubstituted C3-4 alkenylene, substituted or unsubstituted C4-5 alkenylene or substituted or unsubstituted C5-6 alkenylene.
[0053] In certain embodiments, L2 comprises at least one instance of substituted or unsubstituted alkynylene, e.g., substituted or unsubstituted C2-6 alkynylene, substituted or unsubstituted C2-3 alkynylene, substituted or unsubstituted C3-4 alkynylene, substituted or unsubstituted C4-5 alkynylene or substituted or unsubstituted C5-6 alkynylene.
[0054] In certain embodiments, L2 comprises at least one instance of substituted or unsubstituted heteroalkylene, e.g., substituted or unsubstituted heteroCi-6alkylene, substituted or unsubstituted heteroCi-2alkylene, substituted or unsubstituted heteroC2- 3alkylene, substituted or unsubstituted heteroC3-4alkylene, substituted or unsubstituted heteroC4- salkylene or substituted or unsubstituted heteroCs^alkylene. Exemplary heteroalkylene groups include unsubstituted heteroalkylene groups, such as -(CH2)2- 0(CH2)2- -OCH2-, -CH20-, -0(CH2)2-, -(CH2)20-, -0(CH2)3-, -(CH2)30-, -0(CH2)4- - (CH2)40- -0(CH2)5-, -(CH2)50-, -0(CH2)6-, and -0(CH2)60-, and amide groups (e.g., -NH-C(=0)-and -C(=0)NH-).
[0055] In certain embodiments, L2 comprises at least one instance of substituted or unsubstituted heteroalkenylene, e.g., substituted or unsubstituted heteroC2-6alkenylene, substituted or unsubstituted heteroCi-3alkenylene, substituted or unsubstituted heteroC3- 4alkenylene, substituted or unsubstituted heteroC4-salkenylene, or substituted or unsubstituted heteroC ealkenylene.
[0056] In certain embodiments, L2 comprises at least one instance of substituted or unsubstituted heteroalkynylene, e.g., substituted or unsubstituted heteroC2-6alkynylene,
substituted or unsubstituted heteroC2-3alkynylene, substituted or unsubstituted heteroCb-4 alkynylene, substituted or unsubstituted heteroCr-salkynylene, or substituted or unsubstituted heteroC5-6alkynylene.
[0057] In certain embodiments, L2 comprises at least one instance of substituted or unsubstituted carbocyclylene, e.g., substituted or unsubstituted C3-6carbocyclylene, substituted or unsubstituted Cb-icarbocyclylene, substituted or unsubstituted C4- scarbocyclylene, or substituted or unsubstituted C5-6 carbocyclylene.
[0058] In certain embodiments, L2 comprises at least one instance of substituted or unsubstituted heterocyclylene, e g., substituted or un substituted 3-6 membered heterocyclylene, substituted or unsubstituted 3-4 membered heterocyclylene, substituted or unsubstituted 4-5 membered heterocyclylene, or substituted or unsubstituted 5-6 membered heterocyclylene. In certain embodiments, at least one chain atom of the hydrocarbon chain of L2 is independently replaced with a 5-8 membered heterocyclyl group with 1-4 ring heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In certain embodiments, at least one chain atom of the hydrocarbon chain of L2 is independently replaced with a 6-membered heterocyclyl group with 1-3 ring heteroatoms selected from the group consisting of nitrogen and oxygen. In certain embodiments, at least one chain atom of the hydrocarbon chain of L2 is independently replaced with piperidine, piperazine or morpholine.
[0059] In certain embodiments, L2 comprises at least one instance of substituted or unsubstituted arylene, e.g., substituted or unsubstituted phenylene. In certain embodiments, at least one chain atom of the hydrocarbon chain of L2 is independently replaced with an optionally substituted phenyl group.
[0060] In certain embodiments, L2 comprises at least one instance of substituted or unsubstituted heteroaryl ene, e.g., substituted or unsubstituted 5- to 6-membered heteroaryl ene.
[0061] In certain embodiments, L2 is an unsubstituted hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with
-NRal- and each instance ofRal is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group, or optionally two instances of Ral are taken together with their intervening atoms to form a substituted or unsubstituted heterocyclic or substituted or unsubstituted heteroaryl ring. In certain embodiments, at least one instance of Ral is hydrogen. In certain embodiments, at least one instance of Ral is substituted or unsubstituted Ci-6 alkyl (e.g., substituted or unsubstituted methyl or ethyl). In certain embodiments, at least one instance of Ral is a nitrogen protecting group (e g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl or p-toluenesulfonamide (Ts)).
[0062] In certain embodiments, L2 is an optionally substituted Ci-45 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -0-, -NRa1-, -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group. In certain embodiments, L2 is an unsubstituted Ci-45 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -O- -NRal- -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group. In certain embodiments, L2 is an optionally substituted Ci-24 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -0-, -NRa1-, -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group. In certain embodiments, L2 is an unsubstituted Ci-24 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -0-, -NRal- -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group. In certain embodiments, L2 is an optionally substituted Ci-20 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -0-, -NRal- -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl, or a nitrogen
protecting group. In certain embodiments, L2 is an unsubstituted Ci-20 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -0-, -NRa1-, -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group. In certain embodiments, L2 is an optionally substituted Ci-30 hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -O- or -NRal- In certain embodiments, L2 is an unsubstituted Ci-30 hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -O- or-NRal- In certain embodiments, L2 is an unsubstituted Ci-30 hydrocarbon chain, wherein at least one chain atom of the hydrocarbon chain is independently replaced with -0-. In certain embodiments, L2 is an unsubstituted Ci-26 hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -O- or-NRal- In certain embodiments, L2 is an unsubstituted Ci-20 hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -0-. In certain embodiments, L2 is an unsubstituted C5-26 hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -O- or- NRal- In certain embodiments, L2 is an unsubstituted C5-26 hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -0-.
In certain embodiments, L2 is an unsubstituted C5-20 hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -O- or- NRal- In certain embodiments, L2 is an unsubstituted C5-20 hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -0-, or- NRal- In certain embodiments, L2 is an unsubstituted Cs-is hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with — C(=0) — , -O- or-NRal- In certain embodiments, L2 is an unsubstituted C15-20 hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -O- or-NRal- In certain embodiments, L2 is an unsubstituted C2o-2shydrocarbon chain, wherein one or more chain atoms of the hydrocarbon
chain are independently replaced with -C(=0)-, -O- or-NRal- In certain embodiments, L2 is a substituted or unsubstituted Ci-45 hydrocarbon chain. In certain embodiments, L2 is a substituted or unsubstituted C5-40 hydrocarbon chain. In certain embodiments, one or more chain atoms of the hydrocarbon chain of L2 are independently replaced with -C(=0)-, -0-, — S — , -NRa1-, -N= or =N- In certain embodiments, one or more chain atoms of the hydrocarbon chain of L2 are independently replaced with -C(=0)-,-0- or-NRa1-, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group. In certain embodiments, L2 is an unsubstituted Ci-26 hydrocarbon chain, wherein at least one chain atom of the hydrocarbon chain is independently replaced with - O — . The cyclic moiety herein refers to a cycloalkylene or a heterocycloalkylene, such as
[0063] In certain embodiments, L2 is an all-carbon, substituted or unsubstituted Ci-45 hydrocarbon chain. In certain embodiments, L2 is an all-carbon, substituted or unsubstituted Ci-30 hydrocarbon chain. In certain embodiments, L2 is an all-carbon, substituted or unsubstituted Ci-26 hydrocarbon chain. In certain embodiments, L2 is an all-carbon, substituted or unsubstituted Ci-24 hydrocarbon chain. In certain embodiments, L2 is an all-carbon, substituted or unsubstituted Ci-20 hydrocarbon chain. In certain embodiments, L2 is an all-carbon, substituted or unsubstituted Ci-20 hydrocarbon chain.
[0064] In certain embodiments, L2 is
wherein g is 1, 2, 3, 4, 5, or 6. In certain embodiments, g is 1. In certain embodiments, g is 2. In certain embodiments, g is
3. In certain embodiments, g is 4. In certain embodiments, g is 5. In certain embodiments, g is 6.
[0065] In certain embodiments, L2 comprises at least one instance selected from the group consisting of substituted or unsubstituted methylene, ethylene, n-propylene, n-butylene, n-pentylene, n-hexylene, -(CH2)2-0(CH2)2-, -OCH2-, -CH2O-, -0(CH2)2-, - (CHO2O-, -O(CH2)3-, -(CH2)30- -O(CH2) -, -(CH2) O- -O(CH2)5-, -(CH2)50- - 0(CH2)6-, -0(CH2)60-, -C(=0)0-, -0-C(=0)-, -NH-C(=0)- and -C(=0)NH-.
[0066] In certain embodiments, L2 comprises at least one instance selected from the group consisting of substituted or unsubstituted methylene, ethylene, n-propylene, n-butylene, n-pentylene, n-hexylene, -(CH2)2-0(CH2)2-, -OCH2-, -CH2O-, -0(CH2)2-, - (CH2)20-, -0(CH2)3-, -(CH2)30-, -0(CH2)4-, -(CH2)40-, -0(CH2)5-, -(CH2)50- - 0(CH2)6-, -0(CH2)60-, - H-C(=0)- and -C(=0)NH-.
[0067] In certain embodiments, L2 includes the moiety -NHC(=0)-.
[0068] In certain embodiments, L2 includes the moiety -NH-.
[0069] Examples of L2 of the disclosure include, but are not limited to:
, wherein each g is independently 1, 2, 3, 4, 5, or 6; f is 1, 2, 3, 4, 5, or 6, and h is 1, 2, 3, 4, 5, or 6.
[0070] In certain embodiments, L2 is of the formula:
[0071] In certain embodiments, L2 is of the formula:
[0072] In certain embodiments, L2 is of the formula:
wherein g is 1, 2, 3, 4 or 5; h is 0, 1, 2, 3, 4 or 5; and f is 1, 2, 3, 4, 5, 6,
7 or 8.
[0073] In certain embodiments, L2 is of the formula:
[0074] In certain embodiments, L2 is of the formula: wherein g is 1, 2, 3, 4, 5, 6, 7 or 8.
[0075] In certain embodiments, L2 is of the formula:
4, 5, 6, 7 or 8; and f is 1, 2, 3, 4, 5, 6, 7 or 8.
[0076] In certain embodiments, L2 is of the formula:
herein g is 1, 2, 3, 4, 5, 6, 7 or 8; and f is 1, 2, 3, 4, 5, 6, 7 or 8.
[0077] In certain embodiments, L2 is of the formula:
, wherein g is 1, 2, 3, 4, 5, 6, 7 or 8.
[0078] In certain embodiments, the compound of the disclosure is of any one of the structure as follows,
wherein, in Formula 1-1, R3 is H or Ci-6 alkyl; Yi is CH2 or , LI is a bond, -C(=0)-,
-NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L3 is a bond, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L2 is a substituted or unsubstituted Ci-50 hydrocarbon chain; Z is C orN; U is O, S or CH; where Z and U are not heteroatoms at the same time; Q is CH or N; K is CH or N; where Q and K are not N at the same time; each occurrence of R"' is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R' is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-e haloalkyl, Ci-e alkylamino, C3-6 cycloalkyl, C3-6 cycloalkylamino and C3-6 heterocycloalkyl; n is 0, 1 or 2; in Formula P-1, each occurrence of R2 is independently selected from the group consisting of H, OH, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkylamino and NH2; m6 is 0, 1, 2, 3 or 4; Yi is CH2 Li is a bond, -C(=0)-, -NR-, -O-, or -S-, wherein R is hydrogen, optionally
substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L3 is a bond, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L2 is a substituted or unsubstituted Ci-50 hydrocarbon chain; Z is C or N; U is O, S or CH; where Z and U are not heteroatoms at the same time; Q is CH or N; K is CH or N; where Q and K are not N at the same time; each occurrence of R" is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R' is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-6
haloalkyl, Ci-6 alkylamino, C3-6 cycloalkyl, C3-6 cycloalkylamino and C3-6 heterocycloalkyl; n is 0, 1 or 2; in Formula PI-1, Li is a bond, -C(=0)-, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L3 is a bond, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L2 is a substituted or unsubstituted Ci-50 hydrocarbon chain; Z is C or N; U is O, S or CH; where Z and U are not heteroatoms at the same time; Q is CH or N; K is CH or N; where Q and K are not N at the same time; each occurrence of R'" is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R' is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkyl, Ci-6 alkylamino, C3-6 cycloalkyl, C3-6 cycloalkylamino and C3-6 heterocycloalkyl; n is 0, 1 or 2;
bond, -C(=0)-, -NR-, -O-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L3 is a bond, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L2 is a substituted or unsubstituted Ci-50 hydrocarbon chain; Z is C orN; U is O, S or CH; T is CH or N; where only one of U, Z and T is heteroatom; Q is CH or N; K is CH or N; where Q and K are not N at the same time; each occurrence of R"1 is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen, k is 0, 1, 2 or 3; each occurrence of R is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkyl, Ci-6 alkylamino, C3-6 cycloalkyl, C3-6 cycloalkylamino
and C3-6 heterocycloalkyl; n is 0, 1 or 2; X is CR6 or N; Y is CR6 or N; where one of X and Y is N, while the other is CR6; R6 is independently selected from the group consisting of H, NH2, Ci-6 alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo; in Formula V-l, each occurrence of R2 is independently selected from the group consisting of H, OH, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkylamino and NH2; m6 is 0, 1, 2, 3 or 4; Yi is CH2 Li is a bond, -C(=0)-, -NR-, -0-, or -S-, wherein R is hydrogen, optionally
substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L3 is a bond, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L2 is a substituted or unsubstituted Ci-50 hydrocarbon chain; Z is C or N; U is O, S or CH; T is CH or N; where only one of U, Z and T is heteroatom; Q is CH or N; K is CH or N; where Q and K are not N at the same time; each occurrence of R'" is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R1 is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkyl, Ci-6 alkylamino, C3-6 cycloalkyl, C3-6 cycloalkylamino and C3-6 heterocycloalkyl; n is 0, 1 or 2; X is CR6 or N; Y is CR6 or N; where one of X and Y is N, while the other is CR6; R6 is independently selected from the group consisting of H, NH2, Ci-6 alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo; in Formula VI- 1, Li is a bond, -C(=0)-, -NR-, -O-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L3 is a bond, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; L2 is a substituted or unsubstituted Ci-50 hydrocarbon chain; Z is C or N; U is O, S or CH; T is CH or N; where only one of U, Z and
T is heteroatom; Q is CH or N; K is CH or N; where Q and K are not N at the same time; each occurrence of R'" is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R' is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkyl, Ci-6 alkylamino, C3-6 cycloalkyl, C3-6 cycloalkylamino and C3-6 heterocycloalkyl; n is 0, 1 or 2; X is CR6 or N; Y is CR6 or N; where one of X and Y is N, while the other is CR6; R6 is independently selected from the group consisting of H, NH2, Ci-6 alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo.
[0079] In certain embodiments, the compound of Formula 1-1 is of the following
Formula 1, 5, 6, 8, 10 or 13,
[0080] An embodiment of the disclosure is the compound of Formula 1, wherein R' is H, Ci-3 haloalkyl or C1-3 alkoxy, preferably H, CF3, CCb, methoxy or ethoxy, more preferably H, CF3 or methoxy.
[0081] An embodiment of the disclosure is the compound of Formula 1, wherein m is 0, 1, 2, 3 or 4, preferably 0 or 1.
[0082] An embodiment of the disclosure is the compound of Formula 1, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino and C3-5 heterocycloalkyl, preferably H, F, Cl, NH2, methoxy, ethoxy, methylamino, dimethylamino, ethylamino, diethylamino, cyclopropyl, cyclobutyl or cyclopentyl, more preferably H, F, dimethylamino or cyclopropyl.
[0083] An embodiment of the disclosure is the compound of Formula 1, wherein n is 0, 1 or 2, preferably 0 or 1.
[0084] An embodiment of the disclosure is the compound of Formula 1, wherein R'" is H, OH or halogen, preferably H, OH, F or Cl, more preferably H.
[0085] An embodiment of the disclosure is the compound of Formula 1, wherein k is 0, 1, 2 or 3, preferably 0 or 1.
[0086] An embodiment of the disclosure is the compound of Formula 1, wherein R1 is O,
NH, An embodiment of the disclosure is the compound of
Formula 1, wherein R1 is O, NH,
[0087] An embodiment of the disclosure is the compound of Formula 1, wherein A is O,
NH, , preferably O or
[0088] An embodiment of the disclosure is the compound of Formula 1, wherein m2 is 2, 3, 4 or 6, preferably 2 or 6.
[0089] An embodiment of the disclosure is the compound of Formula 1, wherein R3 is H or Ci-3 alkyl, preferably H or methyl, more preferably H.
[0090] An embodiment of the disclosure is the compound of Formula 1 having the structure as shown in Formula 1-1,
U is O, S or CH; Z is C or N; where U and Z are not heteroatoms at the same time; R1 is H, Ci-3 haloalkyl or C1-3 alkoxy; R" is H, F, Cl, OH, NH2, C1-3 alkoxy, methylamino, dimethylamino, diethylamino or cyclopropylamino; n is 0, 1 or 2.
[0092] An embodiment of the disclosure is the compound of Formula 1-1, wherein m2 is 2, 3, 4 or 6, preferably 2 or 6.
[0093] An embodiment of the disclosure is the compound of Formula 1-1, wherein R3 is H or methyl.
[0094] An embodiment of the disclosure is the compound of Formula 1-1, wherein A is O or
[0095] An embodiment of the disclosure is the compound of Formula 1-1, wherein R1 is
O, NH or . An embodiment of the disclosure is the compound of Formula 1-1,
wherein R1 is O, NH,
[0096] An embodiment of the disclosure is the compound of Formula 1-1, wherein Z is N,
U is CH
[0097] An embodiment of the disclosure is the compound of Formula 1-1, wherein Z is C, U is S or O.
[0098] An embodiment of the disclosure is the compound of Formula 1-1, wherein R" is H, F, Cl, OF1, NH2, methoxy, methylamino, dimethylamino, diethylamino, cyclopropyl or cyclopropylamino, preferably H, F, methylamino, dimethylamino or cyclopropylamino. [0099] An embodiment of the disclosure is the compound of Formula 1-1, wherein R' is
H, Ci-3 fluoroalkyl, methoxy or ethoxy, preferably R' is H, methoxy or CF3.
[0100] An embodiment of the disclosure is the compound of Formula 5, wherein R3 is H or Ci-3 alkyl, preferably H or methyl.
[0101] An embodiment of the disclosure is the compound of Formula 5, wherein A is O, H
NH o ; preferably O. An embodiment of the disclosure is the compound of
Formula 5, wherein each A is independently O, NH,
[0102] An embodiment of the disclosure is the compound of Formula 5, wherein m4 is 0,
I, 2, or 3, preferably 0 or 3.
[0103] An embodiment of the disclosure is the compound of Formula 5, wherein m5 is 0,
1, 2 or 3, preferably 0 or 1.
[0104] An embodiment of the disclosure is the compound of Formula 5, wherein m3 is 1,
2, 3, 4, 5 or 6, preferably 3 or 5.
[0105] An embodiment of the disclosure is the compound of Formula 5, wherein R1 is O,
NH or
[0106] An embodiment of the disclosure is the compound of Formula 5, wherein R1" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably H.
[0107] An embodiment of the disclosure is the compound of Formula 5, wherein k is 0, 1, 2 or 3, preferably 0 or 1.
[0108] An embodiment of the disclosure is the compound of Formula 5, wherein Z is C, U is O or S.
[0109] An embodiment of the disclosure is the compound of Formula 5, wherein Z is N,
U is CH
[0110] An embodiment of the disclosure is the compound of Formula 5, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCh, methyl or methoxy, more preferably H or CF3.
[0111] An embodiment of the disclosure is the compound of Formula 5, wherein m is 0, 1, 2 or 3, preferably 0 or 1.
[0112] An embodiment of the disclosure is the compound of Formula 5, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, cyclopropyl or dimethylamino, more preferably H, F, CF3, cyclopropyl, cyclopropylamino or dimethylamino.
[0113] An embodiment of the disclosure is the compound of Formula 5, wherein n is 0, 1 or 2, preferably 0 or 1.
[0114] An embodiment of the disclosure is the compound of Formula 5 having the structure as shown in Formula 5-1, are not heteroatoms at
the same time; R'" is H, OH, C1-3 alkyl, C1-3 alkoxy or halogen; R' is H, halogen, OH, C1-3 alkyl, Ci-3haloalkyl or C1-3 alkoxy; R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino and C3-5 heterocycloalkyl; n is 0, 1 or 2.
[0116] An embodiment of the disclosure is the compound of Formula 5-1, wherein A is O.
[0117] An embodiment of the disclosure is the compound of Formula 5-1, wherein m5 is 0 or 1.
[0118] An embodiment of the disclosure is the compound of Formula 5-1, wherein m4 is 0 or 3.
[0119] An embodiment of the disclosure is the compound of Formula 5-1, wherein m3 is 3, 5.
[0120] An embodiment of the disclosure is the compound of Formula 5-1, wherein R1 is
[0121] An embodiment of the disclosure is the compound of Formula 5-1, wherein Z is C, U is O or S.
[0122] An embodiment of the disclosure is the compound of Formula 5-1, wherein Z is N, U is CH.
[0123] An embodiment of the disclosure is the compound of Formula 5-1, wherein R' is H, halogen, C1-3 alkyl, C1-3 fluoroalkyl or C1-3 alkoxy, preferably H, methyl, CF3, methyl or methoxy, more preferably H or CF3.
[0124] An embodiment of the disclosure is the compound of Formula 5-1, wherein R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, CF3, amino, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H, F, CF3, dimethylamino, cyclopropylamino or cyclopropyl.
[0125] An embodiment of the disclosure is the compound of Formula 6, wherein R3 is H or Ci-3 alkyl, preferably H or methyl.
[0126] An embodiment of the disclosure is the compound of Formula 6, wherein A is O, preferably O or NH.
[0127] An embodiment of the disclosure is the compound of Formula 6, wherein m2 is 1, 2, 3, 4, 5, 6 or 7, preferably 2 or 6.
[0128] An embodiment of the disclosure is the compound of Formula 6, wherein R1 is O,
, preferably O or NH.
[0129] An embodiment of the disclosure is the compound of Formula 6, wherein Z is C or N, and U is O, S or CH, where Z and U are not heteroatoms at the same time; preferably Z is C and U is S.
[0130] An embodiment of the disclosure is the compound of Formula 6, wherein R'" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably H.
[0131] An embodiment of the disclosure is the compound of Formula 6, wherein R is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
[0132] An embodiment of the disclosure is the compound of Formula 6, wherein m is 0, 1, 2 or 3, preferably 0 or 1.
[0133] An embodiment of the disclosure is the compound of Formula 6, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, cyclopropyl, cyclopropylamino or dimethylamino, more preferably H,
F, CF3, dimethylamino, cyclopropyl or cyclopropylamino.
[0134] An embodiment of the disclosure is the compound of Formula 6, wherein n is 0 or
1
[0135] An embodiment of the disclosure is the compound of Formula 6 having the structure as shown in Formula 6-1,
R" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen; k is 0, 1, 2 or 3; Z is C or N; U is O, S or CH; where Z and U are not heteroatoms at the same time; R1 is H, halogen, OH, C1-3 alkyl, Ci-3haloalkyl or C1-3 alkoxy; m is 0, 1, 2 or 3; R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; n is 0, 1 or 2.
[0137] In some embodiments of Formula 6-1, R3 is H or C1-3 alkyl; Yi is CH2 or
; R" is H, OH, C1-3 alkyl, C1-3 alkoxy or halogen; k is 0, 1, 2 or 3; Z is C or N; U is O, S or CH; where Z and U are not heteroatoms at the same time; R1 is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; m is 0, 1, 2 or 3; R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; n is 0, 1 or 2.
[0138] An embodiment of the disclosure is the compound of Formula 6-1, wherein R3 is H or methyl.
[0139] An embodiment of the disclosure is the compound of Formula 6-1, wherein A is O or NI I.
[0140] An embodiment of the disclosure is the compound of Formula 6-1, wherein m2 is 2 or 6.
[0141] An embodiment of the disclosure is the compound of Formula 6-1, wherein R1 is O, or NH.
[0142] An embodiment of the disclosure is the compound of Formula 6-1, wherein R is
H or CEB.
[0143] An embodiment of the disclosure is the compound of Formula 6-1, wherein m is 0, 1, 2 or 3, preferably 0 or 1.
[0144] An embodiment of the disclosure is the compound of Formula 6-1, wherein R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, CF3, methoxy, methyl, dimethylamino, cyclopropyl, cyclopropylamino or methylamino, more preferably H, CF3, F, dimethylamino, cyclopropyl or cyclopropylamino, most preferably H, dimethylamino, cyclopropyl or cyclopropylamino.
[0145] An embodiment of the disclosure is the compound of Formula 6-1, wherein n is 0 or 1.
[0146] An embodiment of the disclosure is the compound of Formula 6-1, wherein R" substitutes at the adjacent position to the N atom.
[0147] An embodiment of the disclosure is the compound of Formula 8, wherein R3 is H or Ci-3 alkyl, preferably H or methyl.
[0148] An embodiment of the disclosure is the compound of Formula 8, wherein Yi is preferably CH2.
[0149] An embodiment of the disclosure is the compound of Formula 8, wherein A is O,
[0150] An embodiment of the disclosure is the compound of Formula 8, wherein m2 is 1, 2, 3 or 4, preferably 2.
[0151] An embodiment of the disclosure is the compound of Formula 8, wherein R1 is O, H,
preferably O.
[0152] An embodiment of the disclosure is the compound of Formula 8, wherein R'" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably
H.
[0153] An embodiment of the disclosure is the compound of Formula 8, wherein k is 0 or
I
[0154] An embodiment of the disclosure is the compound of Formula 8, wherein Z is C or N; U is O, S or CH; where Z and U are not heteroatoms at the same time; preferably Z is N and U is CH; preferably Z is C and U is S.
[0155] An embodiment of the disclosure is the compound of Formula 8, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
[0156] An embodiment of the disclosure is the compound of Formula 8, wherein m is 0, 1 or 2.
[0157] An embodiment of the disclosure is the compound of Formula 8, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
F, CF3, cyclopropyl or cyclopropylamino.
[0158] An embodiment of the disclosure is the compound of Formula 8, wherein n is 0, 1 or 2.
[0159] An embodiment of the disclosure is the compound of Formula 10, wherein R3 is H or Ci-3 alkyl, preferably H or methyl.
[0160] An embodiment of the disclosure is the compound of Formula 10, wherein Yi is
, preferably CH2.
[0161] An embodiment of the disclosure is the compound of Formula 10, wherein each A is independently , An embodiment of the disclosure is the compound of Formula 10, wherein A is preferably
[0162] An embodiment of the disclosure is the compound of Formula 10, wherein m5 is 0 or 1.
[0163] An embodiment of the disclosure is the compound of Formula 10, wherein m4 is 0 or 1.
[0164] An embodiment of the disclosure is the compound of Formula 10, wherein m3 is 1, 2, 3, 4 or 5, preferably 4.
[0165] An embodiment of the disclosure is the compound of Formula 10, wherein R1 is
O, NH, preferably O.
[0166] An embodiment of the disclosure is the compound of Formula 10, wherein R" is H, OH, C1-3 alkyl, C1-3 alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably H.
[0167] An embodiment of the disclosure is the compound of Formula 10, wherein k is 0 or 1.
[0168] An embodiment of the disclosure is the compound of Formula 10, wherein Z is C,
U is S or O.
[0169] An embodiment of the disclosure is the compound of Formula 10, wherein Z is N,
U is CH
[0170] An embodiment of the disclosure is the compound of Formula 10, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
[0171] An embodiment of the disclosure is the compound of Formula 10, wherein m is 0 or 1.
[0172] An embodiment of the disclosure is the compound of Formula 10, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, cyclopropyl, cyclopropylamino or dimethylamino, more preferably H,
F or CF3.
[0173] An embodiment of the disclosure is the compound of Formula 10, wherein n is 0 or 1.
[0174] An embodiment of the disclosure is the compound of Formula 13, wherein R3 is H or Ci-3 alkyl, preferably H or methyl.
[0175] An embodiment of the disclosure is the compound of Formula 13, wherein Yi is preferably CH2.
[0176] An embodiment of the disclosure is the compound of Formula 13, wherein A is O,
[0177] An embodiment of the disclosure is the compound of Formula 13, wherein m2 is 1, 2, 3 or 4, preferably 1.
[0178] An embodiment of the disclosure is the compound of Formula 13, wherein R1 is
, preferably NH.
[0179] An embodiment of the disclosure is the compound of Formula 13, wherein R"' is
H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably H.
[0180] An embodiment of the disclosure is the compound of Formula 13, wherein k is 0,
I, 2 or 3, preferably 0 or 1.
[0181] An embodiment of the disclosure is the compound of Formula 13, wherein Z is C, U is S or O.
[0182] An embodiment of the disclosure is the compound of Formula 13, wherein Z is N, U is CH
[0183] An embodiment of the disclosure is the compound of Formula 13, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
[0184] An embodiment of the disclosure is the compound of Formula 13, wherein m is 0, 1, 2 or 3, preferably 0 or 1.
[0185] An embodiment of the disclosure is the compound of Formula 13, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, cyclopropyl, cyclopropylamino or dimethylamino, more preferably H,
F, CF3, dimethylamino, cyclopropyl or cyclopropylamino, most preferably dimethylamino. [0186] An embodiment of the disclosure is the compound of Formula 13, wherein n is 0,
1 or 2, preferably 0 or 1.
[0187] An embodiment of the compound of Formula II-l is of the following Formula 3,
wherein R1 is O, NH,
[0188] An embodiment of the disclosure is the compound of Formula 3, wherein R2 is H, OH, Ci-3 alkyl, C1-3 alkoxy, C1-3 alkylamino or NH2, preferably H, OH orML·.
[0189] An embodiment of the disclosure is the compound of Formula 3, wherein m6 is 0,
1, 2 or 3, preferably 0 or 1.
[0190] An embodiment of the disclosure is the compound of Formula 3, wherein R1 is O or NH.
[0191] An embodiment of the disclosure is the compound of Formula 3, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, halogen or C1-3 fluoroalkyl, more preferably H or F.
[0192] An embodiment of the disclosure is the compound of Formula 3, wherein m is 0, 1,
2, 3 or 4, preferably 0 or 1.
[0193] An embodiment of the disclosure is the compound of Formula 3, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino, preferably H, halo, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, more preferably H, F or dimethylamino.
[0194] An embodiment of the disclosure is the compound of Formula 3, wherein n is 0, 1, 2 or 3, preferably 0, 1 or 2.
[0195] An embodiment of the disclosure is the compound of Formula 3, wherein Z is C,
U is O or S.
[0196] An embodiment of the disclosure is the compound of Formula 3, wherein Z is N,
U is CH
[0197] An embodiment of the disclosure is the compound of Formula 3, wherein R'" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, F, methyl or methoxy, more preferably H.
[0198] An embodiment of the disclosure is the compound of Formula 3 having the structure as shown in Formula 3-1,
wherein R2 is H, OH, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylamino or H2; m6 is 0, 1, 2 or 3; Yi
Z and U are not heteroatoms at the same time; R" is H, halo, OH, NH2, C1-3 alkoxy, C1-3 haloalkyl, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino; n is 0, 1 or 2.
[0199] An embodiment of the disclosure is the compound of Formula 3-1, wherein R2 is H, NH2 or OH.
[0200] An embodiment of the disclosure is the compound of Formula 3-1, wherein m6 is 0 or 1.
[0201] An embodiment of the disclosure is the compound of Formula 3-1, wherein when substituted at the following position in the phenyl:
[0202] An embodiment of the disclosure is the compound of Formula 3-1, wherein R1 is O or NH.
[0203] An embodiment of the disclosure is the compound of Formula 3-1, wherein R" is F, dimethylamino, methylamino, cyclopropyl or cyclopropylamino.
[0204] An embodiment of the disclosure is the compound of Formula 3-1, wherein n is 0, 1, or 2.
[0205] An embodiment of the compound of Formula III-l is of the following Formula 15,
Formula 15 wherein m2 is 1, 2, 3, 4, 5, 6, or 7; and R1 is O, NH,
[0206] An embodiment of the disclosure is the compound of Formula 15, wherein m2 is 1,
2, 3, 4, 5, 6 or 7, preferably 1, 2, 3, 4, 5 or 6, more preferably 2 or 5.
[0207] An embodiment of the disclosure is the compound of Formula 15, wherein R1 is , preferably O or NH.
[0208] An embodiment of the disclosure is the compound of Formula 15, wherein R" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, F, methyl or methoxy, more preferably H.
[0209] An embodiment of the disclosure is the compound of Formula 15, wherein Z is C, U is O or S.
[0210] An embodiment of the disclosure is the compound of Formula 15, wherein Z is N,
U is CH
[0211] An embodiment of the disclosure is the compound of Formula 15, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, halogen or C1-3 fluoroalkyl, more preferably H, CF3 or F.
[0212] An embodiment of the disclosure is the compound of Formula 15, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
[0213] An embodiment of the disclosure is the compound of Formula 15, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino, preferably H, halo, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, more
preferably H, F, methylamino, cyclopropylamino or dimethylamino, most preferably H or dimethylamino.
[0214] An embodiment of the disclosure is the compound of Formula 15, wherein n is 0,
1 or 2, preferably 0 or 1.
[0215] An embodiment of the compound of Formula IV-1 is of the following Formula 2, 7, 9, 11, 12 or 14,
Formula 11
Formula 14 wherein
[0216] An embodiment of the disclosure is the compound of Formula 2, wherein R3 is H or Ci-3 alkyl, preferably H or methyl.
[0217] An embodiment of the disclosure is the compound of Formula 2, wherein Yi is
[0219] An embodiment of the disclosure is the compound of Formula 2, wherein m2 is 2, 3, 4, 5 or 6, preferably 2 or 6.
[0220] An embodiment of the disclosure is the compound of Formula 2, wherein R1 is O, preferably NH.
[0221] An embodiment of the disclosure is the compound of Formula 2, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, H2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
F, CF3, cyclopropyl or cyclopropylamino.
[0222] An embodiment of the disclosure is the compound of Formula 2, wherein n is 0, 1 or 2, preferably 0 or 1.
[0223] An embodiment of the disclosure is the compound of Formula 2, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
[0224] An embodiment of the disclosure is the compound of Formula 2, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
[0225] An embodiment of the disclosure is the compound of Formula 2, wherein Z is C,
U is O or S, W is CH.
[0226] An embodiment of the disclosure is the compound of Formula 2, wherein Z is N,
U is CH, W is CH
[0227] An embodiment of the disclosure is the compound of Formula 2, wherein Z is C, W is N, U is CH.
[0228] An embodiment of the disclosure is the compound of Formula 2, wherein R'" is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0229] An embodiment of the disclosure is the compound of Formula 2, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
[0230] An embodiment of the disclosure is the compound of Formula 7, wherein R3 is H or Ci-3 alkyl, preferably H or methyl.
[0231] An embodiment of the disclosure is the compound of Formula 7, wherein Yi is
[0232] An embodiment of the disclosure is the compound of Formula 7, wherein A is O,
[0233] An embodiment of the disclosure is the compound of Formula 7, wherein m2 is 2, 3, 4, 5 or 6, preferably 2 or 3.
[0234] An embodiment of the disclosure is the compound of Formula 7, wherein R1 is O,
NH preferably NH.
[0235] An embodiment of the disclosure is the compound of Formula 7, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
F, CF3, cyclopropyl or cyclopropylamino.
[0236] An embodiment of the disclosure is the compound of Formula 7, wherein n is 0, 1, or 2, preferably 0 or 1.
[0237] An embodiment of the disclosure is the compound of Formula 7, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
[0238] An embodiment of the disclosure is the compound of Formula 7, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
[0239] An embodiment of the disclosure is the compound of Formula 7, wherein Z is C,
U is O or S, W is CH.
[0240] An embodiment of the disclosure is the compound of Formula 7, wherein Z is N, U is CH, W is CH
[0241] An embodiment of the disclosure is the compound of Formula 7, wherein Z is C, W is N, U is CH.
[0242] An embodiment of the disclosure is the compound of Formula 7, wherein R'" is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0243] An embodiment of the disclosure is the compound of Formula 7, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
[0244] An embodiment of the disclosure is the compound of Formula 9, wherein R3 is H or Ci-3 alkyl, preferably H or methyl.
[0245] An embodiment of the disclosure is the compound of Formula 9, wherein Yi is
[0246] An embodiment of the disclosure is the compound of Formula 9, wherein A is O,
[0247] An embodiment of the disclosure is the compound of Formula 9, wherein m2 is 2, 3, 4, 5 or 6, preferably 2 or 3.
[0248] An embodiment of the disclosure is the compound of Formula 9, wherein R1 is O, , preferably NH.
[0249] An embodiment of the disclosure is the compound of Formula 9, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H, F, CF3, cyclopropyl or cyclopropylamino.
[0250] An embodiment of the disclosure is the compound of Formula 9, wherein n is 0, 1, or 2, preferably 0 or 1.
[0251] An embodiment of the disclosure is the compound of Formula 9, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
[0252] An embodiment of the disclosure is the compound of Formula 9, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
[0253] An embodiment of the disclosure is the compound of Formula 9, wherein Z is C,
U is O or S, W is CH.
[0254] An embodiment of the disclosure is the compound of Formula 9, wherein Z is N,
U is CH, W is CH
[0255] An embodiment of the disclosure is the compound of Formula 9, wherein Z is C, W is N, U is CH.
[0256] An embodiment of the disclosure is the compound of Formula 9, wherein R'" is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0257] An embodiment of the disclosure is the compound of Formula 9, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
[0258] An embodiment of the disclosure is the compound of Formula 11, wherein R3 is H or Ci-3 alkyl, preferably H or methyl.
[0259] An embodiment of the disclosure is the compound of Formula 11, wherein Yi is
[0260] An embodiment of the disclosure is the compound of Formula 11, wherein A is O,
[0261] An embodiment of the disclosure is the compound of Formula 11, wherein m2 is 2, 3, 4, 5 or 6, preferably 2 or 3.
[0262] An embodiment of the disclosure is the compound of Formula 11, wherein R1 is
O, NH, , preferably NH.
[0263] An embodiment of the disclosure is the compound of Formula 11, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
F, CF3, cyclopropyl or cyclopropylamino.
[0264] An embodiment of the disclosure is the compound of Formula 11, wherein n is 0,
1 or 2, preferably 0 or 1.
[0265] An embodiment of the disclosure is the compound of Formula 11, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
[0266] An embodiment of the disclosure is the compound of Formula 11, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
[0267] An embodiment of the disclosure is the compound of Formula 11, wherein Z is C, U is O or S, W is CH.
[0268] An embodiment of the disclosure is the compound of Formula 11, wherein Z is N, U is CH, W is CH
[0269] An embodiment of the disclosure is the compound of Formula 11, wherein Z is C, W is N, U is CH.
[0270] An embodiment of the disclosure is the compound of Formula 11, wherein R" is
H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0271] An embodiment of the disclosure is the compound of Formula 11, wherein k is 0,
I, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
[0272] An embodiment of the disclosure is the compound of Formula 12, wherein R3 is H or Ci-3 alkyl, preferably H or methyl.
[0273] An embodiment of the disclosure is the compound of Formula 12, wherein Yi is
, preferably CH2.
[0274] An embodiment of the disclosure is the compound of Formula 12, wherein each A is independently O, NH,
An embodiment of the disclosure is the compound of Formula 12, wherein A is O, NH, , preferably O.
[0275] An embodiment of the disclosure is the compound of Formula 12, wherein m3 is 1, 2, 3, 4, 5 or 6, preferably 2 or 3.
[0276] An embodiment of the disclosure is the compound of Formula 12, wherein m4 is 0 or 1, 2 or 3, preferably 0 or 3.
[0277] An embodiment of the disclosure is the compound of Formula 12, wherein m5 is 0 or 1, 2 or 3, preferably 0 or 1.
[0278] An embodiment of the disclosure is the compound of Formula 12, wherein R1 is
O, NH, preferably NH.
[0279] An embodiment of the disclosure is the compound of Formula 12, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
F, CF3, cyclopropyl or cyclopropylamino.
[0280] An embodiment of the disclosure is the compound of Formula 12, wherein n is 0,
1 or 2, preferably 0 or 1.
[0281] An embodiment of the disclosure is the compound of Formula 12, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
[0282] An embodiment of the disclosure is the compound of Formula 12, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
[0283] An embodiment of the disclosure is the compound of Formula 12, wherein Z is C, U is O or S, W is CH.
[0284] An embodiment of the disclosure is the compound of Formula 12, wherein Z is N, U is CH, W is CH
[0285] An embodiment of the disclosure is the compound of Formula 12, wherein Z is C, W is N, U is CH.
[0286] An embodiment of the disclosure is the compound of Formula 12, wherein R"' is
H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0287] An embodiment of the disclosure is the compound of Formula 12, wherein k is 0,
I, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
[0288] An embodiment of the disclosure is the compound of Formula 14, wherein R3 is H or C1-3 alkyl, preferably H or methyl.
[0289] An embodiment of the disclosure is the compound of Formula 14, wherein Yi is , preferably CH2.
[0290] An embodiment of the disclosure is the compound of Formula 14, wherein each A is independently O, NH, An embodiment of the disclosure is the compound of Formula 14, wherein A is O, NH , preferably O.
[0291] An embodiment of the disclosure is the compound of Formula 14, wherein m3 is 1, 2, 3, 4, 5 or 6, preferably 2, 3 or 4.
[0292] An embodiment of the disclosure is the compound of Formula 14, wherein m4 is 0 , 1, 2, 3 or 4, preferably 0 or 3.
[0293] An embodiment of the disclosure is the compound of Formula 14, wherein m5 is 0 or 1, 2 or 3, preferably 0 or 1.
[0294] An embodiment of the disclosure is the compound of Formula 14, wherein R1 is
O, NH, preferably
[0295] An embodiment of the disclosure is the compound of Formula 14, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1.3 haloalkyl, C1.3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, H2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
F, CF3, cyclopropyl or cyclopropylamino.
[0296] An embodiment of the disclosure is the compound of Formula 14, wherein n is 0,
1 , or 2, preferably 0 or 1.
[0297] An embodiment of the disclosure is the compound of Formula 14, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
[0298] An embodiment of the disclosure is the compound of Formula 14, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
[0299] An embodiment of the disclosure is the compound of Formula 14, wherein Z is C, U is O or S, W is CH.
[0300] An embodiment of the disclosure is the compound of Formula 14, wherein Z is N, U is CH, W is CH
[0301] An embodiment of the disclosure is the compound of Formula 14, wherein Z is C, W is N, U is CH.
[0302] An embodiment of the disclosure is the compound of Formula 14, wherein R" is
H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0303] An embodiment of the disclosure is the compound of Formula 14, wherein k is 0,
I, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
[0304] An embodiment of the compound of Formula V-l is of the following Formula 4,
[0305] An embodiment of the disclosure is the compound of Formula 4, wherein R2 is H, OH, Ci-3 alkyl, C1-3 alkoxy, C1-3 alkylamino or NH2, preferably H, OH orML·.
[0306] An embodiment of the disclosure is the compound of Formula 4, wherein m6 is 0,
1, 2 or 3, preferably 0 or 1.
[0307] An embodiment of the disclosure is the compound of Formula 4, wherein R1 is O,
NH, preferably O or NH.
[0308] An embodiment of the disclosure is the compound of Formula 4, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, halogen or C1-3 fluoroalkyl, more preferably H or F.
[0309] An embodiment of the disclosure is the compound of Formula 4, wherein m is 0, 1,
2, 3 or 4, preferably 0 or 1.
[0310] An embodiment of the disclosure is the compound of Formula 4, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino, preferably H, halo, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, more preferably H, F or dimethylamino.
[0311] An embodiment of the disclosure is the compound of Formula 4, wherein n is 0, 1, or 2, preferably 0 or 1.
[0312] An embodiment of the disclosure is the compound of Formula 4, wherein Z is C,
U is O or S, W is CH
[0313] An embodiment of the disclosure is the compound of Formula 4, wherein Z is N, U is CH, W is CH
[0314] An embodiment of the disclosure is the compound of Formula 4, wherein Z is C, U is CH, W is N.
[0315] An embodiment of the disclosure is the compound of Formula 4, wherein R'" is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0316] An embodiment of the disclosure is the compound of Formula 4, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
[0317] An embodiment of the disclosure is the compound of Formula 4 having the structure as shown in Formula 4-1,
alkoxy, C1-3 haloalkyl, C1-3 alkylamino or C3-5 heterocycloalkyl; n is 0, 1 or 2; R is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; m is n is 0, 1 or 2; U is O or S; R1" is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen; k is 0, 1, 2, 3 or 4.
[0319] An embodiment of the disclosure is the compound of Formula 4-1, wherein R1 is NH.
[0320] An embodiment of the disclosure is the compound of Formula 4-1, wherein R" is H.
[0321] An embodiment of the disclosure is the compound of Formula 4-1, wherein R' is H.
[0322] An embodiment of the disclosure is the compound of Formula 4-1, wherein R2 is
OH.
[0323] An embodiment of the disclosure is the compound of Formula 4-1, wherein R'" is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0324] An embodiment of the disclosure is the compound of Formula 4, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
[0325] An embodiment of the disclosure is the compound of Formula 4, wherein U is S. [0326] An embodiment of the compound of Formula VI-1 is of the following Formula 16 or 17,
Formula 17 wherein m2 is 1, 2, 3, 4, 5, 6, or 7; and R1 is O, NH,
[0327] An embodiment of the disclosure is the compound of Formula 16, wherein m2 is 1,
2, 3, 4, 5 or 6, preferably 2 or 5.
[0328] An embodiment of the disclosure is the compound of Formula 16, wherein R1 is
[0329] An embodiment of the disclosure is the compound of Formula 16, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, halogen or C1-3 fluoroalkyl, more preferably H or F.
[0330] An embodiment of the disclosure is the compound of Formula 16, wherein m is 0,
1 , 2, 3 or 4, preferably 0 or 1.
[0331] An embodiment of the disclosure is the compound of Formula 16, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino, preferably H, halo, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, more preferably H, F or dimethylamino.
[0332] An embodiment of the disclosure is the compound of Formula 16, wherein n is 0,
1, or 2, preferably 0 or 1.
[0333] An embodiment of the disclosure is the compound of Formula 16, wherein Z is C, U is O or S, W is CH.
[0334] An embodiment of the disclosure is the compound of Formula 16, wherein Z is N, U is CH, W is CH
[0335] An embodiment of the disclosure is the compound of Formula 16, wherein Z is C, U is CH, W is N.
[0336] An embodiment of the disclosure is the compound of Formula 16, wherein R" is
H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0337] An embodiment of the disclosure is the compound of Formula 16, wherein k is 0,
I, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
[0338] An embodiment of the disclosure is the compound of Formula 17, wherein m2 is 1, 2, 3, 4, 5 or 6, preferably 2 or 5.
[0339] An embodiment of the disclosure is the compound of Formula 17, wherein R1 is preferably NH.
[0340] An embodiment of the disclosure is the compound of Formula 17, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, halogen or C1-3 fluoroalkyl, more preferably H or F.
[0341] An embodiment of the disclosure is the compound of Formula 17, wherein m is 0,
1 , 2, 3 or 4, preferably 0 or 1.
[0342] An embodiment of the disclosure is the compound of Formula 17, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino, preferably H, halo, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, more preferably H, F or dimethylamino.
[0343] An embodiment of the disclosure is the compound of Formula 17, wherein n is 0,
1, or 2, preferably 0 or 1.
[0344] An embodiment of the disclosure is the compound of Formula 17, wherein Z is C, U is O or S, W is CH.
[0345] An embodiment of the disclosure is the compound of Formula 17, wherein Z is N, U is CH, W is CH
[0346] An embodiment of the disclosure is the compound of Formula 17, wherein Z is C, U is CH, W is N.
[0347] An embodiment of the disclosure is the compound of Formula 17, wherein R" is
H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
[0348] An embodiment of the disclosure is the compound of Formula 17, wherein k is 0,
I, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
[0349] Some embodiments of the disclosure are the compounds having a structure depicted in Table 2, or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof.
[0350] In some embodiments, provided herein is a solvate, hydrate, salt, or ester of a compound of the present disclosure.
[0351] Certain compounds of the present disclosure are further discussed in International Patent Application No. PCT/US2020/060459, fded November 13, 2020, which claims priority to U.S. Provisional Application No. 62/935,017, fded November 13, 2019, the contents of each of which are incorporated herein by reference in their entirety.
[0352] An aspect of the disclosure is a composition, comprising a compound disclosed herein and at least one pharmaceutically acceptable excipient.
DEFINITIONS
[0353] Unless otherwise defined, all terms of art, notations, and other scientific terms or terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this application pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art. Many of the techniques and procedures described or referenced herein are well understood and commonly employed using conventional methodology by those skilled in the art.
[0354] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within
the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.
[0355] It is appreciated that certain features of the disclosure, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the disclosure, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. All combinations of the embodiments pertaining to the disclosure are specifically embraced by the present disclosure and are disclosed herein just as if each and every combination was individually and explicitly disclosed. In addition, all sub-combinations of the various embodiments and elements thereof are also specifically embraced by the present disclosure and are disclosed herein just as if each and every such sub-combination was individually and explicitly disclosed herein. When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example “Ci-6” is intended to encompass Ci, C2, C3, C4, Cs, Ce, Ci-6, C1-5, C1-4, C1-3, C1-2, C2-6, C2-5, C2-4, C2-3, C3-6, C3-5, C3-4, C4-6, C4-5, and C5-6.
[0356] “Alkyl” refers to a radical of a straight-chain or branched saturated hydrocarbon group having indicated number of carbon atoms. In some embodiments, an alkyl group has 1 to 6 carbon atoms (“Ci-6 alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“Ci-5 alkyl”). In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C1-4 alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C1-3 alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C1-2 alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“Ci alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C2-6 alkyl”). Examples of Ci-6 alkyl groups include methyl (Ci), ethyl (C2), «-propyl (C3), Ao-propyl (C3), «-butyl (C4), tert- butyl (C4), sec-butyl (C4), /.so-butyl (C4), «-pentyl (Cs), 3-pentyl (Cs), amyl (C5), neopentyl (Cs), 3 -methy 1-2-butyl (C5), tertiary amyl (C5), and «-hexyl (C6).
[0357] "Alkenyl" refers to an alkyl group with one or more carbon-carbon double bonds at any position of the chain, which can be monosub stituted or poly substituted, and can be monovalent, divalent or multivalent. Examples of the alkenyl group include a vinyl group, a propenyl group, a butenyl group, a pentenyl group, a hexenyl group, a butadienyl group, a pentadienyl group, a hexadienyl group, etc.
[0358] "Alkynyl" refers to an alkyl group with one or more carbon-carbon triple bonds at any position of the chain, which can be monosub stituted or poly sub stituted, and can be monovalent, divalent or multivalent. Examples of alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, etc.
[0359] “Cycloalkyl” includes any stable cyclic or polycyclic hydrocarbon group and any carbon atom which is saturated, which can be monosub stituted or polysubstituted, and can be monovalent, divalent or multivalent. Examples of such cycloalkyl groups include, but are not limited to, cyclopropyl, norbornyl, [2.2.2]bicyclooctane, [4.4.0]bicyclononane, etc.
[0360] "Optionally" means that an event or situation described subsequently may, but not necessarily, occur, and the description includes the occurrence of the event or situation mentioned above and the absence of the event or situation described therein.
[0361] "Substituted" means that any one or more hydrogen atoms on a particular atom are replaced with substituents, including deuterium and hydrogen variants, as long as the valence of a particular atom is normal and the substituted compound is stable. When the substituent is a keto (i.e., =0), it means that two hydrogen atoms are substituted. Ketone substitution does not occur on aromatic groups. The term "optionally substituted" means that it may or may not be substituted. Unless otherwise specified, the type and number of substituents may be arbitrary on the basis of being chemically achievable.
[0362] When any variable (e.g., R) occurs more than one time in any constituents or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted by 0-2 of R, then said group may optionally be substituted by up to two R groups and R at each occurrence
is selected independently from the definition of R. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
[0363] When the number of a bonding group is zero, for example, -(A)o-, then this bonding group is a single bond.
[0364] “Alkoxy” refers to refers to said alkyl group with a specified number of carbon atoms attached through an oxygen bridge. Unless otherwise specified, Ci-6 alkoxy includes Ci, Ci, Ci, C4, Cs and Ce alkoxy group. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentyloxy and S- pentyloxy.
[0365] "Aryl" refers to a polyunsaturated, aromatic hydrocarbon substituent which can be monosub stituted or polysubstituted, and can be monovalent, divalent or polyvalent, and can be monocyclic or polycyclic (e.g., 1 to 3 rings; at least one of which is aromatic). They are fused together or covalently linked.
[0366] "Halo" or "halogen" by itself or as part of another substituent refers to a fluorine, chlorine, bromine or iodine atom.
[0367] "Haloalkyl" includes both monohaloalkyl and polyhaloalkyl. For example, the term "halo(Ci-4)alkyl" includes, but is not limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, etc. Unless otherwise specified, examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl.
[0368] “Heterocyclo” refers to a radical of a 3 - to 10-membered non-aromatic ring or aromatic ring system having indicated ring carbon atoms (such as 2 to 6 ring carbon atoms) and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“C2-6 heterocyclo”). In heterocyclo groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. A heterocyclo group can either be monocyclic (“monocyclic heterocyclo”) or a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclo”), and can be saturated or partially unsaturated. Heterocyclo bicyclic ring systems can include one or
more heteroatoms in one or both rings. “Heterocyclo” also includes ring systems wherein the heterocyclic ring, as defined above, is fused with one or more carbocyclic groups wherein the point of attachment is either on the carbocyclic or heterocyclic ring, or ring systems wherein the heterocyclic ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclic ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclic ring system.
[0369] "Nitrogen protecting group" refers to a protecting group for preventing side reactions at the amino nitrogen position. Representative amino protecting groups include, but are not limited to formyl; acyl, such as alkanoyl (e.g., acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, such as tert-butoxycarbonyl (Boc); Arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1, 1-di -(4'-methoxyphenyl)methyl; silyl groups such as trimethyl silyl (TMS) and tert-butyldimethylsilyl (TBS), etc..
[0370] In some embodiments, a heterocyclo group is a 5-10 membered non-aromatic ring system or aromatic ring system having indicated ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur. In some embodiments, a heterocyclo group is a 5-6 membered non-aromatic ring system or aromatic ring system having indicated ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heterocyclo”). In some embodiments, the 5-6 membered heterocyclo has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclo has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclo has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
[0371] Exemplary 3-membered heterocyclo groups containing one heteroatom include, without limitation, azirdinyl, oxiranyl, and thiorenyl. Exemplary 4-membered heterocyclo groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl, and
thietanyl. Exemplary 5-membered heterocyclo groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary
5-membered heterocyclo groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclo groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclo groups containing one heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclo groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary
6-membered heterocyclo groups containing two heteroatoms include, without limitation, triazinanyl. Exemplary 7-membered heterocyclo groups containing one heteroatom include, without limitation, azepanyl, oxepanyl, and thiepanyl. Exemplary 8-membered heterocyclo groups containing one heteroatom include, without limitation, azocanyl, oxecanyl, and thiocanyl. Exemplary 5-membered heterocyclo groups fused to a Cr, aryl ring (also referred to herein as a 5,6-bicyclic heterocyclic ring) include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like. Exemplary 6-membered heterocyclo groups fused to an aryl ring (also referred to herein as a 6,6-bicyclic heterocyclic ring) include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
[0372] The term “pharmaceutically acceptable salt” means a salt that is not harmful to mammals, especially humans. Pharmaceutically acceptable salts can be formed using non-toxic acids or bases, including mineral acids or inorganic bases, or organic acids or organic bases. Examples of pharmaceutically acceptable salts include metal salts formed with aluminum, calcium, lithium, magnesium, potassium, sodium, zinc and so on, and organic salts formed with lysine, N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), procaine and so on. Also, pharmaceutically acceptable salts contain acid-addition salts and base-addition salts.
[0373] The term “solvate” means a solvent-containing compound that is formed by association of one or a plurality of solvent molecules to the compounds of the present disclosure. Solvates include, for example, monosolvates, disolvates, trisolvates, and tetrasolvates. Also, solvates include hydrates. The term “hydrate” means a compound further containing a stoichiometric or a non-stoichiometric amount of water constrained by non-covalent bonding intermolecular force, or a salt thereof. Hydrates include monohydrates, dihydrates, trihydrates, tetrahydrates, and the like.
[0374] Certain ranges are presented herein with numerical values being preceded by the term “about.” The term “about” is used herein to provide literal support for the exact number that it precedes, as well as a number that is near to or approximately the number that the term precedes. In determining whether a number is near to or approximately a specifically recited number, the near or approximating unrecited number may be a number which, in the context in which it is presented, provides the substantial equivalent of the specifically recited number. If there are uses of the term which are not clear to persons of ordinary skill in the art, given the context in which it is used, “about” will mean up to plus or minus 10% of the particular term. [0375] A “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult, or senior adult)) and/or other non-human animals, for example, mammals (e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or dogs) and birds (e.g., commercially relevant birds such as chickens, ducks, geese, and/or turkeys). In certain embodiments, the animal is a mammal. The animal may be a male or female and at any stage of development. A non-human animal may be a transgenic animal.
[0376] The terms “administer,” “administering,” or “administration,” refers to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing an inventive compound, or a pharmaceutical composition thereof.
[0377] The terms “treatment,” “treat,” and “treating” refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a “pathological condition” (e.g., a disease, disorder, or condition, or one or more signs or symptoms thereof) described herein. In some embodiments, treatment may be administered after one or more signs or symptoms of the disease have developed or have been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of the disease or condition. For example, treatment may be administered to a susceptible subj ect prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence.
[0378] The terms “condition,” “disease,” and “disorder” are used interchangeably.
[0379] An “effective amount” of a compound or a composition refers to an amount sufficient to elicit the desired biological response, i.e., treating the condition. As will be appreciated by those of ordinary skill in this art, the effective amount of a compound or a composition may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject. An effective amount encompasses therapeutic and prophylactic treatment.
[0380] A “therapeutically effective amount” of a compound or a composition is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to delay or minimize one or more symptoms associated with the condition. A therapeutically effective amount of a compound or a composition means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces, or avoids symptoms or causes of the condition, or enhances the therapeutic efficacy of another therapeutic agent.
[0381] The terms “alpha-synuclein”, “a-synuclein” and “a-Syn” are used interchangeably herein and refer to a 140 amino acid polypeptide with the following amino acid sequence (wild-type human a-synuclein).
Table 1
[0382] The terms “aggregated a-synuclein”, “a-synuclein aggregate” and “a-synuclein aggregates" are used interchangeably herein.
[0383] For E3 ubiquitin ligase, an exemplary amino acid sequence is shown in Table 2.
Table 2
[0384] For E3 ubiquitin ligase, another exemplary amino acid sequence is shown in Table 3.
Table 3
[0385] The term “binder” refers to a compound that binds to a protein. The binder binds to a protein with a Kd of less than 50,000 nM, less than 20,000 nM, less than 10,000 nM, less than 5,000 nM, less than 2,500 nM, less than 1,000 nM, less than 900 nM, less than 800 nM, less than 700 nM, less than 600 nM, less than 500 nM, less than 400 nM, less than 300 nM, less than 200 nM, less than 100 nM, less than 90 nM, less than 80 nM, less than 70 nM, less than 60 nM, less than 50 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, or less than 1 nM.
[0386] The term “proteasome” refers to a protease complex for carrying out degradation of proteins. Specifically, the proteasome is a multisubunit enzyme complex, which can also play a key role regulating proteins that control cell-cycle progression and apoptosis. The proteasome conducts proteolysis of selected proteins.
[0387] The term “pharmaceutically acceptable excipient” means pharmaceutically acceptable materials, compositions, or vehicles such as physiological saline solutions, liquid or solid fillers, diluents, solvents, or encapsulants. Examples of pharmaceutically acceptable excipients include water, saline water, physiological saline water or phosphate buffered saline water (PBS), sodium chloride injection solution, Ringer’s injection solution, isotonic dextrose injection solution, sterile water injection solution, dextrose, and lactated Ringer’s injection solution.
Synthesis of Compounds
[0388] The compounds of the present disclosure can be prepared by a variety of synthetic methods well known to those skilled in the art, including the embodiments listed below, combinations thereof with other chemical synthesis methods, and equivalent alternatives known to those skilled in the art.
[0389] The following synthetic procedures are provided as examples, using which one of ordinary skill in the art can synthesize the compounds of the disclosure.
[0390] Compounds of Formula (II
[0391] Compounds of the general formula (I) are prepared as set forth in the Scheme below:
[0392] Compounds of Formula (ID
[0393] Compounds of the general formula (II) are prepared as set forth in the Scheme below:
[0394] Compounds of Formula (III)
[0395] Compounds of the general formula (III) are prepared as set forth in the Scheme below:
[0396] Compounds of Formula (I VI
[0397] Compounds of the general formula (IV) are prepared as set forth in the Scheme below:
[0398] Compounds of Formula (V)
[0399] Compounds of the general formula (V) are prepared as set forth in the Scheme below:
[0400] Compounds of Formula (VI)
[0401] Compounds of the general formula (VI) are prepared as set forth in the Scheme below:
[0402] Other compounds within the scope of the disclosure are synthesized by methods like these, and by analogy with methods set forth in the Examples below. Additional synthetic methods can be found in WO2019214681, WO2018102067 and WO2019014429, all of which are incorporated herein by reference in full.
Methods of Treatment
[0403] Another aspect of the present disclosure is a method for aiding in the treatment of a synucleinopathy in a subject, the method comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound as disclosed herein, or a composition as disclosed herein.
[0404] Another aspect of the present disclosure is a method of treating a subject (e.g., a human) suffering from a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein, the method comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound as disclosed herein or a composition as disclosed herein.
[0405] Another aspect of the present disclosure is a method for prophylaxis of a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject, the method comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound or a composition as disclosed herein.
[0406] In another aspect, provided herein are methods of treating a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject, the method comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound or a pharmaceutical composition described herein.
[0407] In another aspect, provided herein are methods of lessening the severity of a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject, the methods comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound or a pharmaceutical composition described herein.
[0408] In another aspect, provided herein are methods of delaying the progression of a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject, the methods comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound or a pharmaceutical composition described herein.
[0409] In another aspect, provided herein are methods of reducing the risk of developing a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject, the methods comprising, consisting essentially of, or consisting of administering to the subject at risk of developing the disease an effective amount of a compound or a pharmaceutical composition described herein.
[0410] In another aspect, provided herein are methods of delaying the onset of a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject at risk of developing the disease, the methods comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound or a pharmaceutical composition described herein.
[0411] In some embodiments, the subject to be treated exhibits one or more symptoms (signs) of synucleinopathies, such as neuropsychiatric manifestations (depression, dementia, hallucinations, anxiety, apathy, anhedonia), autonomic changes (orthostatic hypotension, bladder disturbances, constipation, fecal incontinence, sialorrhea, dysphagia, sexual dysfunction, changes in cerebral blood flow), sensory changes (olfactory, pain, color discrimination abnormal sensations), sleep disorders (REM sleep behavior disorder (RBD), restless legs syndrome/periodic extremity movements, hypersomnia, insomnia), or other signs and symptoms (fatigue, diplopia, blurred vision, seborrhea, weight loss/gain).
[0412] In some embodiments, the subject to be treated does not exhibit one or more symptoms of a synucleinopathy, but is known to have a genetic risk for developing a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in the brain. For instance, such an individual may have one or more relatives with the disease, or their risk is determined by analysis of genetic or biochemical markers. For example, mutations in SNCA (PARK1, encoding a-synuclein), including A30P, E46K, H50Q, G51D, and A53T, as well as duplications and triplications of the entire SNCA gene cause autosomal dominant forms of PD. Mutations in LRRK2 (PARKS, Leucine-rich repeat kinase 2) and mutations in VPS35 (PARK17, vacuolar protein sorting 35) also cause autosomal dominant forms of PD (Hernandez et al., (2016) Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. Journal of Neurochemistry 10.1111/jnc.13593). Mutations in PINK1 (PARK6, PTEN-induced kinase 1), DJ-1 (PARK7), Parkin (PARK2), ATP13A2 (PARK9, ATPase type 13A2), FBX07 (PARK 15, F-box only protein 7), and PLA2 GB (PARK14, phospholipase A2, group VI) have been shown to cause autosomal recessive PD/parkinonism. In addition, 28 different genetic risk loci associated with PD and related synucleinopathies have been identified including SNCA, LRRK2, GBA/SYT11, MAPT, HLA-DRB5, GAK, GCH1, NUCKS1/RAB7L1, SLC41A1, BST1, SIPA1L2,
ACM SD/TMEM 163, STK39, MCCC1, TMEM 175/GAK/DGKQ, FAM47E/SCARB2, GPNMB, FGF20, INPP5F, MIR4697, CCDC62, GCH1, VPS13C, BCKDK/STX1B, SREBF/RAIl, RIT2 and DDRGK1 (Nails et al. (2014) Large-scale meta-analysis of
genome-wide association data identifies six new risk loci for Parkinson's disease. Nature Genetics 46(9): 989-993). Accordingly, in prophylactic applications, the antibodies described herein, or pharmaceutical compositions comprising the same, are administered to a patient susceptible to, or otherwise at risk of the disease in a regime (dose, frequency and route of administration) effective to reduce the risk, lessen the severity, or delay the onset of at least one sign or symptom of the disease. In some prophylactic applications, the regime is effective to inhibit or delay accumulation of a-synuclein in the brain, and/or inhibit or delay its toxic effects and/or inhibit or delay development of behavioral deficits in the patient.
[0413] In some embodiments, the methods described above generate a beneficial therapeutic response in a patient (e.g., reduction of a-synuclein aggregates in the brain, improved cognitive function, and/or reversing, treating or preventing cognitive decline) in the subject. Accordingly, in some embodiments, the compounds or the pharmaceutical compositions described herein are administered to a patient suspected of, or already suffering from a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a regime (dose, frequency and route of administration) effective to ameliorate or at least inhibit further deterioration of at least one sign or symptom of the disease. In some therapeutic applications, the regime is effective to reduce or at least inhibit further increase of levels of a-synuclein, associated toxicities, and/or behavioral deficits. In certain embodiments, the treatments can result in, e.g., a reduction of a-synuclein aggregates in the brain by 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more, relative to before initiating treatment or as compared to a population of untreated control patients.
[0414] In some embodiments, the disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in the brain is Parkinson's disease (including idiopathic Parkinson's disease), DLB, DLBD, LBVAD, pure autonomic failure, Lewy body dysphagia, incidental LBD, inherited LBD (e.g., mutations of SNCA (PARKl), LRRK2 (PARK8), VP S35 (PARK 17), PINK1 (PARK6), DJ-1 (PARK7), Parkin (PARK2), ATP13A2 (PARK9), FBX07 (PARK 15) and PLA2 GB (PARK 14)), or multiple system
atrophy (MSA; e.g., olivopontocerebellar atrophy, striatonigral degeneration and Shy-Drageri syndrome).
[0415] Also provided are methods for preserving or increasing synaptic density and/or dentritic density, as measured using markers of synapse formation (synaptophysin) and/or dendrites (MAP2). Accordingly, in some embodiments, subjects treated with the compounds or the compositions described herein exhibit an elevation of synaptic or dendritic density of 10% or more, 20% or more, 30% or more, 40% or more, or 50% or more, relative to before initiating treatment or as compared to a population of untreated control patients.
A. ADMINISTRATION
[0416] After formulation with an appropriate pharmaceutically acceptable excipient in a desired dosage, the pharmaceutical compositions of the present disclosure can be administered to humans and other animals orally, parenterally, intracisternally, intraperitoneally, intrathecally, intraventricularly, topically, bucally, or the like, depending on the disease or condition being treated.
[0417] In certain embodiments, a pharmaceutical composition comprising a compound of the disclosure is administered orally or parenterally, at dosage levels sufficient to deliver from about 0.001 mg/kg to about 200 mg/kg in one or more doses for one or several days. In some embodiments, the effective amount per dose varies from about 0.001 mg/kg to about 200 mg/kg, about 0.001 mg/kg to about 100 mg/kg, about 0.01 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, from about 0.1 mg/kg to about 40 mg/kg, from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic and/or prophylactic effect. In some embodiments, the compounds described herein are at dosages sufficient to deliver from about 0.001 mg/kg to about 200 mg/kg, from about 0.001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, from about 0.1 mg/kg to about 40 mg/kg, from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, or from about 1 mg/kg to about 25 mg/kg, of subj ect body
weight per day, one or more times a day, to obtain the desired therapeutic and/or prophylactic effect. The desired dosage may be delivered three times a day, twice a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks. In some embodiments, the dosage is delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations). In some embodiments, the composition described herein is administered at a dose that is below the dose at which the agent causes non-specific effects.
B. COMPOSITIONS
[0418] Pharmaceutical compositions described herein can be prepared by methods generally known in the art of pharmacology. In general, such methods include the steps of combining the compound of the disclosure with a carrier and/or one or more other accessory ingredients, and then shaping and/or packaging the product into a desired single- or multi-dose unit.
[0419] Pharmaceutical compositions can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses. As used herein, a “unit dose” is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage, such as, for example, one-half or one-third of such a dosage.
[0420] Pharmaceutically acceptable excipients used in the manufacture of pharmaceutical compositions include inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, stabilizers, buffering agents, lubricating agents, and/or oils. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents may also be present in the composition.
[0421] Suitable diluents include calcium carbonate, sodium carbonate, calcium phosphate, calcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose,
sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, and mixtures thereof.
[0422] Suitable granulating and/or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose, and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate
[0423] All publications and patent applications mentioned in this disclosure are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. [0424] No admission is made that any reference cited herein constitutes prior art. The discussion of the references states what their authors assert, and the inventors reserve the right to challenge the accuracy and pertinence of the cited documents. It will be clearly understood that, although a number of information sources, including scientific journal articles, patent documents, and textbooks, are referred to herein; this reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art.
[0425] The discussion of the general methods given herein is intended for illustrative purposes only. Other alternative methods and alternatives will be apparent to those of skill in the art upon review of this disclosure, and are to be included within the spirit and purview of this application.
EXAMPLES
[0426] The following examples are provided as a further guide for those of ordinary skill in the art, and are not intended to limit the scope of the claimed invention in any way.
[0427] In general in the examples below, chemicals were purchased from Sinopharm Chemical Reagent Co. (SCRC), Sigma- Aldrich, Alfa, or other vendors. 'H NMR and 19F NMR spectra were recorded on a Bruker AVIII 400 or Bruker A VIII 500 spectrometer. [0428] LCMS measurement was run on an Agilent 1200 HPLC/6100 SQ System using the following conditions: Method A: Mobile Phase: A: Water (0.01% TFA) B: CAN (0.01% TFA); Gradient Phase: 5%B increasing to 95%B within 1.4 min, 95%B with 1.6 min (total runtime: 3 min); Flow Rate: 2.3 mL/min; Column: SunFire C18, 4.6*50 mm, 3.5 pm; Column Temperature: 50°C. Detectors: ADC ELSD, DAD (214 nm and 254 nm), ES-API. Method B: Mobile Phase: A: Water (10 mMNFEHCCri) B: Acetonitrile; Gradient Phase: 5% to 95%B within 1.5 min, 95%B with 1.5 min (total runtime: 3 min); Flow Rate: 2.0 mL/min; Column: XBridge C18, 4.6*50 mm, 3.5 pm; Column Temperature: 40°C. Detectors: ADC ELSD, DAD (214 nm and 254 nm), MSD (ES-API). Method C: Mobile Phase: A: Water (10 mM H4HC03)B: Acetonitrile; Gradient Phase: 5% to 95%B within 1.5 min, 95%B with 1.5 min (total runtime: 3 min); Flow Rate: 2.0 mL/min; Column: XBridge C18, 4.6*50mm, 3.5 pm; Column Temperature: 40°C. Detectors: ADC ELSD, DAD (214 nm and 254 nm), MSD (ES-API).
[0429] Abbreviations: THF - tetrahydrofuran; DMF - N,N-dimethylformamide; EtOAc - ethyl acetate; DCM - dichloromethane; MeOH - methanol; EtOH - ethanol; TEA - triethanolamine; TFA - trifluoroacetic acid; RT - room temperature.
[0430] Additional embodiments are disclosed in further detail in the following examples, which are provided by way of illustration and are not in any way intended to limit the scope of this disclosure or the claims. While particular alternatives of the present disclosure have been disclosed, it is to be understood that various modifications and combinations are possible and are contemplated within the true spirit and scope of the appended claims. There is no intention, therefore, of limitations to the exact abstract and disclosure herein presented.
Example 1: Synthesis of Compound 159985
methylpropan-2-yl ioxycarbonyllaininolethoxylethoxylethoxylethoxylethoxylethyl 4-methylbenzenesulfonate: To a solution of tert-butyl
N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]carbamate (500 mg, 1.12 mmol) in DMF (10 mL) was added with NaFI (107.49 mg, 4.48 mmol) at 0°C and stirred at RT for 1 h. 2-[2-[2-[2-[2-[2-(4-methylphenyl)- sulfonyloxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (2.65 g, 4.48 mmol) in DMF (10 mL) was added to the reaction mixture and stirred at RT for 14 h. The mixture was quenched by adding water at 0°C and then extracted with EtOAc (200 mL). The organic layer was washed with water (100 mL), brine (100 mL), dried over Na2SC>4, concentrated and purified by column chromatography (DCM:MeOH = 10: 1, Rf = 0.7) to give 2-[2-[2-[2-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]-[(2- methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (compound 159835, 603 mg, 0.70 mmol, 62% yield) as a pale-yellow solid.
[0432] (B) tert- butyl
N-l 2-14-16-(di methyl ami no)pyridin-3-yl Iphenyl |-L3-benzothiazol-6-yl |-N-|2-|2-|2-|2-|2-(2 -iodoethoxylethoxylethoxylethoxylethoxylethyllcarbamate: A mixture of 2-[2-[2-[2-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]-[(2- methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (200 mg, 0.23 mmol) and Nal (42 mg, 0.28 mmol) in CH3CN (5 mL) was heated at 80°C for 20 h. The residue was taken up in DCM (50 mL) and water (50 mL). The organic layer was washed with water (50 mL), brine (50 mL) dried over Na2SC>4 and concentrated to give tert-butyl
N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzo- thiazol-6-yl]-N-[2-[2-[2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (compound 159890, 185.1 mg, 0.23 mmol, 98% yield) as a yellow solid.
[0433]
phenyl1-L3-benzothiazol-6-yllcarbamate: A mixture of
2-[2,6-bis(oxo)piperidin-3-yl]-5-hydroxy-isoindole-l,3-dione (67 mg, 0.24 mmol), K2CO3 (51 mg, 0.37 mmol) and tert-butyl
N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]-N-[2-[2-[2-[2-[2-(2 -iodoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (100 mg, 0.12 mmol) in DMF (5 mL) was heated at 50°C for 5 h. The mixture was quenched with water and then extracted with DCM (200 mL). The organic layer was dried overlSfeSCL, concentrated, and purified by column chromatography on silica gel (DCM:MeOH = 20:1, Rf = 0.52) to give tert-butyl N-[2-[2-[2-[2-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-l,3-bis(oxo)isoindol-5-yl]oxyethoxy]eth oxy]ethoxy]ethoxy]- ethoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]- carbamate (53 mg, 0.05 mmol, 45% yield) as a pale-yellow solid.
ethoxylisoindole- 1 3 -dione: To a solution of tert-butyl N-[2-[2-[2-[2-[2-[2-[2-[2,6-bis(oxo)- piperidin-3-yl]-l,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N -[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]carbamate (52 mg, 0.05 mmol) in DCM (5 mL) was added TFA (0.08 mL, 1.08 mmol) and stirred at RT for 20 h. The mixture was poured into ice water and neutralized with sat. NaHCCri solution to pH 8. The residue was taken up in DCM (20 mL) and water (10 mL). The organic layer was washed with water (10 mL), brine (10 mL), dried over Na2SC>4 and concentrated to dryness to give 2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[2-[2-[2-[2-[[2-[4-[6-(dimethylamino)- pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]- ethoxy]isoindole- 1,3 -dione (compound 159985, 41 mg, 0.05 mmol, 83% yield) as a yellow solid. ¾ NMR (400 MHz, DMSO-de). MS (ESI) m/z 867 (M+H)+.
Example 2: Synthesis of Compound 160219
[0435] (A) Compound 160087: To a solution of tert-butyl
N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]carbamate (500 mg, 1.12 mmol) in DMF (10 mL) was added NaH (107 mg, 4.48 mmol) at 0°C and stirred at room temperature for 1 h. 2-[2-(4-Methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate (1.86 g, 4.48 mmol) in DMF (10 mL) was added to the reaction mixture and stirred at room temperature for 14 h. The mixture was cooled to 0°C and quenched with water. The precipitation was collected by filtration, washed with water and purified by column chromatography (DCM:MeOH = 20:1, Rf = 0.68) to give 2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]-[(2-methylpropa n-2-yl)oxycarbonyl]amino]ethoxy]ethyl 4-methylbenzenesulfonate (595 mg, 0.86 mmol, 77% yield) as a yellow solid.
[0436] (B) Compound 160150: A mixture of
2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]- phenyl]-l,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethyl 4-methylbenzenesulfonate (595 mg, 0.86 mmol), Nal (156 mg, 1.04 mmol) in MeCN (15 mL) was heated at 80°C for 17 h. The residue was taken up in DCM (50 mL) and water (50 mL). The organic layer was washed with water (50 mL), brine (50 mL), dried over Na2SCL and concentrated to give tert-butyl
N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzo- thiazol-6-yl]-N-[2-(2-iodoethoxy)ethyl]carbamate (449 mg, 0.70 mmol, 81% yield) as a yellow solid.
[0437] (C) Compound 160159: A mixture of
2-[2,6-bis(oxo)piperidin-3-yl]-5-hydroxy-isoindole-l,3-dione (96 mg, 0.35 mmol), K2CO3 (96 mg, 0.70 mmol), tert-butyl N-[2-[4-[6-(di- methylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]-N-[2-(2-iodoethoxy)ethyl]- carbamate (150 mg, 0.23 mmol) in DMF (5 mL) was heated at 50°C for 5 h. Water (10 mL) was added to the mixture and the resulting precipitation was collected by filtration. The residue was purified by column chromatography (DCM:EtOAc = 5:2, Rf = 0.32) to give
tert-butyl N-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-l,3-bis(oxo)isoindol-5-yl]- oxyethoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]- carbamate (121 mg, 0.15 mmol, 66% yield) as a yellow solid.
[0438] (D) Compound 160219: To a solution of tert-butyl N-[2-[2-[2-[2,6-bis-
(oxo)piperidin-3-yl]-l,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethyl]-N-[2-[4-[6-(dimethylamino )pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]carbamate (120 mg, 0.15 mmol) inDCM (5 mL) was added TFA (0.23 mL, 3.03 mmol), and the mixture stirred at room temperature for 20 h. The mixture was poured into ice water and neutralized with sat. NaHCCb to pH 8. The residue was taken up in DCM (20 mL) and water (10 mL). The organic layer was washed with water (10 mL), brine (10 mL), dried over Na2S04, and concentrated to dryness to give 2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-b enzothiazol-6-yl]amino]ethoxy]ethoxy]isoindole-l,3-dione (21 mg, 0.03 mmol, 18% yield) as a yellow solid.
Example 3; Synthesis of Compound 160939
[0439] (A) Compound 160812: To a solution of tert-butyl
N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]carbamate (500 mg,
1.12 mmol) in DMF (10 mL) was added NaH (107 mg, 4.48 mmol) at 0°C and stirred at RT for 1 h. 2-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (1125 mg, 2.24 mmol) in DMF (5 mL) was added to the reaction mixture and stirred at RT for 22 h. The mixture was taken up in water (50 mL) and DCM (50 mL). The organic layer was washed with water (50 mL), brine (50 mL) dried over Na2SCL, concentrated and purified by column chromatography on silica gel (EtOAc:DCM= 1 :5, Rf = 0.13) to give 2-[2-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]- phenyl]-l,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]- ethoxy]ethyl 4-methylbenzenesulfonate (733 mg, 0.94 mmol, 84% yield) as a yellow solid. [0440] (B) Compound 160829: A mixture of
2-[2-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]- phenyl]-l,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]- ethoxyjethyl 4-methylbenzenesulfonate (333 mg, 043 mmol) and Nal (109 mg, 0.73 mmol) in CFLCN (10 mL) was heated at 80°C for 15 h. The solvent was removed by vacuo and the residue was re-dissolved in EtOAc. The mixture was washed with water (50 mL), brine (50 mL), dried over MgSCL and concentrated to give tert-butyl N-[2-[4-[6-(di methyl ami no)pyridin-3-yl]-
phenyl]-l,3-benzothiazol-6-yl]-N-[2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethyl]carbamate (112 mg, 0.15 mmol, 36% yield) as a yellow solid.
[0441] (C) Compound 160889: A mixture of tert-butyl
N-[2-[4-[6-(dimethylamino)pyridin-3-yl]- phenyl]-3a,7a-dihydro-l,3-benzothiazol-6-yl]-N-[2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]- ethyljcarbamate (112 mg, 0.15 mmol), CS2CO3 (149.09 mg, 0.46 mmol) and dimethyl 4-hydroxybenzene-l,2-dicarboxylate (64 mg, 0.30 mmol) in DMF (2 mL) was stirred at 50°C for 1 h. The mixture was cooled to RT and added with water. The precipitation was collected by filtration and then purified by column chromatography (EtOAc:DCM = 1 : 1, Rf = 0.33) to give dimethyl 4-[2-[2-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzo- thiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]- ethoxy]benzene-l,2-dicarboxylate (102 mg, 0.13 mmol, 82% yield) as a yellow solid.
[0442] (D) Compound 160901: To a solution of dimethyl 4-[2-[2-[2-[2-[[2-[4-[6-(di- methylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxy- carbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]benzene-l,2-dicarboxylate (102 mg, 0.13 mmol) in EtOH (2 mL) was added NaOH (40 mg, 1 mmol) in water (2 mL). The resulting mixture was stirred at RT for 40 h. The reaction was diluted with EtOAc (10 mL) and acidified with IN HC1 solution to pH 1. The organic layer was washed with water (10 mL), brine (10 mL) dried over Na2SC>4 and concentrated to dryness to give 4-[2-[2-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]- phenyl]-l,3-benzothiazol-6-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]phthalic acid (86 mg, 0.13 mmol, 99.9% yield) as an orange solid.
[0443] (E) Compound 160939: A mixture of
4-[2-[2-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]amino]e thoxy]ethoxy] ethoxy] ethoxy ]phthalic acid (122 mg, 0.18 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (32 mg, 0.20 mmol) in pyridine (5 mL) was heated at 120°C for 19 h. The mixture was cooled to RT, diluted with DCM (100 mL) and washed with water (50 mL) and brine (50 mL). The organic layer was collected, dried over
Na2SC>4, concentrated and purified by column chromatography (MeOH: DCM = 1 : 10, Rf = 0.73) to afford 2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[2-[2-[[2-[4-[6-(dimethyl- amino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]- isoindole-l,3-dione (49 mg, 0.06 mmol, 35% yield) as a yellow solid.
Example 4: Synthesis of Compound 161103
[0444] (A) Compound 160891: To a solution of tert-butyl
N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]carbamate (500 mg,
1.12 mmol) in DMF (10 mL) was added NaH (107 mg, 4.48 mmol) at 0°C and stirred at RT for 1 h. 5-(4-methylphenyl)sulfonyloxypentyl 4-methylbenzenesulfonate (1.85 g, 4.48 mmol) in DMF (10 mL) was added to the reaction mixture and stirred at RT for 17 h. The mixture
was cooled to 0°C and quenched with water. The resulting precipitation was collected by filtration and purified by column chromatography (DCM:EtOAc = 4:1, Rf = 0.7) to give 5-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]-[(2-methylpropan- 2-yl)oxycarbonyl]amino]pentyl 4-methylbenzenesulfonate (604 mg, 0.88 mmol, 79% yield) as a yellow solid.
[0445] (B) Compound 160938: A mixture of dimethyl
4-hydroxybenzene-l,2-dicarboxylate (122 mg, 0.58 mmol), CS2CO3 (285 mg, 0.87 mmol), KI (5 mg, 0.03 mmol) and 5-[[2-[4-[6-(dimethyl- amino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxy carbonyl]- amino]pentyl 4-methylbenzenesulfonate (200 mg, 0.29 mmol) in DMF (2 mL) was heated at 50°C for 2 h. The reaction was quenched with water. The resulting solid was collected by filtration and washed with water to give dimethyl 4-[5-[[2-[4-[6-(dimethylamino)pyridin-3- yl]phenyl]-l,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]pentoxy]benz ene-l,2-dicarboxylate (206 mg, 0.28 mmol, 98% yield) as a yellow solid.
[0446] (C) Compound 160999: A solution of dimethyl 4-[5-[[2-[4-[6-(dimethylamino) pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]- pentoxy]benzene-l,2-dicarboxylate (100 mg, 0.14 mmol) in EtOH (2 mL) was added NaOH (110 mg, 2.76 mmol) in water (2 mL) and stirred at RT for 40 h. The reaction was neutralized to pH 1 with IN HC1 solution. The precipitation was collected by filtration and washed with water to afford
4-[5-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]-[(2-methylpropa n-2-yl)oxycarbonyl]amino]pentoxy]phthalic acid (93 mg, 0.13 mmol, 97% yield) as a yellow solid.
[0447] (D) Compound 161054: A mixture of
4-[5-[[2-[4-[6-(dimethylamino)pyridin-3-yl]- phenyl]-l,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]pentoxy]phthalic acid (93 mg, 0.13 mmol), and 3-aminopiperidine-2,6-dione hydrochloride (48 mg, 0.29 mmol) in pyridine (3 mL) was heated at 120°C for 40 h. Water was then added to the mixture.
The precipitate was collected by filtration and purified by column chromatography
(DCM:EtOAc = 4:1, Rf = 0.28) to afford tert-butyl
N- [5 -[2-[2,6-bi s(oxo)piperi din-3 -yl] - 1 ,3 -bi s(oxo)i soindol-
5-yl]oxypentyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]car bamate (61 mg, 0.08 mmol, 58% yield) as a yellow solid.
[0448] (E) Compound 161103: A solution of tert-butyl
N-[5-[2-[2,6-bis(oxo)piperidin-3-yl]- l,3-bis(oxo)isoindol-5-yl]oxypentyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-b enzothiazol-6-yl]carbamate (61 mg, 0.08 mmol) in DCM (5 mL) was added TFA (0.12 mL, 1.55 mmol) and stirred at RT for 6 h. The mixture was poured into iced water and neutralized with sat. NaHCCb solution to pH 8. The residue was taken up in DCM (20 mL) and water (10 mL). The organic layer was washed with water (10 mL), brine (10 mL), dried over INfeSCri, and concentrated to dryness to give 2-[2,6-bis(oxo)piperidin-3-yl]-5-[5-[[2-[4-[6-(dimethyl- amino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]amino]pentoxy]isoindole-l,3-dione (44 mg, 0.06 mmol, 80% yield) as a yellow solid.
Example 5: Synthesis of Compound 160273
[0449] (A) Compound 160210: A mixture of
3-(6-hydroxy-3-oxo-lH-isoindol-2-yl)piperidine-2,6-dione (95 mg, 0.37 mmol), K2CO3 (101
mg, 0.73 mmol), tert-butyl N-[2-[4-[6-(dimethyl- amino)pyridin-3-yl]phenyl]-l,3-benzothiazol- 6-yl]-N-[2-[2-[2-[2-[2-(2-iodoethoxy)- ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (200 mg, 0.24 mmol) in DMF (5 mL) was heated at 50°C for 5 h. The mixture was quenched with water and extracted with DCM (200 mL). The organic layer was collected, dried over Na2SC>4, concentrated and purified by column chromatography (DCM:MeOH = 20: 1, Rf = 0.48) to give tert-butyl N-[2-[2-[2-[2-[2-[2-[[2-[2,6-bis(oxo)piperidin-3-yl]-l-oxo-3H-isoindol-5-yl]- oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]p henyl]-l,3-benzothiazol-6-yl]carbamate (83 mg, 0.09 mmol, 36% yield) as a pale-yellow solid.
[0450] (B) Compound 160273: To a solution of tert-butyl
N-[2-[2-[2-[2-[2-[2-[[2-[2,6-bis(oxo)- piperidin-3-yl]-l-oxo-3H-isoindol-5-yl]oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]- ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]carbamate (83 mg, 0.09 mmol) in DCM (5 mL) was added TFA (0.13 mL, 1.74 mmol) and stirred at RT for 7 h. The mixture was poured into ice water and neutralized with sat. NaHCCh solution to pH 8. The residue was taken up in DCM (20 mL) and water (10 mL). The organic layer was washed with water (10 mL), brine (10 mL) dried over Na2SC>4 and concentrated to dryness to give 3-[6-[2-[2-[2-[2-[2-[2-[[2-[4-[6-(dimethylamino)- pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]- ethoxy]ethoxy]-3-oxo-lH-isoindol-2-yl]piperidine-2,6-dione (73 mg, 0.08 mmol, 92% yield) as a yellow solid.
Example 6: Synthesis of Compound 160313
[0451] (A) Compound 160284: A mixture of 3-(6-hydroxy-3-oxo-lH-isoindol-2-yl)- piperidine-2,6-dione (58 mg, 0.22 mmol), K2CO3 (61 mg, 0.44 mmol), tert-butyl N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]-N-[2-(2- iodoethoxy)ethyl]carbamate (95 mg, 0.15 mmol) in DMF (2 mL) was heated at 50°C for 5 h. Water (10 mL) was added to the mixture. The resulting precipitate was collected by filtration and then purified by column chromatography (DCM:MeOH = 20: 1, Rf = 0.52) to give tert-butyl N-[2-[2-[[2-[2,6-bis(oxo)piperidin-3-yl]-l-oxo-3H-isoindol-5-yl]oxy]ethoxy]- ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]carbamate (57 mg, 0.07 mmol, 50% yield) as a yellow solid.
[0452] (B) Compound 160313: To a solution of tert-butyl
N-[2-[2-[[2-[2,6-bis(oxo)piperidin-3-yl]-l-oxo-3H-isoindol-5-yl]oxy]ethoxy]ethyl]-N-[2-[4 -[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]carbamate (54 mg, 0.07 mmol) in DCM (5 mL) was added TFA (0.11 mL, 1.39 mmol), and the mixture stirred at room temperature for 20 h. The mixture was poured into ice water and neutralized with sat. NaHCCb solution to pH 8. The residue was taken up in DCM (20 mL) and water (10 mL). The organic layer was washed with water (10 mL), brine (10 mL), dried over Na2SC>4, and concentrated to dryness to give
3-[6-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-
6-yl]amino]ethoxy]ethoxy]-3-oxo-lH-isoindol-2-yl]piperidine-2,6-dione (39 mg, 0.05 mmol, 77% yield) as a yellow solid.
[0453] Compound 162640 were synthesized according to methods similar to Example 6. [0454] ¾ NMR (600 MHz, DMSO-d6) d 10.97 (s, 1H), 8.36 (s, 1H), 8.24 (d, J= 2.3 Hz,
1H), 8.01-8.05 (m, 4H), 7.72 (d, J= 8.4 Hz, 2H), 7.62 (d, J= 8.4 Hz, 1H), 7.52 (d, J= 9.7 Hz, 1H), 7.17 (d, = 1.7 Hz, 1H), 7.05-7.09 (m, 2H), 6.81-6.85 (m, 2H), 6.61 (t, J= 5.8 Hz, 1H), 5.07 (dd, J= 13.2, 5.1 Hz, 1H), 4.36 (d, J= 17.2 Hz, 1H), 4.19-4.27 (m, 4H), 3.79-3.85 (m, 7H), 3.66 (t, J= 5.8 Hz, 3H), 3.48-3.54 (m, 3H), 2.85-2.93 (m, 1H), 1.92-1.99 (m, 1H).
Example 8: Synthesis of Compound 162842
[0455] Compound 162842 were synthesized according to methods similar to Example 6. [0456] ¾ NMR (600 MHz, DMSO-d6) d 10.96 (s, 1H), 8.50 (d, J= 2.5 Hz, 1H), 8.40 (s,
1H), 8.13 (d, J= 6.6 Hz, 1H), 7.99 (d, J= 8.2 Hz, 2H), 7.89 (dd, J= 8.9, 2.5 Hz, 1H), 7.68 (d, J= 8.2 Hz, 2H), 7.60 (d, J= 8.4 Hz, 1H), 7.19 (s, 1H), 7.08 (d, J= 8.4 Hz, 1H), 6.79 (t, J= 7.4 Hz, 1H), 6.75 (d , J= 8.9 Hz, 1H), 6.70 (d, J= 7.4 Hz, 1H), 5.06 (dd, J= 13.2, 5.1 Hz, 1H), 4.35-4.38 (m, 2H), 4.32 (d , J= 17.2 Hz, 1H), 4.28 (dd, J= 8.2, 4.5 Hz, 2H), 4.20 (d, J= 17.2 Hz, 1H), 3.96-3.99 (m, 2H), 3.92-3.95 (m, 2H), 3.08 (s, 7H), 2.85-2.93 (m, 1H), 2.26-2.37 (m, 2H), 1.91-1.98 (m, 2H).
Example 9: Synthesis of Compound 162903
[0457] Compound 162903 were synthesized according to methods similar to Example 6. [0458] 1HNMR(600MHz, DMS-d6) d 10.97 (s, 1H), 8.63 (d,7=2.4 Hz, 1H), 8.12 (s, 1H), 8.08 (d, J= 8.0 Hz, 1H), 8.03 (dd, J= 8.9, 2.6 Hz, 1H), 7.99 (d, J = 8.9 Hz, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.78 (d, 7= 2.4 Hz, 1H), 7.63 (d, 7= 8.4 Hz, 1H), 7.18-7.21 (m, 1H), 7.08 (dd, 7 = 8.4, 2.4 Hz, 1H), 6.79 (d, 7 = 8.8 Hz, 1H), 5.08 (dd, 7= 13.4, 5.1 Hz, 1H), 4.38 (d, 7 = 17.2 Hz, 1H), 4.22-4.29 (m, 4H), 3.89 (dd, 7 = 9.2, 5.0 Hz, 3H), 3.11 (s, 3H), 2.56-2.63 (m, 1H), 2.33-2.40 (m, 1H).
Example 10: Synthesis of Compound 163123
[0459] Compound 163123 were synthesized according to methods similar to Example 6. [0460] ¾ NMR (600 MHz, DMSO-d6) d 10.97 (s, 1H), 8.56 (d, 7= 2.5 Hz, 1H), 8.06 (d, 7 = 8.4 Hz, 2H), Ί: 92-7.96 (m, 2H), 7.82 (d, 7= 8.4 Hz, 2H), 7.74 (d, 7= 2.5 Hz, 1H), 7.62 (d, 7 = 8.4 Hz, 1H), 7.13-7.18 (m, 2H), 7.07 (dd, 7= 8.4, 2.1 Hz, 1H), 6.77 (d, 7= 9.0 Hz, 1H), 5.07 (dd, 7 = 13.4, 5.2 Hz, 1H), 4.35 (d, 7 = 17.1 Hz, 1H), 4.22-4.27 (m, 6H), 3.85-3.91 (m, 5H), 3.10 (s, 7H), 2.85-2.96 (m, 1H), 2.55-2.63 (m, 2H), 2.31-2.42 (m, 2H).
Example 11: Synthesis of Compound 163365
[0461] Compound 163365 were synthesized according to methods similar to Example 6. [0462] ¾ NMR (600 MHz, DMSO-d6) d 10.96 (s, 1H), 8.57 (d, = 2.5 Hz, 1H), 8.16 (d, J = 8.4 Hz, 2H), 8.09 (s, 1H), 7.96 (dd, J= 8.9, 2.4 Hz, 1H), 7.86 (d, J= 8.4 Hz, 2H), 7.68 (d, J = 8.7 Hz, 1H), 7.62 (d, J= 8.4 Hz, 1H), 7.45 (d, 7= 2.1 Hz, lH), 7.18 (s, 1H), 7.08 (d, J= 8.3
Hz, 1H), 7.02 (dd, J= 8.7, 2.2 Hz, 1H), 6.77 (d, J= 8.9 Hz, 1H), 5.07 (dd, J= 13.3, 5.2 Hz, 1H), 4.36 (d, J= 17.2 Hz, 1H), 4.22-4.28 (m, 5H), 3.86-3.91 (m, 3H), 3.10 (s, 5H), 2.84-2.94 (m, 2H).
Example 12; Synthesis of Compound 161247
[0463] (A) Compound 161084: To a solution of tert-butyl
N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]carbamate (200 mg, 0.45 mmol) in DMF (3 mL) was added NaH (32 mg, 1.34 mmol) at 0°C. The resulting mixture was stirred at RT for 1 h.
2-[2-[2-[2-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (454 mg, 0.90 mmol) was added to the reaction mixture and stirred at RT for 22 h. The mixture was quenched with water. The precipitation was collected by filtration and purified by column chromatography (EtOAC:DCM= 2: 3, Rf = 0.48) to give tert-butyl N-[2-[2-[2-[2-[2-[tert-butyl-
(dimethyl)silyl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin -3-yl]phenyl]-l,3-benzothiazol-6-yl]carbamate (235 mg, 0.30 mmol, 67% yield) as a yellow solid.
[0464] (B) Compound 161112: To a solution of tert-butyl N-[2-[2-[2-[2-[2-[tert-butyl-(di- methyl)- silyl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]- phenyl]-l,3-benzothiazol-6-yl]carbamate (235 mg, 0.30 mmol) in THF (5 mL) was added 1 M TBAF solution in THF (1.81 mL, 1.81 mmol) dropwise. The reaction mixture was stirred at RT for 7 h. The reaction mixture was concentrated to dryness and the residue was taken up in EtOAc (100 mL). The mixture was washed with water (100 mL) and brine (100 mL). The organic layer was collected, dried over Na2SC>4 and concentrated to give tert-butyl N-[2-[4-[6-(dimethylamino)- pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]-N-[2-[2-[2-[2-(2 -hydroxy ethyl oxy)ethoxy]- ethoxy]ethoxy]ethyl]carbamate (200 mg, 0.30 mmol, 99.7% yield) as a yellow solid.
[0465] (C) Compound 161181: To a solution of tert-butyl
N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]-N-[2-[2-[2-[2-(2-h ydroxyethyloxy)ethoxy]ethoxy]ethoxy]ethyl]carbamate (120 mg, 0.18 mmol) in THF (3 mL) was added NaH (9 mg, 0.36 mmol) at 0°C and stirred for 30 min. tert-Butyl 2-bromoethanoate (0.08 mL, 0.54 mmol) was then added and the mixture was heated at 50°C for 8 h. The solvent was removed by vacuum. The residue was purified by column chromatography (EtOAc:DCM = 2:3, Rf = 0.35) to afford tert-butyl
2-[2-[2-[2-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]-[(2-
methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanoate (84 mg, 0.11 mmol, 60% yield) as a yellow solid.
[0466] (D) Compound 161218: A mixture of tert-butyl 2-[2-[2-[2-[2-[2-[[2-[4-[6-(di- methylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxy- carbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanoate (84 mg, 0.11 mmol) and TFA (0.12 mL, 1.61 mmol) in DCM (2 mL) was stirred at RT for 23 h. The mixture was acidified to pH 1 with IN HC1 solution. The mixture was extracted with DCM. The organic layer was washed with brine, dried over Na2SC>4 and was concentrated to dryness to afford 2-[2-[2-[2-[2-[2-[[2-[4-[6-(dimethyl- amino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]- ethoxy]ethanoic acid (60 mg, 0.10 mmol, 89% yield) as a yellow solid.
[0467] (E) Compound 161247: A mixture of
(2S,4R)-l-[(2S)-2-amino-3,3-dimethyl-butanoyl]-N-[[4-(4-methyl-l,3-thiazol-5-yl)phenyl] methyl]-4-hydroxy-pyrrolidine-2-carboxamide (45 mg, 0.11 mmol), 2-[2-[2-[2-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]- amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanoic acid (60 mg, 0.10 mmol), DIPEA (0.03 mL, 0.14 mmol) and HATU (73 mg, 0.19 mmol) in anhydrous DMF (3 mL) was stirred at RT for 18 h. The mixture was diluted with DCM, washed with water and brine, dried over Na2SC>4, concentrated and purified by column chromatography on NH silica gel (MeOH:DCM = 97:3, Rf = 0.48) to give rac-(2R,4S)-N-[[4-(4-methyl-l,3-thiazol-5-yl)phenyl]methyl]-4-hydroxy-l-[rac-(2R)-2-[2-[ 2-[2-[2-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]- amino] ethoxy ] ethoxy] - ethoxy]ethoxy]ethoxy]ethanoylamino]-3,3-dimethyl-butanoyl]pyrrolidine-2-carboxamide (16 mg, 0.01 mmol, 14% yield) as a yellow solid.
Example 13: Synthesis of Compound 160275
[0468] (A) Compound 160161: To a solution of NaH (81 mg, 2.02 mmol) in DMF (1 mL) was added tert-butyl
N-[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbamate (300 mg, 0.67 mmol) in DMF (6 mL) at 0°C and stirred at 25°C for 30 min.
2-[2-[2-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (794 mg, 1.34 mmol) in DMF (3 mL) was added to the reaction mixture and heated at 50°C for 2 h. The mixture was quenched with saturated NHiCl solution and extracted with DCM. The organic layer was washed with brine, dried over MgSCU, concentrated and purified by column chromatography (MeOH:DCM = 3:97, Rf = 0.3) to afford
2-[2-[2-[2-[2-[2-[[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-[(2- methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (273 mg, 0.32 mmol, 47% yield) as a yellow oil.
[0469] (B) Compound 160244: A mixture of
2-[2-[2-[2-[2-[2-[[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-[(2- methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (270 mg, 0.31 mmol) and Nal (56.18 mg, 0.37 mmol) in CH3CN (5 mL) was heated at 80°C for 19 h. The mixture was diluted with DCM and extracted with water (50 mL) and brine (50 mL). The organic layer was dried over MgSCri and concentrated to dryness to afford tert-butyl
N-[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-N-[2-[2-[2-[2-[2-(2 -iodoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (256 mg, 0.31 mmol, 99.9% yield) as an orange oil.
[0470] (C) Compound 160252: A mixture of
2-[2,6-bis(oxo)piperidin-3-yl]-5-hydroxy-isoindole-l,3-dione (102 mg, 0.37 mmol), K2CO3 (77 mg, 0.56 mmol) and tert-butyl N-[5-[4-[6-(di- methylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-N-[2-[2-[2-[2-[2-(2-iodoethoxy)- ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (153 mg, 0.19 mmol) in DMF (4 mL) was heated at 50°C for 18 h. The mixture was diluted with DCM (200 mL) and extracted with water. The organic layer was collected, dried over MgSCri, concentrated and purified by column chromatography (MeOfLDCM = 5:95, Rf = 0.3) to give tert-butyl N-[2-[2-[2-[2-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-l,3-bis(oxo)isoindol-5-yl]oxy ethoxy]- ethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]- phenyl]pyridin-2-yl]carbamate (61 mg, 0.06 mmol, 34% yield) as a yellow solid.
[0471] (D) Compound 160275: To a solution of tert-butyl N-[2-[2-[2-[2-[2-[2-[2-[2,6-bis-
(oxo)piperidin-3-yl]-l,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]- ethoxy]ethyl]-N-[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]- carbamate (61 mg, 0.06 mmol) in DCM (1 mL) was added TFA (0.5 mL, 6.53 mmol) at 0°C. The resulting mixture was stirred at RT for 5 h. The solution was neutralized with saturated NaHCCh solution at 0°C and extracted with DCM. The organic layer was washed with brine, dried over MgSCL, concentrated and purified by column chromatography on NH silica gel
(MeOH:DCM = 99: 1, Rf = 0.3) to afford
2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[2-[2-[2-[2-[[5-[4-[6-(dimethylamino)-l,3-benzothiaz ol-2-yl]phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]- ethoxy]ethoxy]ethoxy]ethoxy]isoindole-l,3-dione (51 mg, 0.05 mmol, 86% yield) as a yellow solid.
Example 14: Synthesis of Compound 161177
[0472] (A) Compound 161026: A mixture of dimethyl 4-hydroxyphthalate (139 mg, 0.62 mmol), CS2CO3 (303 mg, 0.93 mmol), tert-butyl N-[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]- phenyl]pyridin-2-yl]-N-[2-(2-iodoethoxy)ethyl]carbamate (200 mg, 0.31 mmol) in DMF (5 mL) was heated at 50°C for 1 h. The mixture was quenched with water and extracted with DCM. The organic layer was dried over MgSCri, concentrated and purified by column chromatography (EtOAc:Hex = 1:1, Rf = 0.4) to give dimethyl 4-[2-[2-[[5-[4-[6-(dimethylamino)-l,3-benzo- thiazol-2-yl]phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]- ethoxy]benzene-l,2-dicarboxylate (148 mg, 0.20 mmol, 66% yield) as a yellow solid.
[0473] (B) Compound 161083: To a solution of dimethyl
4-[2-[2-[[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-[(2-methylpr opan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]benzene-l,2-dicarboxylate (148 mg, 0.20 mmol) in MeOH (1 mL) and water (1 mL) was added LiOH (39 mg, 1.63 mmol). The reaction mixture was stirred at RT for 5 days. The solution was acidified with 1 N HC1 to pH 4~5. The resulting precipitate was collected by filtration, washed with water and dried over vacuo to afford
4-[2-[2-[[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-[(2-methylpr opan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]phthalic acid (119 mg, 0.17 mmol, 84% yield) as a yellow solid.
[0474] (C) Compound 161115: A mixture of
4-[2-[2-[[5-[4-[6-(dimethylamino)-l,3-benzo- thiazol-2-yl]phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]- ethoxy]phthalic acid (119 mg, 0.17 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (31 mg, 0.19 mmol) in pyridine (2 mL) was heated at 120°C for 2 days. The mixture was concentrated to dryness and purified by column chromatography (MeOH:DCM = 5:95, Rf = 0.3) to afford tert-butyl
N-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-l,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethyl]-N-[5-[4 -[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbamate (39 mg, 0.05 mmol, 29% yield) as a yellow solid.
[0475] (D) Compound 161177: To a solution of tert-butyl N-[2-[2-[2-[2,6-bis(oxo)- piperidin-3-yl]-l,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethyl]-N-[5-[4-[6-(dimethyl- amino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbamate (39 mg, 0.05 mmol) in DCM (1 mL) was added TFA (1 mL, 13.06 mmol) at 0°C. The resulting mixture was stirred at RT for 2 h. The solution was neutralized with sat. NaHCCb solution and extracted with DCM. The organic layer was washed with brine, dried over MgS04, concentrated and purified by chromatography (MeOH:DCM = 1:99, Rf= 0.1) to afford 2-[2,6-bis(oxo)-
piperidin-3-yl]-5-[2-[2-[[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-y l]amino]ethoxy]ethoxy]isoindole-l,3-dione (11 mg, 0.02 mmol, 31% yield) as ayellow solid.
Example 15: Synthesis of Compound 160383
[0476] (A) Compound 160366: A mixture of
3-(6-hydroxy-3-oxo-lH-isoindol-2-yl)piperidine-2,6-dione (63 mg, 0.24 mmol), K2CO3 (51 mg, 0.37 mmol), tert-butyl N-[5-[4-[6-(dimethyl- amino)-l, 3-benzothiazol-2-yl]phenyl]pyri din-2 -yl]-N-[2-[2-[2-[2-[2-(2-iodoethoxy)ethoxy]- ethoxy]ethoxy]ethoxy]ethyl]carbamate (100 mg, 0.12 mmol) in DMF (2 mL) was heated at 50°C for 3 h. The mixture was quenched with water, extracted with DCM (200 mL) dried over MgSCri, concentrated and purified by chromatography (MeOH:DCM = 5:95, Rf = 0.3) to afford tert-butyl
N-[2-[2-[2-[2-[2-[2-[[2-[2,6-bis(oxo)piperidin-3-yl]-l-oxo-3H-isoindol-5-yl]oxy]ethoxy]- ethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]- phenyl]pyridin-2-yl]carbamate (26 mg, 0.03 mmol, 22% yield) as a yellow solid.
[0477] (B) Compound 160383: To a solution of tert-butyl
N-[2-[2-[2-[2-[2-[2-[[2-[2,6-bis(oxo)- piperidin-3-yl]-l-oxo-3H-isoindol-5-yl]oxy]ethoxy]ethoxy]ethoxy]-
ethoxy]ethoxy]ethyl]-N-[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-y ljcarbamate (26 mg, 0.03 mmol) in DCM (1 mL) was added TFA (0.5 mL, 6.53 mmol) at 0°C and the mixture was stirred at RT for 3 h. The solution was neutralized with sat. NaHCCb solution at 0°C and then extracted with DCM. The organic layer was washed with brine, dried over MgSCri, concentrated and purified by chromatography (MeOH:DCM = 5:95, Rf = 0.2) to afford 3-[6-[2-[2-[2-[2-[2-[2-[[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]- phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]- ethoxy]ethoxy]-3-oxo-lH-isoindol-2-yl]piperidine-2,6-dione (9 mg, 0.01 mmol, 33% yield) as a yellow solid.
Example 16; Synthesis of Compound 160744
[0478] (A) Compound 160690: To a solution of
2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[l,2-a]pyridin-6-ol (400 mg, 1.15 mmol) in DMF (10 mL) was added NaH (184 mg, 4.59 mmol) at 0°C and stirred at RT for 1 h. 2-[2-[2-[2-[2-[2-(4-methylphenyl)sulfonyloxy- ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (2 mL, 4.13 mmol) was added to the mixture and stirred at RT for 14 h under argon. The mixture was diluted with DCM (10 mL), washed with water (10 mL) and brine (10 mL). The organic layer was collected, dried over Na2SC>4, concentrated and purified by column chromatography (DCM:MeOH = 50:1, Rf = 0.29) to give
2-[2-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo- [ 1 ,2-a]pyridin-6-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzene- sulfonate (520 mg, 0.68 mmol, 59% yield) as pale yellow solid.
[0479] (B) Compound 160707: A mixture of
2-[2-[2-[2-[2-[2-[2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[l,2-a]pyri din-6-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (520 mg, 0.68 mmol) and Nal (122 mg, 0.81 mmol) in CH3CN (6 mL) was heated at 80°C for 5 h. The mixture was added water and extracted with DCM. The organic layer was washed with water (20 mL), brine (20 mL), dried over Na2S04, concentrated and purified by chromatography (MeOH:DCM = 1:50, Rf = 0.39) to give
6-fluoro-5-[4-[6-[2-[2-[2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]- imidazo[l,2-a]pyridin-2-yl]phenyl]-N,N-dimethyl-pyridin-2-amine (427 mg, 0.59 mmol, 87% yield) as pale-yellow solid.
[0480] (C) Compound 160744: A mixture of
2-[2,6-bis(oxo)piperidin-3-yl]-5-hydroxy-isoindole-l,3-dione (114 mg, 0.41 mmol), CS2CO3 (202 mg, 0.62 mmol) and
6-fluoro-5-[4-[6-[2-[2-[2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3,8a-d ihydroimidazo[l,2-a]pyridin-2-yl]phenyl]-N,N-dimethyl-pyridin-2-amine (150 mg, 0.21 mmol) in DMF (3 mL) was heated at 50°C for 20 h. The mixture was quenched with water and the resulting precipitation was collected by filtration. The residue was purified by column chromatography (MeOH:DCM = 1 :20, Rf = 0.34) to give 2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[2-[2-[2-[2-[2-[4-[6-(dimethyl- amino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[l,2-a]pyridin-6-yl]oxyethoxy]ethoxy]- ethoxy]ethoxy]ethoxy]ethoxy]isoindole-l,3-dione (28 mg, 0.03 mmol, 15% yield) as brown solid.
[0481] ¾ NMR (400 MHz, DMSO-d6) d 11.09 (s, 1H), 8.28 (s, 1H), 8.23 (d, J= 2.3Hz,
1H), 7.97 (d, J= 7.8, 2H), 7.87 (dd, J= 10.8, 8.4Hz, 1H), 7.81 (d, J= 8.4Hz, 1H), 7.57 (d, J= 7.8Hz, 2H), 7.50 (d, J= 9.7 Hz, 1H), 7.43 (d, J= 2.3Hz, 1H), 7.34 (dd, J= 8.4, 2.3 Hz, 1H),
7.05 (dd, J= 9.7, 2.3 Hz, 1H), 6.63 (dd, .7= 8.4, 2.0 Hz, 1H), 5.11 (dd, J= 12.9, 5.5 Hz, 1H), 4.25-4.32 (m, 2H), 4.06-4.14 (m, 2H), 3.74-3.79 (m, 4H), 3.47-3.63 (m, 18H), 3.06 (s, 6H), 2.80-2.96 (m, 2H).
Example 17: Synthesis of Compound 161111
[0482] (A) Compound 160947: To a solution of
2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[l,2-a]pyridin-6-ol (400 mg, 1.15 mmol) in dry DMF (8 mL) was added NaH (0.14 g, 3.44 mmol) at 0°C and stirred at RT for 1 h. 2- [2-(4-methylphenyl)sulfonyloxy ethoxy] ethyl 4-methylbenzenesulfonate (1.43 g, 3.44 mmol) was added to the mixture and stirred at the same temperature for 16 h. The reaction was quenched with water and extracted with DCM. The organic layer was washed with water, brine, dried over Na2SC>4, concentrated and purified by column chromatography on silica gel (EtOAc:DCM = 1:5, Rf = 0.33) to give 2-[2-[2-[4-[6-(di- methylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[l,2-a]pyridin-6-yl]oxyethoxy]ethyl 4-methylbenzenesulfonate (227 mg, 0.38 mmol, 33% yield) as orange solid.
[0483] (B) Compound 160997: A mixture of dimethyl
4-hydroxybenzene-l,2-dicarboxylate (161 mg, 0.77 mmol), CS2CO3 (374.2 mg, 1.15 mmol),
KI (6 mg, 0.04 mmol) and
2-[2-[2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[l,2-a]pyridin-6-yl]oxy ethoxy]ethyl 4-methylbenzenesulfonate (226 mg, 0.38 mmol) in DMF (4 mL) was heated at 50°C for 4 h. The mixture was quenched with water and the resulting precipitation was collected by filtration and washed with water to give dimethyl 4- [2- [2-[2- [4- [6-(dimethylamino)-2-fluoro-pyridin-3 -yl] - phenyl]imidazo[l,2-a]pyridin-6-yl]oxyethoxy]ethoxy]benzene-l,2-dicarboxylate (212 mg, 0.34 mmol, 88% yield) as an orange solid.
[0484] (C) Compound 161006: To a solution of dimethyl
4-[2-[2-[2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[l,2-a]pyridin-6-yl] oxyethoxy]ethoxy]benzene-l,2-dicarboxylate (211 mg, 0.34 mmol) in MeOH (2 mL) was added NaOH (443 mg, 11.08 mmol) in water (2 mL) and stirred at RT for 5 days. The reaction was diluted with EtOAc (50 mL) and acidified with 1 N HC1 solution to pH 1. The organic layer was washed with water (50 mL), brine (50 mL) dried over Na2SC>4 and concentrated to give 4-[2-[2-[2-[4-[6-(dimethyl- amino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[l,2-a]pyridin-6-yl]oxyethoxy]ethoxy]phthalic acid (185 mg, 0.31 mmol, 92% yield) as a yellow solid.
[0485] (D) Compound 161111: A mixture of
4-[2-[2-[2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[l,2-a]pyridin-6-yl] oxyethoxy]ethoxy]phthalic acid (67 mg, 0.11 mmol), and 3-aminopiperidine-2,6-dione hydrochloride (20 mg, 0.15 mmol) in pyridine (3 mL) was heated at 120°C for 14 h. The solvent was removed by vacuum. The residue was redissolved in DCM and water was added. The resulting precipitate was collected by filtration and purified by column chromatography (MeOH DCM = 1 : 100, Rf = 0 19) to afford 2-[2,6-bis(oxo)- piperidin-3-yl]-5-[2-[2-[2-[4-[6-(dimethylamino)-2-fluoro-pyridin-3-yl]phenyl]imidazo[l,2- a]pyridin-6-yl]oxyethoxy]ethoxy]isoindole-l,3-dione (18 mg, 0.02 mmol, 22% yield) as a yellow solid.
Example 18: Synthesis of Compound 161215
[0486] (A) Compound 160806: To a solution of NaH (138 mg, 3.45 mmol) in DMF (2 mL) was added tert-butyl
N-[6-fluoro-5-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]carbamate (500 mg, 1.15 mmol) in DMF (10 mL) at 0°C. The resulting mixture was stirred at room temperature for 30 min. 2-[2-(4-Methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzene- sulfonate (954 mg, 2.30 mmol) in DMF (3 mL) was added to the reaction mixture and stirred at room temperature for 21 h. The mixture was quenched with saturated NFLCl solution and extracted with EtOAc. The organic layer was washed with brine, dried over MgSCri, concentrated and purified by column chromatography (EtOAc:DCM = 3:17, Rf = 0.3) to afford
2-[2-[[6-fluoro-5-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]-[(2-methyl
propan-2 -yl)oxycarbonyl]amino]ethoxy]ethyl 4-methylbenzenesulfonate (339 mg, 0.50 mmol, 44% yield) as a yellow solid.
[0487] (B) Compound 160814: A mixture of
2-[2-[[6-fluoro-5-[4-(6-methoxyimidazo[l,2-a]- pyridin-2-yl)phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethyl 4-methylbenzenesulfonate (339 mg, 0.50 mmol) and Nal (90 mg, 0.60 mmol) in MeCN (10 mL) was heated at 80°C for 19 h. The mixture was added to water and extracted with EtOAc. The organic layer was washed with water (50 mL), brine (50 mL), dried over MgSCU, concentrated, and purified by column chromatography (EtOAc:DCM = 1 :9, Rf = 0.3) to afford tert-butyl
N-[6-fluoro-5-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]-N-[2-(2-iodoe thoxy)ethyl]carbamate (197 mg, 0.31 mmol, 62% yield) as a yellow solid.
[0488] (C) Compound 161091: A mixture of dimethyl 4-oxobenzene-l,2-dicarboxylate
(131 mg, 0.62 mmol), CS2CO3 (305 mg, 0.93 mmol), tert-butyl N- [6-fluoro-5 - [4-(6-methoxyimidazo-
[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]-N-[2-(2-iodoethoxy)ethyl]carbamate (197 mg, 0.31 mmol) in DMF (5 mL) was heated at 50°C for 1 h. The mixture was quenched with water, extracted with DCM, dried over MgSCri, concentrated, and purified by column chromatography (EtOAc:hexane = 1:1, Rf = 0.3) to give dimethyl 4-[2-[2-[[6-fluoro-5-[4-(6-methoxyimidazo-
[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]- ethoxy]ethoxy]benzene-l,2-dicarboxylate (147 mg, 0.21 mmol, 66% yield) as a yellow solid. [0489] (D) Compound 161105: To a solution of dimethyl
4-[2-[2-[[6-fluoro-5-[4-(6-methoxy- imidazo[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxy carbonyl]- amino]ethoxy]ethoxy]benzene-l,2-dicarboxylate (147 mg, 0.21 mmol) in MeOH (2 mL) was added NaOH (66 mg, 1.65 mmol) in water (2 mL), and the mixture stirred at room temperature for 3 days. The reaction was neutralized with IN HC1 solution to pH 1. The
precipitate was collected by filtration and washed with water to give 4-[2-[2-[[6-fluoro-5-[4-(6-methoxyimidazo[l,2-a]- pyridin-2-yl)phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]- ethoxy]phthalic acid (135 mg, 0.20 mmol, 96% yield) as a white solid.
[0490] (E) Compound 161183: A mixture of
4-[2-[2-[[6-fluoro-5-[4-(6-methoxyimidazo[l,2-a]- pyridin-2-yl)phenyl]pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]- ethoxy]phthalic acid (135 mg, 0.20 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (49 mg, 0.29 mmol) in pyridine (2 mL) was heated at 120°C for 20 h. The mixture was concentrated to dryness, and purified by column chromatography on NH silica gel (MeOH:DCM = 1 :99, Rf = 0.1) to afford tert-butyl N-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-l,3-bis(oxo)isoindol-5-yl]oxy- ethoxy]ethyl]-N-[6-fluoro-5-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyri din-2 -yl] carbamate (47 mg, 0.06 mmol, 30% yield) as a yellow solid.
(F) Compound 161215: To a solution of tert-butyl
N-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-l,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethyl]-N-[6-flu oro-5-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]carbamate (47 mg, 0.06 mmol) in DCM (1 mL) was added TFA (1 mL, 13 mmol) at 0°C, and the mixture stirred at room temperature for 2 h. The solution was neutralized with saturated NaHCCb solution and extracted with DCM. The organic layer was washed with brine, dried over MgS04, concentrated and purified by chromatography on NH silica gel (MeOH:DCM = 1:99, Rf = 0.1) to afford
2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[[6-fluoro-5-[4-(6-methoxyimidazo[l,2-a]pyridin-2-y l)phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]isoindole-l,3-dione (17 mg, 0.02 mmol, 38% yield) as a yellow solid. ¾NMR (400 MHz, DMSO-d6) d 11.07 (s, 1H), 8.28 (s, 1H), 8.19 (d, J= 2.3 Hz, 1H), 7.92 (d, J= 8.3 Hz, 2H), 7.79 (d, J= 8.3 Hz, 1H), 7.70 (dd, J= 10.3, 8.2 Hz, 1H), 7.46-7.52 (m, 3H), 7.43 (d, J= 2.2 Hz, 1H), 7.34 (dd, J= 8.2, 2.3 Hz, 1H), 7.14 (t, J= 5.7 Hz, 1H), 7.01 (dd, J= 10.3, 2.2 Hz, 1H), 6.49 (d, = 8.5 Hz, 1H), 5.08 (dd, J= 13.1, 5.3 Hz,
1H), 4.34-4.28 (m, 2H), 3.75-3.83 (m, 5H), 3.62 (t, J= 5.5 Hz, 2H), 3.39-3.44 (m, 2H), 2.77-2.91 (m, 1H), 2.49-2.66 (m, 2).
Example 19: Synthesis of Compound 161409
Compound 161409 could be synthesized by method similar to example 19.
1HNMR (400 MHz, DMSO-d6) d 11.09 (s, 1H), 8.27 (s, 1H), 8.19 (d, J= 2.5 Hz, 1H), 7.92 (d,
J= 8.0 Hz, 2H), 7.78 (d, J= 8.4 Hz, 1H), 7.71 (dd, J= 10.2, 8.6 Hz, 1H), 7.45-7.53 (m, 3H), 7.41 (d, J= 2.0 Hz, 1H), 7.32 (dd, J= 8.6, 2.1 Hz, 1H), 7.13 (t, = 5.3 Hz, 1H), 7.00 (dd, J = 9.7, 1.6 Hz, 1H), 6.49 (d, J= 9.2 Hz, 1H), 5.07 (dd, J= 12.8, 5.3 Hz, 1H), 4.24-4.29 (m, 2H),
3.77 (s, 3H), 3.72-3.76 (m, 2H), 3.44-3.58 (m, 20H), 3.34-3.41 (m, 3H), 2.77-2.91 (m, 2H).
Example 20: Synthesis of Compound 161104
[0491] (A) Compound 160937: To a solution of tert-butyl
2-[4-[6-[(2-methylpropan-2-yl)oxycarbonylamino]pyridin-3-yl]- phenyl]pyrrolo[2,3-c]-pyridine-l-carboxylate (500 mg, 1.03 mmol) in DMF (10 mL) was added NaH (49 mg, 1.23 mmol) at 0°C and stirred at RT for 30 min. 2-[2-[2-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (789 mg, 1.34 mmol) was added to the reaction mixture and stirred at RT for 6 h. The mixture was quenched with sat. H4CI solution and extracted with DCM. The organic layer was washed with brine, dried over MgSCri, concentrated and purified by column chromatography (EtOAc:DCM = 1 :4, Rf = 0.33) to afford tert-butyl 2-[4-[6-[2-[2-[2-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]ethoxy]- ethoxy]ethyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pyridin-3-yl]phenyl]pyrrolo- [2,3 -c]pyri dine- 1-carboxylate (280 mg, 0.31 mmol, 30% yield) as pale-yellow oil.
[0492] (B) Compound 160987: A solution of dimethyl 4-hydroxybenzene-l,2-di- carboxylate (130.05 mg, 0.62 mmol), CS2CO3 (303 mg, 0.93 mmol), and tert-butyl 2-[4-[6-[2-[2-[2-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy ]ethyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pyridin-3-yl]phenyl]pyrrolo[2,3-c]pyridin e- 1-carboxylate (280 mg, 0.31 mmol) in DMF (3 mL) was heated at 50°C for 3 h. The mixture was quenched with water and the resulting precipitation was collected by filtration. The solid was then purified by column chromatography (EtOAc:DCM = 4: 1, Rf = 0.32) to provide dimethyl
4-[2-[2-[2-[2-[2-[2-[(2-methylpropan-2-yl)oxycarbonyl-[5-[4-[l-[(2-methylpropan-2-yl)oxy carb ony 1 ]py rrol o [2, 3 -c] -
pyridin-2-yl]phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]benze ne-l,2-dicarboxylate (98 mg, 0.10 mmol, 34% yield) as pale-yellow oil.
[0493] (C) Compound 161004: To a solution of dimethyl 4-[2-[2-[2-[2-[2-[2-[(2-methyl- propan-2-yl)oxycarbonyl-[5-[4-[l-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolo[2,3-c]pyridi n-2-yl]- phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]benzene-l,2-di- carboxylate (98 mg, 0.10 mmol) in EtOH (5 mL) was added NaOH (33 mg, 0.83 mmol) in water (5 mL) and stirred at RT for 4 days. The reaction was diluted with DCM (10 mL) and acidified with 1 N HC1 solution to pH 1. The organic layer was washed with water (10 mL), brine (10 mL) dried over Na2SC>4 and concentrated to dryness to give 4-[2-[2-[2-[2-[2-[2-[[5-[4-[l-[(2-methyl- propan-2-yl)oxycarbonyl]pyrrolo[2,3-c]pyridin-2-yl]phenyl]pyridin-2-yl]amino]ethoxy]- ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]phthalic acid (79 mg, 0.10 mmol, 93% yield) as pale-yellow solid.
[0494] (D) Compound 161045: A mixture of 4-[2-[2-[2-[2-[2-[2-[[5-[4-[l-[(2-methyl- propan-2-yl)oxycarbonyl]pyrrolo[2,3-c]pyridin-2-yl]phenyl]pyridin-2-yl]amino]ethoxy]- ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]phthalic acid (79 mg, 0.10 mmol) and 3-aminopiperidine-2,6-dione HC1 (18 mg, 0.11 mmol) in pyridine (3 mL) was heated at 120°C for 42 h. The solvent was removed in vacuo. The residue was re-dissolved in with DCM (10 mL), washed with brine, dried over Na2S04, concentrated and purified by column chromatography (MeOH: DCM= 1:19, Rf = 0.3) to give tert-butyl 2-[4-[6-[2-[2-[2-[2-[2-[2-[2-[2,6-bis(oxo)piperidin-3-yl]-l,3-bis(oxo)- isoindol-5-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]pyridin-3-yl]phenyl]- pyrrolo[2,3-c]pyridine-l-carboxylate (22 mg, 0.02 mmol, 25 % yield) as a yellow solid [0495] (E) Compound 161104: To a solution of tert-butyl
2-[4-[6-[2-[2-[2-[2-[2-[2-[2-[2,6-bis(oxo)- piperidin-3-yl]-l,3-bis(oxo)isoindol-5-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl- amino]pyridin-3-yl]phenyl]pyrrolo[2,3-c]pyridine-l-carboxylate (22 mg, 0.02 mmol) in
DCM (3 rtiL) was added TFA (0.03 mL, 0.36 mmol), and the mixture stirred at RT for 42 h. The mixture was neutralized with sat. NaHCCh to pH 8 and extracted with DCM (10 mL). The organic layer was washed with brine, dried over ISfeSCL and concentrated to dryness to give 2-[2,6-bis(oxo)piperidin-3-yl]-5-[2-[2-[2-[2-[2-[2-[[5-[4-(lH-pyrrolo- [2,3-c]pyridin-2-yl)phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]- ethoxy]isoindole-l,3-dione (15 mg, 0.02 mmol, 73% yield) as a yellow solid.
Example 21: Synthesis of Compound 160624
160624 (51 mg, 85%)
[0496] Compound 160557: A mixture of
3-(6-oxidanyl-3-oxidanylidene-lH-isoindol-2-yl)piperidine-2,6-dione (169 mg, 0.65 mmol), CS2CO3 (317 mg, 0.97 mmol), tert-butyl
N-[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-N-[2-(2-iodanyleth oxy)ethyl]carbamate (209 mg, 0.32 mmol) in DMF (5 mL) was heated at 50°C for 1 h. The mixture was quenched with water, extracted with DCM, dried over MgSCri, concentrated and purified by column chromatography (solvent gradient 0% to 3% MeOH in DCM, Rf = 0.2) to give tert-butyl
(5-(4-(6-(dimethylamino)benzo[d]thiazol-2-yl)phenyl)pyridin-2-yl)(2-(2-(3-(5-hydroxy-l-o xoisoindolin-2-yl)-2,6-dioxopiperidin-l-yl)ethoxy)ethyl)carbamate (68 mg, 0.09 mmol, 27% yield) as a yellow solid.
[0497] Compound 160624: To a solution of tert-butyl
(5-(4-(6-(dimethylamino)benzo[d]thiazol-2-yl)phenyl)pyridin-2-yl)(2-(2-(3-(5-hydroxy-l-o xoisoindolin-2-yl)-2,6-dioxopiperidin-l-yl)ethoxy)ethyl)carbamate (68 mg, 0.09 mmol) in DCM (2 mL) was added TFA (1 mL, 13.06 mmol) at 0°C and stirred at room temperature for 6 h. The solution was neutralized with saturated NaHCCb solution at 0°C and the solution was extracted with DCM. The organic layer was washed with brine, dried over MgSCL and concentrated to dryness to afford l-(2-(2-((5-(4-(6-(dimethylamino)benzo[d]thiazol-2-yl)phenyl)pyridin-2-yl)amino)ethoxy)e thyl)-3-(5-hydroxy-l-oxoisoindolin-2-yl)piperidine-2,6-dione (51 mg, 0.07 mmol, 85% yield) as a yellow solid.
Example 22: Synthesis of Compound 162641
[0498] Compound 162586: A solution of tert-butyl
N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]-N-[2-(2-iodanyleth oxy)ethyl]carbamate (100 mg, 0.16 mmol) in DMF (5 mL) was added 3-(7-azanyl-3-oxidanylidene-lH-isoindol-2-yl)piperidine-2,6-dione (48 mg, 0.19 mmol) and K2CO3 (101 mg, 0.31 mmol) and heated at 80°C for 3 h. The mixture was diluted with DCM, washed with water and brine, dried over Na2SC>4, concentrated and purified by column chromatography (MeOH:DCM = 1 :20, Rf = 0.3) to give tert-butyl N-[2-[2-[3-(7-azanyl-3-oxidanylidene-lH-isoindol-2-yl)-2,6-bis(oxidanylidene)piperidin-l-
yl]ethoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]car bamate (70 mg, 0.09 mmol, 58% yield) as a yellow solid.
[0499] Compound 162641: To a solution of tert-butyl
N-[2-[2-[3-(7-azanyl-3-oxidanylidene-lH-isoindol-2-yl)-2,6-bis(oxidanylidene)piperidin-l- yl]ethoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]car bamate (70 mg, 0.09 mmol) in DCM (2 mL) was added TFA (0.1 mL, 1.35 mmol) and stirred at room temperature for 20 h. The mixture was neutralized with sat. NaHCCb solution to pH 8. The residue was taken up in DCM (20 mL) and water (10 mL). The organic layer was washed with water (10 mL) and brine (10 mL), dried over Na2SC>4 and concentrated to give 3-(7-azanyl-3-oxidanylidene-lH-isoindol-2-yl)-l-[2-[2-[[2-[4-[6-(dimethylamino)pyri din-3- yl]phenyl]-l,3-benzothiazol-6-yl]amino]ethoxy]ethyl]piperidine-2,6-dione (30 mg, 0.04 mmol, 46% yield) as a yellow solid.
Example 23: Synthesis of Compound 161598
[0500] Compound 161444: To a solution of tert-butyl
N-[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbamate (200 mg, 0.45 mmol) in DMF (5 mL) was added NaH (43 mg, 1.79 mmol) at 0°C and stirred at room temperature for 1 h. The mixture was added
2-[2-[2-[2-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (681 mg, 1.34 mmol) and stirred at the same temperature for 24 h. The reaction was quenched by adding water. The resulting solid was collected by filtration and purified by column chromatography (EtOAc:DCM = 7:3, Rf = 0.4) to give tert-butyl N-[2-[2-[2-[2-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[5-[4- [6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbamate (252 mg, 0.32 mmol, 72% yield) as a yellow oil.
[0501] Compound 161467: A solution of tert-butyl
N-[2-[2-[2-[2-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethyl]-N-[5-[4- [6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbamate (252 mg, 0.32 mmol) in THF (5 mL) was added TBAF (1M in THF, 1.94 mL, 1.94 mmol) dropwise and stirred at room temperature for 19 h. The reaction mixture was concentrated to dryness and the residue was taken up in EtOAc (50 mL). The mixture was washed with water (50 mL) and brine (50 mL), dried over NaiSCri. And concentrated to dryness to give tert-butyl N-[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-N-[2-[2-[2-[2-(2-h
ydroxyethyloxy)ethoxy]ethoxy]ethoxy]ethyl]carbamate (214 mg, 0.32 mmol, 99% yield) as a yellow oil.
[0502] Compound 161530: A mixture of tert-butyl
N-[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-N-[2-[2-[2-[2-(2-h ydroxyethyloxy)ethoxy]ethoxy]ethoxy]ethyl]carbamate (214 mg, 0.32 mmol) and tert-butyl 2-bromanylethanoate (0.14 mL, 0.96 mmol) in THF (3 mL) was added NaH (19 mg, 0.80 mmol) at 0°C and stirred at room temperature for 42 h. The reaction was quenched by adding water. The mixture was diluted with DCM (50 mL), washed with water (50 mL) and brine (50 mL), dried over Na2SC>4, concentrated to dryness and purified by column chromatography (EtOAc:Hex = 1 : 1, Rf = 0.35) to afford tert-butyl
2-[2-[2-[2-[2-[2-[[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-[(2- methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanoate (130 mg, 0.17 mmol, 52% yield) as a yellow oil.
[0503] Compound 161586: To a solution of tert-butyl
2-[2-[2-[2-[2-[2-[[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-[(2- methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanoate (130 mg, 0.17 mmol) in DCM (2mL) was added TFA (0.38 mL, 4.99 mmol) and stirred at room temperature for 22 h. The mixture was concentrated to dryness to afford 2-[2-[2-[2-[2-[2-[[5-[4-[6-(dimethylamino)-l, 3-benzothiazol-2-yl]phenyl]pyri din-2 -yl]amin o]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanoic acid TFA salt (179 mg, 0.29 mmol, >99% yield) as an orange oil.
[0504] Compound 161598: A mixture of
(2S,4R)-l-[(2S)-2-azanyl-3,3-dimethyl-butanoyl]-N-[[4-(4-methyl-l,3-thiazol-5-yl)phenyl] methyl]-4-oxidanyl-pyrrolidine-2-carboxamide (79 mg, 0.18 mmol), 2-[2-[2-[2-[2-[2-[[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyri din-2- yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanoic acid (104 mg, 0.17 mmol), DIPEA (0.04 mL, 0.25 mmol) and HATU (127 mg, 0.33 mmol) in anhydrous DMF (3 mL) was stirred at room temperature for 18 h. The mixture was taken up in DCM, washed with water
and brine, dried over anhydrous Na2SC>4, concentrated and purified by column chromatography (MeOH:DCM = 3 : 100, Rf = 0.32) to give rac-(2R,4S)-N-[[4-(4-methyl-l,3-thiazol-5-yl)phenyl]methyl]-4-oxidanyl-l-[rac-(2R)-2-[2-[ 2-[2-[2-[2-[2-[[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]amino]e thoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanoylamino]-3,3-dimethyl-butanoyl]pyrrolidine-2-c arboxamide (16 mg, 0.01 mmol, 8% yield) as a yellow solid.
Example 24: Synthesis of Compound 160570
[0505] Compound 160491: To a solution of
2-[4-[6-(dimethylamino)-2-fluoranyl-pyridin-3-yl]phenyl]imidazo[l,2-a]pyridin-6-ol (0.43 g, 1.24 mmol) in dry DMF (4 mL) was added NaH (0.10 g, 2.48 mmol) at 0°C and stirred at room temperature for 1 h. 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate (1.54 g, 3.72 mmol) in dry DMF (4 mL) was added to the reaction mixture and stirred at the same temperature for 14 h. The mixture was cooled to 0°C, quenched with water (30 mL) and extracted with DCM (30 mL) was added. The organic layer was washed with water (30 mL) and brine (30 mL), dried over anhydrous Na2SC>4, concentrated and purified by column chromatography (EtOAc: DCM = 1 : 5, Rf = 0.33) to give
2-[2-[2-[4-[6-(dimethylamino)-2-fluoranyl-pyridin-3-yl]phenyl]imidazo[l,2-a]pyridin-6-yl]
oxyethoxy]ethyl 4-methylbenzenesulfonate (234 mg, 0.40 mmol, 32% yield) as an orange solid.
[0506] Compound 160508: A mixture of
2-[2-[[2-[4-[6-(dimethylamino)-2-fluoranyl-pyridin-3-yl]phenyl]-3,8a-dihydroimidazo[l,2-a ]pyridin-6-yl]oxy]ethoxy]ethyl 4-methylbenzenesulfonate (232 mg, 0.39 mmol) and Nal (70 mg, 0.47 mmol) in ACN (2 mL) was heated at 80°C for 14 h. The mixture was added water and extracted with DCM. The organic layer was washed with water (20 mL) and brine (20 mL), dried over Na2SC>4, concentrated and purified by chromatography (EtOAc:DCM = 1 : 10, Rf = 0.20) to give 6-fluoranyl-5-[4-[6-[2-(2-iodanylethoxy)ethoxy]-3,8a-dihydroimidazo[l,2-a]pyri din-2- yl]phenyl]-N,N-dimethyl-pyridin-2-amine (204 mg, 0.37 mmol, 95% yield) as a pale-yellow solid.
[0507] Compound 160570: A mixture of
2-[2,6-bis(oxidanylidene)piperidin-3-yl]-5-oxidanyl-isoindole-l,3-dione (101 mg, 0.37 mmol), CS2CO3 (180 mg, 0.55 mmol) and
6-fluoranyl-5-[4-[6-[2-(2-iodanylethoxy)ethoxy]-3,8a-dihydroimidazo[l,2-a]pyridin-2-yl]ph enyl]-N,N-dimethyl-pyridin-2-amine (101 mg, 0.18 mmol) in DMF (3 mL) was heated at 50°C for 4 h and then stirred at room temperature for 3 days. The mixture was triturated with water and the resulting precipitate was collected and purified by column chromatography (EtOAc: DCM = 1: 4, Rf = 0.05) to give
2-[l-[2-[2-[2-[4-[6-(dimethylamino)-2-fluoranyl-pyridin-3-yl]phenyl]imidazo[l,2-a]pyridin -6-yl]oxyethoxy]ethyl]-2,6-bis(oxidanylidene)piperidin-3-yl]-5-oxidanyl-isoindole-l,3-dion e (15 mg, 0.02 mmol, 11% yield) as a brown solid.
Example 25: Synthesis of Compound 160703
[0508] Compound 160686: A mixture of
2-[2,6-bis(oxidanylidene)piperidin-3-yl]-5-oxidanyl-isoindole-l,3-dione (68 mg, 0.25 mmol), CS2CO3 (121 mg, 0.37 mmol) and tert-butyl
N-[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]-N-[2-(2-iodanyleth oxy)ethyl]carbamate (80 mg, 0.12 mmol) in DMF (5 mL) was heated at 50°C for 3 h. The mixture was diluted with DCM, extracted with water, dried over MgSC , concentrated and purified by column chromatography on NH silica gel (MeOH:DCM = 1 :20, Rf = 0.2) to give tert-butyl
N-[2-[2-[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l,3-bis(oxidanylidene)isoindol-5-yl]oxyet hoxy]ethyl]-N-[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbam ate (25 mg, 0.03 mmol, 25% yield) as a yellow solid.
[0509] Compound 160703: To a solution of tert-butyl
N-[2-[2-[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l,3-bis(oxidanylidene)isoindol-5-yl]oxyet hoxy]ethyl]-N-[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]carbam ate (42 mg, 0.05 mmol) in DCM (5 mL) was added TFA (0.04 mL, 0.53 mmol) at 0°C and stirred at room temperature for 23 h. The mixture was neutralized with sat. NaHCCL solution to pH 8 and extracted with DCM. The organic layer was dried over Na2SCL and concentrated to dryness to give
2-[l-[2-[2-[[5-[4-[6-(dimethylamino)-l,3-benzothiazol-2-yl]phenyl]pyridin-2-yl]amino]etho
xy]ethyl]-2,6-bis(oxidanylidene)piperidin-3-yl]-5-oxidanyl-isoindole-l,3-dione (34 mg, 0.05 mmol, 88% yield) as a yellow solid.
Example 26: Synthesis of Compound 161262
[0510] Compound 161176: To a solution of tert-butyl
2-[4-[6-[(2-methylpropan-2-yl)oxycarbonylamino]pyridin-3-yl]phenyl]pyrrolo[2,3-c]pyridi ne-l-carboxylate (250 mg, 0.51 mmol) in DMF (5 mL) was cooled to 0°C, added NaH (37 mg, 0.92 mmol) and stirred at the same temperature for 30 min. Dimethyl
4-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]benzene-l,2-dicarboxylate (302 mg, 0.67 mmol) was added to the reaction mixture and stirred at room temperature for 20 h and heated to 50°C for 20 h. The mixture was quenched with water and extracted with DCM. The organic layer was washed with brine, dried over MgSC , concentrated and purified by
column chromatography on silica gel (EtOAc:DCM = 1 : 2.3, Rf = 0.375) to afford dimethyl 4-[2-[2-[(2-methylpropan-2-yl)oxycarbonyl-[5-[4-[l-[(2-methylpropan-2-yl)oxycarbonyl]py rrolo[2,3-c]pyridin-2-yl]phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]benzene-l,2-dicarboxyla te (183 mg, 0.24 mmol, 46% yield) as a yellow oil.
[0511] Compound 161217: To a solution of dimethyl
4-[2-[2-[(2-methylpropan-2-yl)oxycarbonyl-[5-[4-[l-[(2-methylpropan-2-yl)oxycarbonyl]py rrolo[2,3-c]pyridin-2-yl]phenyl]pyridin-2-yl]amino]ethoxy]ethoxy]benzene-l,2-dicarboxyla te (273 mg, 0.36 mmol) in EtOH (3 mL) was added NaOH (228 mg, 5.70 mmol) in water (3 mL) and stirred at room temperature for 4 days. The reaction was neutralized with IN HC1 solution to pH 1. The resulting precipitate was collected, washed with water (10 mL) and dried over vacuo to give 4-[2-[2-[[5-[4-[l-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolo[2,3-c]pyridin-2-yl]pheny l]pyridin-2-yl]amino]ethoxy]ethoxy]phthalic acid (201 mg, 0.31 mmol, 88% yield) as a white solid.
[0512] Compound 161230: A mixture of
4-[2-[2-[[5-[4-[l-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolo[2,3-c]pyridin-2-yl]phenyl]pyr idin-2-yl]amino]ethoxy]ethoxy]phthalic acid (201 mg, 0.31 mmol) and 3-azanylpiperidine-2,6-dione hydrochloride (78 mg, 0.47 mmol) in pyridine (3 mL) was heated at 120°C for 19 h. The solvent was removed by vacuum and the resulting residue was triturated with water. The precipitate was collected and purified by column chromatography on NH silica gel (MeOH:DCM = 3 : 100, Rf = 0.25) to give tert-butyl 2-[4-[6-[2-[2-[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l,3-bis(oxidanylidene)isoindol-5-yl] oxyethoxy]ethylamino]pyridin-3-yl]phenyl]pyrrolo[2,3-c]pyridine-l-carboxylate (47 mg, 0.06 mmol, 20% yield) as a yellow solid.
[0513] Compound 161262: A solution of tert-butyl
2-[4-[6-[2-[2-[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l,3-bis(oxidanylidene)isoindol-5-yl] oxyethoxy]ethylamino]pyridin-3-yl]phenyl]pyrrolo[2,3-c]pyridine-l-carboxylate (47 mg, 0.06 mmol) in DCM (3 mL) was added TFA (0.07 mL, 0.96 mmol) and stirred at room
temperature for 23 h. The mixture was neutralized with sat. NaHCCb solution to pH 8. The resulting precipitate was collected, washed with water and dried over vacuum to give 2-[2,6-bis(oxidanylidene)piperidin-3-yl]-5-[2-[2-[[5-[4-(lH-pyrrolo[2,3-c]pyridin-2-yl)phen yl]pyridin-2-yl]amino]ethoxy]ethoxy]isoindole-l,3-dione (36 mg, 0.05 mmol, 82% yield) as a yellow solid.
Example 27: Synthesis of Compound 164625
[0514] Compound 164581: A mixture of tert-butyl
3-[2-(2-iodanylethoxy)ethoxy]propanoate (500 mg, 1.45 mmol), K2CO3 (602 mg, 4.36 mmol) and methyl
5-azanyl-5-oxidanylidene-4-(6-oxidanyl-3-oxidanylidene-lH-isoindol-2-yl)pentanoate (467 mg, 1.60 mmol) in DMF (15 mL) was heated at 80°C for 7 h. The mixture was diluted with EtOAc, extracted with brine, dried over MgSCri, concentrated and purified by column chromatography (MeOFFDCM = 1 :20, Rf = 0.48) to give tert-butyl
3-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]et hoxy]ethoxy]propanoate (387 mg, 0.81 mmol, 56% yield) as a white solid.
[0515] Compound 164617: To a solution of tert-butyl
3-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]et hoxy] ethoxy ]propanoate (387 mg, 0.81 mmol) in DCM (10 mL) was added TFA (0.62 mL, 8.12 mmol) and stirred at room temperature for 15 h. The mixture was concentrated to dryness to give 3-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]o xy]ethoxy]ethoxy]propanoic acid TFA salt (494 mg, 1.18 mmol) as a white oil.
[0516] Compound 164625: A mixture of
3-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]et hoxy]ethoxy]propanoic acid (346 mg, 0.82 mmol), TBTU (352 mg, 1.10 mmol) and 2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-amine (190 mg, 0.55 mmol) in pyridine (3 mL) was stirred at room temperature for 17 h. The mixture was added with water and the resulting precipitate was collected by filtration and purified by column chromatography (MeOFLDCM = 1 : 19, Rf = 0.3) to give
3-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]et hoxy]ethoxy]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]propa namide (285 mg, 0.36 mmol, 66% yield) as a yellow solid.
Example 28: Synthesis of Compound 164657
[0517] Compound 164263: A mixture of tert-butyl N-(2-bromanyl-l,3-benzothiazol-6-yl)carbamate (1100 mg, 3.34 mmol), N,N-dimethyl-5-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl )phenyl]pyridin-2-amine (1704 mg, 4.34 mmol), Pd(dppf)Ch (247 mg, 0.33 mmol) and 2M Na2CC>3(aq) solution (5 mL, 10.02 mmol) in dioxane (35 mL) was heated at 80°C for 16 h under argon. The mixture was filtered through a Celite pad and the residue was taken up in EtOAc (100 mL) and water (50 mL). The organic layer was washed with water (50 mL), brine (50 mL), dried over Na2S04 and concentrated to dryness. The residue was purified by column chromatography (EtOAc: Hex = 1:4, Rf= 0.15) to give tert-butyl
N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6-yl] carbamate (1.06 g, 2.05 mmol, 61% yield) as a yellow oil.
[0518] Compound 164346: To a solution of tert-butyl
N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6-yl] carbamate (1056 mg, 2.05 mmol) in DMF (20 mL) was added NaH (148 mg, 6.16 mmol) at 0°C and stirred at 25°C for 1 h. 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate (2.55 g, 6.16 mmol) in DMF (20 mL) was added to the reaction
mixture and stirred at room temperature for 14 h. The mixture was quenched with water at 0°C. The residue was taken up in EtOAc (50 mL) and water (50 mL). The organic layer was washed with water (50 mL), brine (50 mL), dried over Na2SC>4 and concentrated to dryness. The residue was purified by column chromatography (EtOAc:Hex = 1:1, Rf = 0.4) to give 2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6- yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethyl 4-methylbenzenesulfonate (955 mg, 1.26 mmol, 61% yield) as a yellow oil.
[0519] Compound 164398: A mixture of
2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6- yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]ethyl 4-methylbenzenesulfonate (955 mg, 1.26 mmol), Nal (378 mg, 2.52 mmol) in MeCN (20 mL) was heated at 80°C for 17 h. The residue was taken up in EtOAc (50 mL) and water (50 mL). The organic layer was washed with water (50 mL), brine (50 mL), dried over Na2S04 and concentrated. The residue was purified by column chromatography (EtOAc:Hex = 1 :1, Rf = 0.7) to give tert-butyl N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6-yl] -N-[2-(2-iodanylethoxy)ethyl]carbamate (805 mg, 1.13 mmol, 90% yield) as a yellow oil. [0520] Compound 164350: A mixture of tert-butyl
N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6-yl] -N-[2-(2-iodanylethoxy)ethyl]carbamate (110 mg, 0.15 mmol), K2CO3 (64 mg, 0.46 mmol), and methyl
5-azanyl-5-oxidanylidene-4-(6-oxidanyl-3-oxidanylidene-lH-isoindol-2-yl)pentanoate (50 mg, 0.17 mmol) in DMF (2.5 mL) was heated at 80°C for 8 h. The mixture was added water, extracted with DCM, dried over MgSCri and concentrated to dryness. The residue was purified by column chromatography (MeOH:DCM = 1 :20, Rf = 0.4) to give tert-butyl N-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]et hoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzo thiazol-6-yl]carbamate (110 mg, 0.13 mmol, 84% yield) as a yellow solid.
[0521] Compound 164657: To a solution of tert-butyl
N-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]et hoxy]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzo thiazol-6-yl]carbamate (550 mg, 0.65 mmol) in DCM (10 mL) was added TFA (0.75 mL, 9.76 mmol) at 25°C and stirred for 15 h. The mixture was poured into ice water and neutralized with sat. NaHCCb solution to pH 8. The residue was taken up in DCM (20 mL) and water (10 mL). The organic layer was washed with water (10 mL), brine (10 mL), dried over Na2SC>4 and concentrated to dryness. The residue was purified by column chromatography (DCM:MeOH = 10:1, Rf = 0.58) to give 3-[6-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benz othiazol-6-yl]amino]ethoxy]ethoxy]-3-oxidanylidene-lH-isoindol-2-yl]piperidine-2,6-dione (254 mg, 0.34 mmol, 52% yield) as a yellow solid.
Example 29: Synthesis of Compound 162640
[0522] Compound 162534: A solution of tert-butyl
N-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-yl]carbamate (1.52 g, 4.75 mmol), 2-(4-bromophenyl)-6-methoxy-imidazo[l,2-a]pyridine (1.2 g, 3.96 mmol), and triphenylphosphine (34.6 mg, 0.13 mmol) in EtOH (4 mL) and toluene (2.8 mL) was purged with argon and then added with K2CO3 solution (1.75M, 7.92 mL, 13.85 mmol) dropwise. The mixture was added with Pd(OAc)2 (87 mg, 0.40 mmol) under argon and heated at 90°C for 4 h. The mixture was filtered through celite pad, poured into saturated NaHCCh solution, and extracted with EtOAc. The organic layer was dried over MgSCri, concentrated and purified by column chromatography (EtOAc:DCM = 1:4, Rf = 0.3) to give tert-butyl
N-[4-[4-(6-methoxyimidazo[l, 2-a]pyri din-2 -yl)phenyl]pyridin-2-yl]carbamate (987 mg,
2.37 mmol, 60% yield) as a pale-brown solid.
[0523] Compound 162547: A solution of 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate (2.86 g, 6.90 mmol) in DMF (10 mL) was added NaH (368 mg, 9.20 mmol) at 0°C and stirred at room temperature for 1 h. The mixture was added with 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate (2.86 g, 6.90 mmol) in DMF (10 mL) and stirred at room temperature for 19 h. The mixture was cooled to 0°C, quenched by adding water and diluted with DCM. The resulting mixture was washed with water and brine, dried over Na2SC>4, concentrated and purified by column chromatography (EtOAc:DCM = 4: 1, Rf = 0.4) to give 2-[2-[[4-[4-(6-methoxyimidazo[l,2-a]pyri din-2 -yl)phenyl]pyridin-2-yl]-[(2-methylpro pan-2 -yl)oxycarbonyl]amino]ethoxy]ethyl 4-methylbenzenesulfonate (924 mg, 1.40 mmol, 61% yield) as an orange oil.
[0524] Compound 162568: A mixture of
2-[2-[[4-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]-[(2-methylpropan-2
-yl)oxycarbonyl]amino]ethoxy]ethyl 4-methylbenzenesulfonate (924 mg, 1 40 mmol) and Nal (421 mg, 2.81 mmol) in CELCN (20 mL) was heated at 80°C for 17 h. The
mixture was diluted with DCM, washed with water (50 mL) and brine (50 mL), dried over Na2SC>4, concentrated and purified by column chromatography (MeOH: DCM = 1 : 100, Rf = 0.19) to give tert-butyl
N-[2-(2-iodanylethoxy)ethyl]-N-[4-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridi n-2-yl]carbamate (585 mg, 0.95 mmol, 68% yield) as an orange solid.
[0525] Compound 162599: A solution of tert-butyl
N-[2-(2-iodanylethoxy)ethyl]-N-[4-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridi n-2-yl]carbamate (250 mg, 0.41 mmol),
3-(6-oxidanyl-3-oxidanylidene-lH-isoindol-2-yl)piperidine-2,6-dione (212 mg, 0.81 mmol) and K2CO3 (169 mg, 1.22 mmol) in DMF (4 mL) was heated at 50°C for 3 h. The mixture was quenched with water and the resulting solid was collected by filtration. The solid was washed with water and the residue was purified by NH gel column chromatography (MeOH: DCM = 3:100 , Rf = 0.33) to give tert-butyl
N-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]et hoxy]ethyl]-N-[4-[4-(6-methoxyimidazo[l, 2-a]pyri din-2 -yl)phenyl]pyridin-2-yl]carbamate (76 mg, 0.10 mmol, 25% yield) as a white solid.
[0526] Compound 162640: To a solution of tert-butyl
N-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]et hoxy]ethyl]-N-[4-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]carbamate (76 mg, 0.10 mmol) in DCM (2 mL) was added TFA (0.12 mL, 1.53 mmol) and stirred for 38 h. The mixture was poured into iced water and neutralized with sat. NaHC03 solution to pH 8. The residue was taken up in DCM (20 mL) and water (10 mL). The organic layer was washed with water (10 mL), brine (10 mL), dried over NaiSCL, concentrated and purified by column chromatography (DCM:MeOH = 100:3, Rf = 0 35) to give 3-[6-[2-[2-[[4-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]amino]eth oxy]ethoxy]-3-oxidanylidene-lH-isoindol-2-yl]piperidine-2,6-dione (22 mg, 0.03 mmol, 33% yield) as a pale-brown solid.
Example 30: Synthesis of Compound 162843
[0527] Compound 162723: To a solution of
2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate (4.72 g, 11.38 mmol) in DMF (30 mL) was added NaH (455 mg, 11.38 mmol) at 0°C and stirred at room temperature for 1 h 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl
4-methylbenzenesulfonate (4.72 g, 11.38 mmol) in DMF (30 mL) was added to the reaction mixture and stirred at room temperature for another 16 h. The mixture was cooled to 0°C and quenched with water. The mixture was diluted with DCM, washed with water and brine, dried over a2S04, concentrated and purified by column chromatography (EtOAc:Hex = 1:1, Rf = 0.23) to give 2-[2-[[5-[4-(6-methoxyimidazo[l, 2-a]pyri din-2 -yl)phenyl]pyridin-2-yl]-[(2-methylpro pan-2 -yl)oxycarbonyl]amino]ethoxy]ethyl 4-methylbenzenesulfonate (1.3 g, 1.97 mmol, 69% yield) as an orange solid.
[0528] Compound 162762: A mixture of
2-[2-[[5-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]-[(2-methylpropan-2
-yl)oxycarbonyl]amino]ethoxy]ethyl 4-methylbenzenesulfonate (1.3 g, 1.97 mmol) andNal (592 mg, 3.95 mmol) in ACN (10 mL) was heated at 80°C for 15 h. The mixture was added water and extracted with DCM. The organic layer was washed with water (50 mL), brine (50 mL), dried over INfeSCri, concentrated to dryness and purified by chromatography (MeOH: DCM = 1 : 100, Rf = 0.19) to give tert-butyl
N-[2-(2-iodanylethoxy)ethyl]-N-[5-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridi n-2-yl]carbamate (920 mg, 1.50 mmol, 76% yield) as a yellow solid.
[0529] Compound 162798: A mixture of tert-butyl
N-[2-(2-iodanylethoxy)ethyl]-N-[5-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridi n-2-yl]carbamate (200 mg, 0.33 mmol),
3-(6-oxidanyl-3-oxidanylidene-lH-isoindol-2-yl)piperidine-2,6-dione (169 mg, 0.65 mmol) and Na2CC>3 (103 mg, 0.98 mmol) in DMF (4 mL) was heated at 50°C for 37 h. The mixture was added with water and the resulting precipitate was collected by filtration, washed with water and purified by column chromatography on H gel (MeOH: DCM = 1:100, Rf = 0.21) to give tert-butyl
N-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]et hoxy]ethyl]-N-[5-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]carbamate (68 mg, 0.09 mmol, 28% yield) as a yellow solid.
[0530] Compound 162843: To a solution of tert-butyl
N-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]et hoxy]ethyl]-N-[5-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]carbamate (68 mg, 0.09 mmol) in DCM (2 mL) was added TFA (0.07 mL, 0.9100mmol) and stirred at room temperature for 48 h. The mixture was diluted with DCM (3 mL) and neutralized with sat. NaHC03(aq.) solution to pH 8. The precipitate was collected and washed with DCM to give 3-[6-[2-[2-[[5-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]amino]eth oxy]ethoxy]-3-oxidanylidene-lH-isoindol-2-yl]piperidine-2,6-dione (38 mg, 0.05 mmol, 59% yield) as a yellow solid.
Example 31: Synthesis of Compound 165559
[0531] Compound 165511: A solution of 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl
4-methylbenzenesulfonate (2567 mg, 6.19 mmol) in DMF (10 mL) was cooled to 0°C, added NaH (248 mg, 6.19 mmol) and then stirred at room temperature for 1 h. 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate (2567 mg, 6.19 mmol) was added to the reaction mixture and stirred at room temperature for 17 h. The reaction was cooled to 0°C and quenched by adding water. The mixture was diluted with DCM, washed with water and brine, dried over Na2SC>4, concentrated and purified by column chromatography (DCM:EtOAc = 10:1, Rf = 0.3) to give 2-[2-[[4-[4-(6-fluoranyl-l,3-benzothiazol-2-yl)phenyl]pyridin-2-yl]-[(2-methylpropan- 2-yl)oxycarbonyl]amino]ethoxy]ethyl 4-methylbenzenesulfonate (455 mg, 0.68 mmol, 33% yield) as a white solid.
[0532] Compound 165547: A mixture of methyl
5-azanyl-5-oxidanylidene-4-(6-oxidanyl-3-oxidanylidene-lH-isoindol-2-yl)pentanoate (220 mg, 0.75 mmol), K2CO3 (284 mg, 2.06 mmol), KI (11 mg, 0.07 mmol) and 2-[2-[[4-[4-(6-fluoranyl-l,3-benzothiazol-2-yl)phenyl]pyridin-2-yl]-[(2-methylp ropan-2-yl)oxycarbonyl]amino]ethoxy]ethyl 4-methylbenzenesulfonate (455 mg, 0.69
mmol) in DMF (6 mL) was heated at 80°C for 7 h. The mixture was diluted with EtOAc (20 mL), extracted with water (10 mL) and brine (10 mL), dried over Na2S04, concentrated and purified by column chromatography (MeOH:DCM= 1:20 , Rf= 0.4) to give tert-butyl N-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]et hoxy]ethyl]-N-[4-[4-(6-fluoranyl-l, 3-benzothiazol-2-yl)phenyl]pyri din-2 -yl]carbamate (245 mg, 0.33 mmol, 48% yield) as white solid.
[0533] Compound 165559: A solution of tert-butyl
N-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]et hoxy]ethyl]-N-[4-[4-(6-fluoranyl-l, 3-benzothiazol-2-yl)phenyl]pyri din-2 -yl]carbamate (245 mg, 0.33 mmol) in DCM (5 mL) was added TFA (0.38 mL, 4.89 mmol) and stirred at room temperature for 20 h. The mixture was diluted with DCM (20 mL) and neutralized with sat. NaHCCb solution to pH 8. The mixture extracted with water, dried over MgS04, concentrated and purified by column chromatography (DCM:MeOH = 20: 1, Rf = 0.3) to give 3-[6-[2-[2-[[4-[4-(6-fluoranyl-l,3-benzothiazol-2-yl)phenyl]pyridin-2-yl]amino]ethoxy]etho xy]-3-oxidanylidene-lH-isoindol-2-yl]piperidine-2,6-dione (160 mg, 0.24 mmol, 75% yield) as a white solid.
Example 32: Synthesis of Compound 163685
[0534] Compound 162862: To a solution of
2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6-ol (516 mg, 1.24 mmol) in dry DMF (12 mL) was added NaH (149 mg, 3.72 mmol) at 0°C and stirred at room temperature for 1 h. 2- [2-(4-methylphenyl)sulfonyloxy ethoxy] ethyl
4-methylbenzenesulfonate (1543 mg, 3.72 mmol) in dry DMF (12 mL) was added to the reaction mixture and stirred at the same temperature for 18 h. The mixture was poured into water (50 mL) and extracted with DCM (50 mL). The organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na2SC>4, concentrated and purified by column chromatography (Rf = 0.51, EtOAc:DCM = 1 :9) to give
2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6- yl]oxy]ethoxy]ethyl 4-methylbenzenesulfonate (627 mg, 0.95 mmol, 77% yield) as a pale yellow solid.
[0535] Compound 162891: A mixture of
2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6- yl]oxy]ethoxy]ethyl 4-methylbenzenesulfonate (627 mg, 0.95 mmol) and Nal (286 mg, 1.91 mmol) in ACN (10 mL) was heated at 80°C for 17 h. The mixture was added water (20 mL) and extracted with EtOAc. The organic layer was washed with brine, dried over MgSCL and concentrated to dryness to give 5-[4-[6-[2-(2-iodanylethoxy)ethoxy]-l,3-benzothiazol-2-yl]-3-(trifluoromethyl)phenyl] -N,N-dimethyl-pyridin-2-amine (540 mg, 0.88 mmol, 92% yield) as a yellow solid.
[0536] Compound 163685: A mixture of
5-[4-[6-[2-(2-iodanylethoxy)ethoxy]-l,3-benzothiazol-2-yl]-3-(trifluoromethyl)phenyl]-N,N -dimethyl-pyridin-2-amine (100 mg, 0.16 mmol),
3-(7-oxidanyl-3-oxidanylidene-lH-isoindol-2-yl)piperidine-2,6-dione (85 mg, 0.33 mmol) and K2CO3 (68 mg, 0.49 mmol) in DMF (5 mL) was heated at 50°C for 18 h. The mixture was added water and extracted with DCM. The organic layer was washed with brine, dried over MgSCL, concentrated and purified by column chromatography (MeOFhDCM =
1:20, Rf= 0.45) to give 3-[7-[2-[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benz othiazol-6-yl]oxy]ethoxy]ethoxy]-3-oxidanylidene-lH-isoindol-2-yl]piperidine-2,6-dione (33 mg, 0.04 mmol, 25% yield) as a yellow solid.
Example 33: Synthesis of Compound 163863
[0537] Compound 163863: A mixture of
2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-ol (166 mg, 0.48 mmol),
3-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]etho xyjpropanoic acid (90 mg, 0.24 mmol), DMAP (3 mg, 0.02 mmol) and DCC (52 mg, 0.25 mmol) in pyridine (2 mL) was stirred at room temperature for 15 h. The solvent was removed by reduced pressure. The residue was redissolved in DCM (10 mL), washed with water (5 mL) and brine (5 mL), dried over MgS04, concentrated and purified by column chromatography (MeOH:DCM = 5:100, Rf = 0.14) to give [2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl] 3-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]etho xy]propanoate (14 mg, 0.02 mmol, 8% yield) as a yellow solids
[0538] Compound 164431: A solution of tert-butyl
N-[4-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]carbamate (400 mg,
0.96 mmol) in dry DMF (10 mL) was cooled to 0°C and added NaH (115 mg, 2.88 mmol). The resulting mixture was stirred at room temperature for 1 h.
2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (1321 mg, 2.88 mmol) in dry DMF (10 mL) was added to the reaction mixture and stirred at the same temperature for 17 h. The mixture was quenched with water (30 mL) and extracted with DCM (30 mL). The organic layer was washed with brine (30 mL), dried over anhydrous Na2SC>4, concentrated and purified by column chromatography (EtOAc:DCM = 1 :4, Rf = 0.4) to give
2-[2-[2-[[4-[4-(6-methoxyimidazo[l, 2-a]pyri din-2 -yl)phenyl]pyri din-2 -yl]-[(2-methylpropa n-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (350 mg, 0.50 mmol, 52% yield) as a yellow solid.
[0539] Compound 164438: A mixture of
2-[2-[2-[[4-[4-(6-methoxyimidazo[l, 2-a]pyri din-2 -yl)phenyl]pyridin-2-yl]-[(2-methylpropa n-2-yl)oxycarbonyl]amino]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (350 mg, 0.50 mmol) and Nal (149 mg, 1.00 mmol) in ACN (10 mL) was heated at 80°C for 6 h. The
mixture was added water and extracted with DCM. The organic layer was washed with water (50 mL) and brine (50 mL), dried over Na2S04 and concentrated to dryness to give tert-butyl N-[2-[2-(2-iodanylethoxy)ethoxy]ethyl]-N-[4-[4-(6-methoxyimidazo[l,2-a]pyri din-2 -yl)phe nyl]pyridin-2-yl]carbamate (317 mg, 0.48 mmol, 97% yield) as a yellow solid.
[0540] Compound 164465: A mixture of tert-butyl
N-[2-[2-(2-iodanylethoxy)ethoxy]ethyl]-N-[4-[4-(6-methoxyimidazo[l,2-a]pyri din-2 -yl)phe nyl]pyridin-2-yl]carbamate (100 mg, 0.15 mmol), K2CO3 (63 mg, 0.46 mmol) and methyl 5-azanyl-5-oxidanylidene-4-(6-oxidanyl-3-oxidanylidene-lH-isoindol-2-yl)pentanoate (49 mg, 0.17 mmol) in DMF (5 mL) was heated at 80°C for 6 h. The mixture was added water and extracted with DCM. The organic layer was dried over MgSCri, concentrated and purified by column chromatography (MeOH:DCM = 3: 100, Rf = 0.3) to give tert-butyl N-[2-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]ox y]ethoxy]ethoxy]ethyl]-N-[4-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl] carbamate (63 mg, 0.08 mmol, 52% yield) as a white solid.
[0541] Compound 164484: To a solution of tert-butyl
N-[2-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]ox y]ethoxy]ethoxy]ethyl]-N-[4-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl] carbamate (63 mg, 0.08 mmol) in DCM (5 mL) was added TFA (0.09 mL, 1.19 mmol) and stirred at room temperature for 14 h. The mixture was poured into iced water and neutralized with sat. NaFlCCL solution to pFI 8. The mixture was diluted with DCM (20 mL) and extracted with water (10 mL) and brine (10 mL), dried over Na2S04 and concentrated to dryness to give
3-[6-[2-[2-[2-[[4-[4-(6-methoxyimidazo[l,2-a]pyridin-2-yl)phenyl]pyridin-2-yl]amino]etho xy]ethoxy]ethoxy]-3-oxidanylidene-lFl-isoindol-2-yl]piperidine-2,6-dione (52 mg, 0.07 mmol, 89% yield) as a pale-brown solid.
Example 35: Synthesis of Compound 165013
[0542] Compound 164953: To a solution of tert-butyl
N-methyl-N-[5-[4-[6-[(2-methylpropan-2-yl)oxycarbonylamino]-l,3-benzothiazol-2-yl]-3-(t rifluoromethyl)phenyl]pyridin-2-yl]carbamate (200 mg, 0.33 mmol) in dry DMF (5 mL) was added NaH (40 mg, 1.00 mmol) at 0°C and stirred at room temperature for 1 h. 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate (414 mg, 1.00 mmol) in dry DMF (5 mL) was added to the reaction mixture and stirred at the same temperature for 14 h. The mixture was quenched with water (30 mL) and extracted with DCM (30 mL). The organic layer was washed with water (30 mL) and brine (30 mL), dried over anhydrous Na2SC>4, concentrated and purified by column chromatography (EtOAc:DCM = 1 :9, Rf = 0.4) to give 2-[2-[[2-[4-[6-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pyridin-3-yl]-2-(trifl uoromethyl)phenyl]-l,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]etho xy]ethyl 4-methylbenzenesulfonate (130 mg, 0.15 mmol, 46% yield) as a yellow solid. [0543] Compound 164984: A mixture of methyl
5-azanyl-5-oxidanylidene-4-(6-oxidanyl-3-oxidanylidene-lH-isoindol-2-yl)pentanoate (50 mg, 0.17 mmol), K2CO3 (64 mg, 0.46 mmol), KI (2.56 mg, 0.02 mmol) and 2-[2-[[2-[4-[6-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pyridin-3-yl]-2-(trifluoro methyl)phenyl]-l,3-benzothiazol-6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethoxy]e
thyl 4-methylbenzenesulfonate (130 mg, 0.15 mmol) in DMF (5 mL) was heated at 80°C for 6 h. The mixture was diluted with DCM (5 mL), cooled to 0°C and added water (5 mL) dropwise. The mixture was extracted with water (10 mL) and brine (10 mL), dried over Na2SC>4, concentrated and purified by column chromatography (MeOH:DCM= 3:100 , Rf = 0.3) to give tert-butyl
N-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]et hoxy]ethyl]-N-[2-[4-[6-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pyridin-3-yl]-2- (trifluoromethyl)phenyl]-l,3-benzothiazol-6-yl]carbamate (79 mg, 0.08 mmol, 55% yield) as colorless oil.
[0544] Compound 165013: To a solution of tert-butyl
N-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]et hoxy]ethyl]-N-[2-[4-[6-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pyridin-3-yl]-2- (trifluoromethyl)phenyl]-l,3-benzothiazol-6-yl]carbamate (79 mg, 0.08 mmol) in DCM (3 mL) was added TFA (0.1 mL, 1.27 mmol) and stirred at room temperature for 14 h. The mixture was poured into ice water and neutralized with sat. NaHCCh solution to pH 8. The mixture was diluted with DCM (20 mL) and extracted with water (10 mL) and brine (10 mL). The organic layer was collected, dried over Na2S04, concentrated and purified by column chromatography on silica gel (MeOH:DCM = 3:100, Rf = 0.2) to give 3-[6-[2-[2-[[2-[4-[6-(methylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiaz ol-6-yl]amino]ethoxy]ethoxy]-3-oxidanylidene-lH-isoindol-2-yl]piperidine-2,6-dione (29 mg, 0.04 mmol, 45% yield) as a yellow solid.
Example 36: Synthesis of Compound 166288
[0545] Compound 166191: A solution of tert-butyl
N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6-yl] carbamate (447 mg, 0.87 mmol) in DMF (8 mL) was added NaH (63 mg, 2.61 mmol) at 0°C, stirred at room temperature for 1 h and then added 5-(4-methylphenyl)sulfonyloxypentyl
4-methylbenzenesulfonate (1075 mg, 2.61 mmol) in DMF (8 mL). The resulting mixture was stirred at room temperature for another 16 h, cooled to 0°C and quenched by adding water. The residue was taken up in DCM (50 mL) and water (50 mL). The organic layer was washed with water (50 mL), brine (50 mL), dried over Na2SC>4, and purified by column chromatography on silica gel (DCM:EtOAc = 9:1, Rf = 0.52) to give 5-[[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol- 6-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]pentyl 4-methylbenzenesulfonate (515 mg, 0.68 mmol, 79% yield) as a yellow solid.
[0546] Compound 166226: A mixture of
5-[[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6-yl] -[(2-methylpropan-2-yl)oxycarbonyl]amino]pentyl 4-methylbenzenesulfonate (514 mg, 0.68 mmol), K2CO3 (282 mg, 2.04 mmol), KI (11 mg, 0.07 mmol) and methyl 5-azanyl-5-oxidanylidene-4-(6-oxidanyl-3-oxidanylidene-lH-isoindol-2-yl)pentanoate (219 mg, 0.75 mmol) in DMF (8 mL) was stirred at room temperature for 22 h and then heated to 80°C for 6 h. The mixture was diluted with DCM (5 mL), cooled to 0°C and added water (5 mL) dropwise. The mixture was washed with water (10 mL) and brine (10 mL), dried over Na2SC>4, concentrated and purified by column chromatography on silica gel (MeOFfDCM = 1:20 , Rf = 0.55) to give tert-butyl
N-[5-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]pent yl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6 -yl]carbamate (205 mg, 0.24 mmol, 36% yield) as yellow solid.
[0547] Compound 166288: To a solution of tert-butyl
N-[5-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]pent yl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6 -yl]carbamate (205 mg, 0.24 mmol) in DCM (3 mL) was added TFA (0.28 mL, 3.65 mmol) and stirred at room temperature for 16 h. The mixture was poured into iced water and neutralized with sat. NaHC03 solution to pH 8. The residue was taken up in DCM (20 mL) and water (10 mL). The organic layer was washed with water (10 mL) and brine (10 mL), dried over Na2SC>4 and concentrated to dryness to give 3-[6-[5-[[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzoth iazol-6-yl]amino]pentoxy]-3-oxidanylidene-lH-isoindol-2-yl]piperidine-2,6-dione (132 mg, 0.17 mmol, 71% yield) as a yellow solid.
Example 37; Synthesis of Compound 166399
[0548] Compound 166196: A solution of tert-butyl
N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6-yl] carbamate (300 mg, 0.58 mmol) in DMF (5 mL) was cooled to 0°C and added NaH (56 mg, 2.33 mmol). The mixture was stirred at room temperature for 1 h, added 2-azidoethyl 4-methylbenzenesulfonate (281 mg, 1.17 mmol) in DMF (5 mL) and heated at 50°C for 20 h. The mixture was cooled to 0°C and added water (5 mL). The resulting precipitation was collected by filtration, washed with water and dried over vacuum. The residue was purified by column chromatography on silica gel (EtOAc:DCM = 1 :20, Rf = 0.6) to give tert-butyl N-(2-azidoethyl)-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-b enzothiazol-6-yl]carbamate (320 mg, 0.55 mmol, 94% yield) as a yellow solid.
[0549] Compound 166264: A solution of tert-butyl
N-(2-azidoethyl)-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-b enzothiazol-6-yl]carbamate (341 mg, 0.58 mmol) in THF (5mL)/EtOH (5mL) was added Pd(OH)2 (1701 mg, 1.61 mmol) and stirred under 1 atmosphere of Lb for 4 h. The mixture was filtered through a Celite pad and the filtrate was concentrated to dryness. The residue was purified by column chromatography (DCM:EtOAc = 20: 1, Rf = 0.15) to give tert-butyl N-(2-azanylethyl)-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3- benzothiazol-6-yl]carbamate (226 mg, 0.41 mmol, 69% yield) as pale-yellow solid.
[0550] Compound 166306: A mixture of tert-butyl
N-(2-azanylethyl)-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3- benzothiazol-6-yl]carbamate (326 mg, 0.59 mmol),
2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]ethanoi c acid (372 mg, 1.17 mmol), EDC (280 mg, 1.46 mmol) and HOBt (198 mg, 1.46 mmol) in pyridine (6 mL) was stirred at room temperature for 16 h. The solvent was removed by vacuum and the resulting residue was redissolved in EtOAc (100 mL) and washed with water (50 mL) and brine (50 mL). The organic layer was dried overNa2SC>4, concentrated and purified by column chromatography on silica gel (MeOH:DCM = 1:20, Rf = 0.3) to give tert-butyl
N-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]et hanoylamino]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l, 3-benzothiazol-6-yl]carbamate (277 mg, 0.32 mmol, 55% yield) as a yellow solid.
[0551] Compound 166399: A solution of tert-butyl
N-[2-[2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]et hanoylamino]ethyl]-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l, 3-benzothiazol-6-yl]carbamate (277 mg, 0.32 mmol) in DCM (3 mL) was added TFA (0.37 mL, 4.85 mmol) and stirred at room temperature for 23 h. The mixture was poured into iced water and neutralized with sat. NaHC03 solution to pH 8. The residue was taken up in DCM (20 mL) and water (10 mL). The organic layer was washed with water (10 mL) and brine (10 mL), dried over Na2SC>4 and concentrated to give 2-[[2-[2,6-bis(oxidanylidene)piperidin-3-yl]-l-oxidanylidene-3H-isoindol-5-yl]oxy]-N -[2-[[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6-y l]amino]ethyl]ethanamide (239 mg, 0.30 mmol, 93% yield) as a yellow solid.
Example 38: Alpha-svnuclein Competitive Binding Assay
[0552] (A) Expression and purification of recombinant wild-type human a-synuclein: 0.5 mM IPTG was used to induce production of wild type human a-synuclein by bacteria transformed with a full-length a-synuclein expression plasmid. After shaking at 16 °C for 20 hours, cell pellet was resuspended in lysis buffer (10 mM Tris, 1 mM EGTA, 0.75 mM NaCl, 1 mM PMSF, pH 7.5) and lysed by sonication followed by centrifugation (6000 g, 30 min, 4 °C). The supernatant was then boiled at 95 °C for 15 min with manual agitation by every 5 minutes, followed by centrifugation (6000 g, 30 min, 4 °C). Supernatant was dialyzed with (10 mM Tris, 1 mM EGTA, 50 mMNaCl, pH 7.5) buffer and concentrated with concentrator. The collected sample was loaded onto a Superdex200 column, the flow-through fraction was then loaded onto a Q-HP column. Collected fractions with a-synuclein eluates were pooled, concentrated and stored at -80 °C.
[0553] (B) Preparation of aggregated a-synuclein: 5 mg/mL of a-synuclein in PBS buffer
(pH 7.4) was incubated in tube with at 37°C with shaking (700 rpm) for 5-10 days.
[0554] (C) In vitro fluorometric a-synuclein binding assays: 2 mM a-synuclein was incubated with serially diluted compound (three-fold serial dilutions, from 10 to 0.001 mM) in a 96-well plate at 37°C for 1 hour. Fluorescence intensity was read by microplate spectrometer. Compound Kd values were calculated using the following equation: Y= Bmax * X / (Kd + X), where X is the concentration of compound; Y is the fluorescence signal of (compound + a-synuclein) - (compound + DMSO); and Bmax is the maximum signal.
[0555] (D) PBB5 competition assay: 2 mM of a-synuclein was incubated with 0.26 mM
2-(4-(2-(methylamino)pyridine-5-yl)-l,3-butadiene-l-yl)benzothiazole-6-ol (PBB5) and serially diluted compound (three-fold serial dilution, from 10 to 0.001 mM) in a 96-well plate at 37°C for 1 hour. Fluorescence intensity (excitation/emission = 530/690 nm) of PBB5 was read by microplate spectrometer. Percentage of competition was calculated using the following equation: (Max - well of compound alone)/(Max - Min)* 100%, where Max = (a-synuclein + PBB5) signals - (buffer + PBB5) signals; and Min = (buffer + PBB5) signals - (buffer + PBB5) signals. The ICso value of each compound was calculated with GraphPad Prism software using the “4 Parameter Logistic Model or Sigmoidal Dose-Response Model”: Y=Bottom + (Top-Bottom )/( 1 +(IC50/X)/Hill Slope)
Table 2. Competition Assay with PBB5
Example 39: In Vitro Assay For Degrading -Synuclein Aggregates
[0556] The ReNcell VM a-synuclein aggregation assay was conducted at Charles River Laboratories (CRL). ReNcell VM is an immortalized human neural progenitor cell line derived from the ventral mesencephalon region of the brain. ReNcell VM cells were selected as in vitro cellular model for the a-synuclein aggregation assay, based on their growth features, differentiation potential into terminally differentiated neurons and amenability to adenoviral transduction. Aggregated human wild type a-synuclein was overexpressed through adenoviral delivery. Aggregated a-synuclein was detected with the aggregate-selective anti-a-synuclein antibody MJFR14 using immunocytochemistry; total a-synuclein levels were detected with Syn205 (a/b-synuclein-specific antibody).
[0557] The ReNcell VM a-synuclein aggregation assay was applied for compound screening to identify compounds capable of degrading a-synuclein aggregates. Specifically, adenovirally transduced ReNcell VM cells were treated with test compounds (serially diluted) for 24 hours, followed by fixation, and then processed for ReNcell immunocytochemistry by staining with Syn205 and MJFR14. Immunoreactivity toward aggregated (MJFR14) and total a-synuclein (Syn205) was quantified using high content-based segmentation of immunoactive areas in immunocytochemical images (performed with the IN Cell 2200 (GE Healthcare)), followed by quantification of immunofluorescent intensity (performed by CRL’s developed algorithm using IN Cell Developer Toolbox software).
[0558] A set of more than 100 compounds was tested for inhibition of MJFR14 immunoreactivity. Figure 1 shows the high content-based quantifications of aggregated a-synuclein species in combination with determination of nuclei count (% remaining cells) in differentiated ReNcell VM cells. Results showed that 24 hour treatment with test compounds 166362, 170357, 162640 and 180948, respectively, induced a concentration-dependent inhibition of MJFR14 immunoreactivity, indicative of decreased a-synuclein aggregation. Each panel of graph displays normalized data for percentage effect (PE) and remaining cells (%).
[0559] Percentage effect (PE): Inhibition in comparison to BLANK (0.1% DMSO).
[0560] PE = 100 - (signal of compound/average signal BLANK) x 100 [0561] Compound-induced cytotoxicity (% remaining cells)
[0562] % remaining cells = (nuclei count of compound/average nuclei count of BLANK) x 100
[0563] Figures 2A-2D show the representative immunocytochemical images of cells treated with vehicle (0.1% DMSO) and test compounds 132168, 166362, and 170357, and immunostained with MJFR14, illustrating the reduction in a-synuclein expression following treatment with compounds 132168 and 166362. The results demonstrated that 6-day treatment with compound 132168 and 166362, respectively, induced a clear inhibition of MJFR14 immunoreactivity, indicating compounds 132168 and 166362 effectively reduce a-synuclein aggregation.
[0564] Some embodiments of compounds were evaluated in the ReNcell VM a-synuclein aggregation assay. Results are summarized in Table 3.
Table 3.
Notes:
DC50 indicates the concentration at which 50% of a-synuclein aggregates has been degraded.
Example 40: In Vivo Assay For Degrading a-Synuclein Ag2regates
[0565] Male transgenic Line61 mice at age of three-month-old were used for the study. Mice were treated once via intravenous injection with the compound 132168 (25 mpk). Plasma and brain samples were collected at 0.25, 0.5, 1, 2, 4, 8 and 24 h post treatment. Blood samples were collected via cardiac puncture into MiniCollect® 0.5 mL K2EDTA (Potassium ethylenediaminetetraacetic acid) tubes. The blood samples were centrifuged at 3000 x g for 10 minutes at room temperature (22°C). Plasma was transferred to a pre-labeled 1.5 ml LoBind Eppendorf tube (2 aliquot, each ~75 mΐ), frozen on dry ice and stored at -80°C until analysis. For brain samples, a perfusion with 0.9% saline was performed before collection. Brain was weighed, hemisected on a cooled surface, weighed and snap frozen. The hemibrain was used for WES System analysis of human a-synuclein in soluble and insoluble fraction. Upon treatment of compound 132168, insoluble a-synuclein fraction decreases 30% compared to DMSO vehicle control, reflecting the reduction of insoluble a-synuclein aggregates. Results are shown in Figure 3.
Example 41: In Vivo Pharmacokinetic Study
[0566] To determine whether the compounds of the present disclosure are capable of crossing the blood brain barrier (BBB), example compound 132168 was administered to mice in a pharmacokinetic study (10 and 25 mg/kg, intravenous).
[0567] Animal Husbandry: Mice were housed at animal room environment with ventilation 15 times/hour, lighting 12 hours/day, temperature 20 °C to 24 °C and humidity 40 % to 70 %. The study rooms were disinfected and cleaned prior to the start of the study and the operation area was cleaned after each dosing or sampling during the study conduct. All animals had free access to food and water during the study. The animals had access to Certified Rodent Diet and water ad libitum. The nutritional composition and levels of contaminants of the diet and impurities and contaminants of the water were monitored by third organization. The health status of the animals was evaluated in accordance with accepted animal husbandry procedures and deemed suitable for experimental use.
[0568] Sample Collection & Processing: Approximately 110 pL of whole blood were collected from all animals via facial or cardiac puncture under anesthesia with Isoflurane into test tubes containing potassium ethylenediaminetetraacetate (K2EDTA) at 0.25, 0.5, 1, 2, 4, 8 and 24 hr post dose. Brian samples were collected at 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose. A perfusion with pre-cold saline will be conducted via cardiac puncture before brain collection. Blood samples were centrifuged at 2000g at 4°C for 5 minutes to obtain plasma samples by transferring the supernatants into new tubes. All plasma and brain samples were stored at approximately -70 °C until analysis.
[0569] Bioanalytical Method Development: The concentrations of compound in plasma and brain samples were determined using a liquid chromatography with tandem mass spectrometry (LC-MS/MS) based method.
Results: The PK parameters were summarized in Table 4. Compound 132168 was able to penetrate BBB in short period of time.
Table 4. In vivo pharmacokinetic profile of Compound 132168
[0570] Certain embodiments are as follows:
[0571] Embodiment 1. A method to treat synucleinopathy in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula A,
EBM-L-SBM (Formula A) wherein
EBM is an E3 ubiquitin ligase binding moiety;
L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula:
or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein
is covalently linked to L; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring
heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0
to 2 ring heteroatoms selected from O, S, and N;
) is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
[0572] Embodiment 2. A method to reduce a-synuclein aggregation in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula A,
EBM-L-SBM (Formula A) wherein
EBM is an E3 ubiquitin ligase binding moiety;
L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula:
or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein is covalently linked to L; and is a substituted or unsubstituted bicyclic fused aromatic ring containing
at least 1 ring heteroatom selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0
to 2 ring heteroatoms selected from O, S, and N; )
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
[0573] Embodiment 3. A method to reduce Lewy bodies in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula A,
EBM-L-SBM (Formula A) wherein
EBM is an E3 ubiquitin ligase binding moiety;
L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula:
or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein is covalently linked to L; and is a substituted or unsubstituted bicyclic fused aromatic ring containing
at least 1 ring heteroatom selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
[0574] Embodiment 4. Use of a compound of Formula A:
EBM-L-SBM (Formula A) or a pharmaceutical acceptable salt, a enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug thereof, in the manufacture of a medicament for treating synucleinopathy, wherein
EBM is an E3 ubiquitin ligase binding moiety;
L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula: wherein
covalently linked to L, and is a substituted or unsubstituted bicyclic fused aromatic ring containing
at least 1 ring heteroatom selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or
is a substituted or unsubstituted monocyclic aromatic ring containing 0
to 2 ring heteroatoms selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
s a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
[0575] Embodiment 5. Use of a compound of Formula A:
EBM-L-SBM (Formula A) or a pharmaceutical acceptable salt, a enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug thereof, in the manufacture of a medicament for reducing a-synuclein aggregation, wherein
EBM is an E3 ubiquitin ligase binding moiety;
L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula: wherein
is covalently linked to L; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing
at least 1 ring heteroatom selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
[0576] Embodiment 6. Use of a compound of Formula A:
EBM-L-SBM (Formula A) or a pharmaceutical acceptable salt, a enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug thereof, in the manufacture of a medicament for reducing Lewy bodies, wherein
EBM is an E3 ubiquitin ligase binding moiety;
L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula: wherein
is covalently linked to L; and is a substituted or unsubstituted bicyclic fused aromatic ring containing
at least 1 ring heteroatom selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
s a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
[0577] Embodiment 7. The method of Embodiment 1 or the use of Embodiment 4, wherein the synucleinopathy is Parkinson’s Disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), or a combination of two or more thereof [0578] Embodiment 8. The method or use of any one of Embodiments 1-7, wherein the substituted or unsubstituted bicyclic fused aromatic ring is a substituted or unsubstituted bicyclic 5-6 system.
[0579] Embodiment 9. The method or use of any one of Embodiments 1-8, wherein SBM is of Formula B or Formula C
wherein
Z is C or N; U is O, S or CH; V is N or Mi;
K is CH or N; Q is CH or N; where K and Q are not N at the same time; each occurrence of R'" is independently selected from the group consisting of H, OH, ML·, Ci-e alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R' is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, ML·, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkyl, Ci-6 alkylamino, C3-6 cycloalkylamino, C3-6 cycloalkyl and C3-6 heterocycloalkyl; n is 0, 1 or 2;
J is CR6 or N; X is CR6 or N; Y is CR6 or N; where at least one of J, X and Y is N, but J and Y are not N at the same time, X and Y are not N at the same time;
R6 is independently selected from the group consisting of H, NH2, Ci-6 alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo; and in Formula B, V is N, where Z and U are not heteroatoms at the same time; and in Formula C, V is N or NH; T is CH or N; where up to two of U, Z, V and T contain heteroatoms.
[0580] Embodiment 10. The method or use of any one of Embodiments 1-9, wherein EBM is
wherein
R3 is H or Ci-6 alkyl; each occurrence of R2 is independently selected from the group consisting of H, OH, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkylamino andMB; m6 is 0, 1, 2, 3 or 4; and
[0581] Embodiment 11. The method or use of any one of Embodiments 1-10, wherein the compound is of any one of Formula I to Formula YI,
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof;
wherein,
Li is a bond, -C(=0)-, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group;
L2 is a substituted or unsubstituted Ci-50 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with - C(=0)-, -0-, -NRal- -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group;
Z is C or N; U is O, S or CH;
K is CH or N; Q is CH or N; where K and Q are not N at the same time; each occurrence of R'" is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkyl, Ci-6 alkylamino, C3-6 cycloalkylamino, C3-6 cycloalkyl and C3-6 heterocycloalkyl; n is 0, 1 or 2;
J is CR6 or N; X is CR6 or N; Y is CR6 or N; where at least one of J, X and Y is N, but J and Y are not N at the same time, X and Y are not N at the same time;
R6 is independently selected from the group consisting of H, NH2, Ci-6 alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo; in Formula I, L3 is a bond, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; R3 is H or Ci-6 alkyl; Yi is CH2 or V is N, where Z and U are not heteroatoms at the same time;
in Formula II, each occurrence of R2 is independently selected from the group consisting of H, OH, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkylamino and NH2; m6 is 0, 1, 2, 3 or 4;
Yi is CH2 or
V is N, where Z and U are not heteroatoms at the same time; in Formula III, V is N, where Z and U are not heteroatoms at the same time; in Formula IV, L3 is a bond, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; R3 is H or Ci-6 alkyl; two of U, Z, V and T
contain heteroatoms; in Formula V, each occurrence of R2 is independently selected from the group consisting of H, OH, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkylamino and NH2; m6 is 0, 1, 2, 3 or 4; two of U, Z, V and T contain
heteroatoms; in Formula VI, V is N; T is CH or N; where up to two of U, Z, V and T contain heteroatoms.
[0582] Embodiment 12. The method or use of Embodiment 11, wherein L2 is an optionally substituted Ci-45 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -0-, -NRa1-, -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group; preferably, L2 is a substituted or unsubstituted C5-40 hydrocarbon chain; preferably, L2 is a substituted or unsubstituted Ci-30, Ci-24, or Ci-20 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with - or a cyclic moiety, wherein Ral is
independently hydrogen, substituted or unsubstituted Ci-e alkyl or a nitrogen protecting group;
preferably, L2 is an unsubstituted Ci-26, C5-26, C5-20, C5-15, C15-20, or C20-25 hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -O- or-NRa1-, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group.
[0583] Embodiment 13. The method or use of Embodiment 11, wherein L2 is an optionally substituted Ci-30 hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -O- or -NRal- wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group; preferably, at least one chain atom of the hydrocarbon chain of L2 is independently replaced with -C(=0)-, -0-, -S-, -NRa1-, -N= or =N-, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group; preferably replaced with -0-.
[0584] Embodiment 14. The method or use of Embodiment 11, wherein L2 is selected from the group consisting of substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroaryl ene, or substituted or unsubstituted heteroalkylene, and combinations thereof; preferably, L2 is selected from the group consisting of substituted and unsubstituted alkylene, substituted and unsubstituted alkenylene, substituted and unsubstituted alkynylene, substituted and unsubstituted heteroalkylene, substituted and unsubstituted heteroalkenylene, substituted and unsubstituted heteroalkynylene, substituted and unsubstituted heterocyclylene, substituted and unsubstituted carbocyclylene, substituted and unsubstituted arylene, substituted and unsubstituted heteroarylene, and combinations thereof.
[0585] Embodiment 15. The method or use of Embodiment 14, wherein the carbocyclylene or the heterocyclylene is
[0586] Embodiment 16. The method or use of Embodiment 14, wherein L2 comprises at least one instance selected from the group consisting of substituted or unsubstituted Ci-6 alkylene, substituted or unsubstituted C2-6 alkenylene, substituted or unsubstituted C2-6 alkynylene, substituted or unsubstituted heteroCi-6alkylene, substituted or unsubstituted heteroC2-6alkenylene, substituted or unsubstituted heteroC2-6alkynylene, substituted or unsubstituted C3-6carbocyclylene, substituted or unsubstituted 3-6 membered heterocyclylene, substituted or unsubstituted phenylene, and substituted or unsubstituted 5- to 6-membered heteroarylene.
[0587] Embodiment 17. The method or use of Embodiment 14, wherein L2 comprises at least one instance selected from the group consisting of substituted or unsubstituted methylene, ethylene, n-propylene, n-butylene, n-pentylene, n-hexylene, -
[0588] Embodiment 18. The method or use of Embodiment 14, wherein at least one chain atom of the hydrocarbon chain of L2 is independently replaced with a 6-membered heterocyclyl group with 1-3 ring heteroatoms selected from the group consisting of nitrogen and oxygen; preferably, at least one chain atom of the hydrocarbon chain of L2 is independently replaced with piperidine, piperazine or morpholine; preferably, at least one chain atom of the hydrocarbon chain of L2 is independently replaced with an optionally substituted phenyl group.
[0589] Embodiment 19. The method or use of Embodiment 14, wherein L2 is an unsubstituted hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -NRa1-, and each instance of Ral is independently hydrogen, substituted or unsubstituted Ci-e alkyl or a nitrogen protecting group, or optionally two instances of Ral are taken together with their intervening atoms to form a substituted or unsubstituted heterocyclic or substituted or unsubstituted heteroaryl ring.
[0590] Embodiment 20. The method or use of Embodiment 19, wherein at least one instance of Ral is hydrogen, substituted or unsubstituted Ci-6 alkyl (e.g., substituted or unsubstituted methyl or ethyl), or a nitrogen protecting group (e.g., benzyl, t-butyl carbonate, benzyl carbamate, 9-fluorenylmethyl carbonate, trifluoroacetyl, triphenylmethyl, acetyl or p-toluenesulfonamide).
[0591] Embodiment 21. The method or use of Embodiment 11, wherein Li i iss wherein g is 1, 2, 3, 4, 5, or 6.
[0592] Embodiment 22. The method or use of Embodiment 11, wherein L2 includes the moiety
[0593] Embodiment 23. The method or use of Embodiment 11, wherein L2 is selected from the group consisting of
wherein each g is independently 1, 2, 3, 4, 5, or 6; f is 1, 2, 3, 4, 5, or 6, and h is 1, 2, 3, 4, 5, or 6.
[0594] Embodiment 24. The method or use of Embodiment 11, wherein the compound of Formula I is of Formula 1-1;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0595] Embodiment 25. The method or use of Embodiment 11, wherein the compound of Formula II is of Formula II- 1;
racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0596] Embodiment 26. The method or use of Embodiment 11, wherein the compound of Formula III is of Formula III- 1 ;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0597] Embodiment 27. The method or use of Embodiment 11, wherein the compound of Formula IV is of Formula IV-1;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0598] Embodiment 28. The method or use of Embodiment 11, wherein the compound of Formula V is of Formula V-l;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0599] Embodiment 29. The method or use of Embodiment 11, wherein the compound of Formula VI is of Formula VI-1;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0600] Embodiment 30. The method or use of Embodiment 24, wherein the compound of Formula 1-1 is of Formula 1, 5, 6, 8, 10 or 13;
Formula 5
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof; wherein
[0601] Embodiment 31. The method or use of Embodiment 30, wherein the compound is of Formula 1, and wherein R' is H, C1-3 haloalkyl or C1-3 alkoxy; and/or, R" is H, halo, OH,
ME, Ci-3 alkoxy, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino and C3-5 heterocycloalkyl; and/or, R'" is H, OH or halogen; and/or, R1 is O, NH,
4 or 6; and/or, R3 is H or C1-3 alkyl; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0602] Embodiment 32. The method or use of Embodiment 30, wherein the compound is of Formula 5, and wherein R3 is H or C1-3 alkyl; and/or, each A is independently O, NH,
y or halogen; and/or, R is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; and/or, m is 0, 1, 2 or 3; and/or, R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; or the
pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0603] Embodiment 33. The method or use of Embodiment 30, wherein the compound is of Formula 6, and wherein R3 is El or C1-3 alkyl; and/or, A is O, NH or ; and/or,
m2 is 1, 2, 3, 4, 5, 6 or 7; and/or, R1 is O, NH or ; and/or, R"1 is H, OH, C1-3 alkyl,
Ci-3 alkoxy or halogen; and/or, R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; and/or, m is 0, 1, 2 or 3; and/or, R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; and/or, n is 0 or 1; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0604] Embodiment 34. The method or use of Embodiment 30, wherein the compound is of Formula 8, and wherein R3 is H or Ci-3 alkyl; and/or, A is O, NH,
or
R1" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen; and/or, k is 0 or 1; and/or, R1 is H, halogen, OH, Ci-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; and/or, m is 0, 1 or 2; and/or, R" is H, halo,
OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; and/or, n is 0, 1 or 2; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0605] Embodiment 35. The method or use of Embodiment 30, wherein the compound is of Formula 10, and wherein R3 is H or C1-3 alkyl; and/or, each A is independently O, NH,
alkyl, C1-3 alkoxy or halogen; and/or, k is 0 or 1; and/or, R' is H, halogen, OH, C1-3 alkyl, Ci-3 haloalkyl or C1-3 alkoxy; and/or, m is 0 or 1; and/or, R" is H, halo, OH, NH2, C1-3 alkyl, Ci-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; and/or, n is 0 or 1; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0606] Embodiment 36. The method or use of Embodiment 30, wherein the compound is of Formula 13, and wherein R3 is H or Ci-3 alkyl; and/or, A is O, NH,
or
R1" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen; and/or, R1 is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; and/or, m is 0, 1, 2 or 3; and/or, R" is H, halo, OH, NH2, C1-3 alkyl, Ci-3 alkoxy, C1.3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof. [0607] Embodiment 37. The method or use of Embodiment 30, wherein the compound of Formula 1 is of Formula 1-1;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof [0608] Embodiment 38. The method or use of Embodiment 30, wherein the compound of Formula 5 is of Formula 5-1;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0609] Embodiment 39. The method or use of Embodiment 30, wherein the compound of Formula 6 is of Formula 6-1;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0610] Embodiment 40. The method or use of Embodiment 37, wherein R3 is H or C1-3
Cl, OFI, NEh, Ci-3 alkoxy, methylamino, dimethylamino, diethylamino or cyclopropylamino.
[0611] Embodiment 41. The method or use of Embodiment 38, wherein R3 is H or C1-3
alkoxy or halogen; R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; R" is H,
halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino and C3-5 heterocycloalkyl.
[0612] Embodiment 42. The method or use of Embodiment 39, wherein R3 is H or C1-3 alkyl; A is O, NH,
R'" is H, OH, Ci-3 alkyl, Ci-3 alkoxy or halogen; R' is H, halogen,
OH, Ci-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; m is 0, 1, 2 or 3; R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl.
[0613] Embodiment 43. The method or use of Embodiment 30, wherein the compound is of Formula 1, 5, 6, 8, 10 or 13, and wherein K is CH and Q is N, or K is N and Q is CH, or both of K and Q are CH; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0614] Embodiment 44. The method or use of Embodiment 25, wherein the compound is of Formula 3;
wherein R1 is O, NH,
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0615] Embodiment 45. The method or use of Embodiment 44, wherein R2 is H, OH, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylamino or H2; and/or, m6 is 0, 1, 2 or 3; and/or, R1 is O or NH; and/or, R is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; and/or, R" is H, halo,
OH, NH2, Ci-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino; and/or, R"' is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen.
[0616] Embodiment 46. The method or use of Embodiment 44, wherein Z is C and El is O or S; or Z is N and El is CH; and/or, K is CH and Q is N, or K is N and Q is CH, or both of K and Q are CH.
[0617] Embodiment 47. The method or use of Embodiment 44, wherein the compound is of Formula 3-1;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0618] Embodiment 48. The method or use of Embodiment 47, wherein R2 is H, OH, C1-3
H
cycloalkylamino or C1-3 alkylamino.
[0619] Embodiment 49. The method or use of Embodiment 26, wherein the compound is of Formula 15;
wherein m2 is 1, 2, 3, 4, 5, 6, or 7; and R1 is O, NH,
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0620] Embodiment 50. The method or use of Embodiment 49, wherein m2 is 1, 2, 3, 4, 5,
6 or 7; and/or, R1 is O, NH,
alkoxy or halogen; and/or, R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; m is 0, 1, 2 or 3; and/or, R" is H, halo, OH, NH2, C1-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino.
[0621] Embodiment 51. The method or use of Embodiment 27, wherein the compound is of Formula 2, 7, 9, 11, 12 or 14;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof; wherein
[0622] Embodiment 52. The method or use of Embodiment 51, wherein the compound is of Formula 2, and wherein R3 is H or Ci-3 alkyl; and/or, A is O, NH,
and/or, R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; and/or, R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; and/or, m is 0, 1, 2 or 3; and/or, R" is H, OH, NH2, C1-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0623] Embodiment 53. The method or use of Embodiment 51, wherein the compound is of Formula 7, and wherein R3 is H or Ci-3 alkyl; and/or, A is O, NH,
and/or, R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; and/or, R is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; and/or, m is 0, 1, 2 or 3; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0624] Embodiment 54. The method or use of Embodiment 51, wherein the compound is of Formula 9, and wherein R3 is H or Ci-3 alkyl; and/or, A is O, NH,
and/or, R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; and/or, R is H, halogen, OH, C1-3
alkyl, C1-3 haloalkyl or C1-3 alkoxy; and/or, m is 0, 1, 2 or 3; and/or, R'" is H, OH, NH2, C1-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0625] Embodiment 55. The method or use of Embodiment 51, wherein the compound is of Formula 11, and wherein R3 is H or C1-3 alkyl; and/or, A is O, NH,
and/or, R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; and/or, R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; and/or, m is 0, 1, 2 or 3; and/or, R"' is H, OH, NH2, C1-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0626] Embodiment 56. The method or use of Embodiment 51, wherein the compound is of Formula 12, and wherein R3 is H or Ci-3 alkyl; each A is independently O, NH,
NH, ; R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl,
Ci-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; m is 0, 1, 2 or 3; R" is H, OH, NH2,
Ci-3 alkyl, Ci-3 alkylamino, Ci-3 alkoxy or halogen; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0627] Embodiment 57. The method or use of Embodiment 51, wherein the compound is of Formula 14, and wherein R3 is H or C1-3 alkyl; and/or, each A is independently O, NH,
NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; and/or, R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; m is 0, 1, 2 or 3; and/or, R'" is H, OH, NH2, C1-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0628] Embodiment 58. The method or use of Embodiment 28, wherein the compound is of Formula 4;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof
[0629] Embodiment 59. The method or use of Embodiment 58, wherein R2 is H, OH, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylamino or NH2; and/or, m6 is 0, 1, 2 or 3; and/or, R1 is O, NH, ; and/or, R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3
alkoxy; R" is H, halo, OH, NH2, C1-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino; and/or, R"' is H, OH, NH2, C1-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen. [0630] Embodiment 60. The method or use of Embodiment 58, wherein the compound is of Formula 4-1;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0631] Embodiment 61. The method or use of Embodiment 29, wherein the compound is of Formula 16 or 17,
Formula 17 wherein m2 is 1, 2, 3, 4, 5, 6, or 7; and R1 is O, NH,
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0632] Embodiment 62. The method or use of Embodiment 61, wherein the compound is of Formula 16, and wherein Z is C, U is O or S and T is CH; or, Z is N, U is CH and T is CH; Z is C, T is N and U is CH; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0633] Embodiment 63. The method or use of Embodiment 61, wherein the compound is of Formula 17, and wherein Z is C, U is O or S and T is CH; or, Z is N, U is CH and T is CH; Z is C, T is N and U is CH; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0634] Embodiment 64. The method or use of any one of Embodiments 1-7, wherein the compound is selected from the compounds listed in Table 2, or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
[0635] Embodiment 65. A compound of Formula A:
EBM-L-SBM (Formula A) or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof, for treating synucleinopathy, wherein
EBM is an E3 ubiquitin ligase binding moiety;
L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula:
or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein
covalently linked to L; and
(i)
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or
(ii)
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted
monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
[0636] Embodiment 66. A compound of Formula A:
EBM-L-SBM (Formula A) or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof, for reducing a-synuclein aggregation, wherein
EBM is an E3 ubiquitin ligase binding moiety;
L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula:
or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein covalently linked to L; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing
at least 1 ring heteroatom selected from O, S, and N; is a substituted or unsubstituted
monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
[0637] Embodiment 67. A compound of Formula A:
EBM-L-SBM (Formula A) or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof, for reducing Lewy bodies, wherein
EBM is an E3 ubiquitin ligase binding moiety;
L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula:
or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein
covalently linked to L; and
(i)
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or
(ii)
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
Claims
WHAT IS CLAIMED IS:
1. A method to treat synucleinopathy in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula A,
EBM-L-SBM (Formula A) wherein
EBM is an E3 ubiquitin ligase binding moiety;
L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula:
or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein covalently linked to L, and
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or
s a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted
monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
2. A method to reduce a-synuclein aggregation in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of
Formula A,
EBM-L-SBM (Formula A) wherein
EBM is an E3 ubiquitin ligase binding moiety;
L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula:
or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein is covalently linked to L; and
i . s a substituted or unsubstituted bicyclic fused aromatic ring containing
) at least 1 ring heteroatom selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0
to 2 ring heteroatoms selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
3. A method to reduce Lewy bodies in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula A,
EBM-L-SBM (Formula A) wherein
EBM is an E3 ubiquitin ligase binding moiety;
L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula:
or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein is covalently linked to L; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing
at least 1 ring heteroatom selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring
heteroatoms selected from O, S, and N; or
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
4. Use of a compound of Formula A:
EBM-L-SBM (Formula A)
or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, in the manufacture of a medicament for treating synucleinopathy, wherein
EBM is an E3 ubiquitin ligase binding moiety;
L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula: wherein
is covalently linked to L; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing ) at least 1 ring heteroatom selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0
to 2 ring heteroatoms selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
5. Use of a compound of Formula A:
EBM-L-SBM (Formula A) or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, in the manufacture of a medicament for reducing a-synuclein aggregation, wherein
EBM is an E3 ubiquitin ligase binding moiety;
L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula:
wherein
covalently linked to L; and is a substituted or unsubstituted bicyclic fused aromatic ring containing
at least 1 ring heteroatom selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0
to 2 ring heteroatoms selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
6. Use of a compound of Formula A:
EBM-L-SBM (Formula A) or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, in the manufacture of a medicament for reducing Lewy bodies, wherein
EBM is an E3 ubiquitin ligase binding moiety;
L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula:
wherein covalently linked to L; and
(i)
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or
(ii)
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N;
is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and
is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
7. The method of claim 1 or the use of claim 4, wherein the synucleinopathy is
Parkinson’s Disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), or a combination of two or more thereof.
8. The method or use of any one of claims 1-7, wherein the substituted or unsubstituted bicyclic fused aromatic ring is a substituted or unsubstituted bicyclic 5-6 system.
9. The method or use of any one of claims 1-8, wherein SBM is of Formula B or
Formul C
wherein
Z is C or N; U is O, S or CH; V is N or NH;
K is CH or N; Q is CH or N; where K and Q are not N at the same time; each occurrence of R'" is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R' is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkyl, Ci-6 alkylamino, C3-6 cycloalkylamino, C3-6 cycloalkyl and C3-6 heterocycloalkyl; n is 0, 1 or 2;
J is CR6 or N; X is CR6 or N; Y is CR6 or N; where at least one of J, X and Y is N, but J and Y are not N at the same time, X and Y are not N at the same time;
R6 is independently selected from the group consisting of H, NH2, Ci-6 alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo; and in Formula B, V is N, where Z and U are not heteroatoms at the same time; and in Formula C, V is N or NH; T is CH or N; where up to two of U, Z, V and T contain heteroatoms.
10 The method or use of any one of claims 1-9, wherein EBM is
wherein
R3 is H or Ci-6 alkyl; each occurrence of R2 is independently selected from the group consisting of H, OH, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkylamino andMH; m6 is 0, 1, 2, 3 or 4; and
11. The method or use of any one of claims 1-10, wherein the compound is of any one of Formula I to Formula VI,
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof, wherein,
Li is a bond, -C(=0)-, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group;
L2 is a substituted or unsubstituted Ci-50 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with - C(=0)-, -0-, -NRal- -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group;
Z is C or N; U is O, S or CH;
K is CH or N; Q is CH or N; where K and Q are not N at the same time; each occurrence of R'" is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R' is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkyl, Ci-6 alkylamino, C3-6 cycloalkylamino, C3-6 cycloalkyl and C3-6 heterocycloalkyl; n is 0, 1 or 2;
J is CR6 or N; X is CR6 or N; Y is CR6 or N; where at least one of J, X and Y is N, but J and Y are not N at the same time, X and Y are not N at the same time;
R6 is independently selected from the group consisting of H, NH2, Ci-6 alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo; in Formula I, L3 is a bond, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; R3 is H or Ci-6 alkyl; Yi is CH2
; V is N, where Z and U are not heteroatoms at the same time; in Formula II, each occurrence of R2 is independently selected from the group consisting of H, OH, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkylamino and NH2; m6 is 0, 1, 2, 3 or 4;
Yi is CH2 or
; V is N, where Z and U are not heteroatoms at the same time; in Formula III, V is N, where Z and U are not heteroatoms at the same time;
in Formula IV, L3 is a bond, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; R3 is H or Ci-6 two of U, Z, V and T
contain heteroatoms; in Formula V, each occurrence of R2 is independently selected from the group consisting of H, OH, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkylamino and NH2; m6 is 0, 1, 2, 3 or 4; two of U, Z, V and T contain
heteroatoms; and in Formula VI, V is N; T is CH or N; where up to two of U, Z, V and T contain heteroatoms.
12. The method or use of claim 11, wherein L2 is an optionally substituted Ci-45 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -0-, -NRa1-, -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group; preferably, L2 is a substituted or unsubstituted C5-40 hydrocarbon chain; preferably, L2 is a substituted or unsubstituted Ci-30, Ci-24, or Ci-20 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -0-, -NRa1-, -S- or a cyclic moiety, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group; preferably, L2 is an unsubstituted Ci-26, C5-26, C5-20, C5-15, C15-20, or C20-25 hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -C(=0)-, -O- or-NRa1-, wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group.
13. The method or use of claim 11, wherein L2 is an optionally substituted Ci-30 hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -O- or -NRal- wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group; preferably, at least one chain atom of the hydrocarbon chain of L2 is independently replaced with -C(=0)-, -0-, -S-, -NRa1-, -N= or =N- wherein Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group; preferably replaced with -0-.
14. The method or use of claim 11, wherein L2 is selected from the group consisting of substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroaryl ene, or substituted or unsubstituted heteroalkylene, and combinations thereof; preferably, L2 is selected from the group consisting of substituted and unsubstituted alkylene, substituted and unsubstituted alkenylene, substituted and unsubstituted alkynylene, substituted and unsubstituted heteroalkylene, substituted and unsubstituted heteroalkenylene, substituted and unsubstituted heteroalkynylene, substituted and unsubstituted heterocyclylene, substituted and unsubstituted carbocyclylene, substituted and unsubstituted arylene, substituted and unsubstituted heteroarylene, and combinations thereof.
15. The method or use of claim 14, wherein the carbocyclylene or the heterocyclylene
16. The method or use of claim 14, wherein L2 comprises at least one instance selected from the group consisting of substituted or unsubstituted Ci-6 alkylene, substituted or unsubstituted C2-6 alkenylene, substituted or unsubstituted C2-6 alkynylene, substituted or unsubstituted heteroCi-6alkylene, substituted or unsubstituted heteroC2-6alkenylene, substituted or unsubstituted heteroC2-6alkynylene, substituted or unsubstituted C3-
6carbocyclylene, substituted or unsubstituted 3-6 membered heterocyclylene, substituted or unsubstituted phenylene, and substituted or unsubstituted 5- to 6-membered heteroarylene.
17. The method or use of claim 14, wherein L2 comprises at least one instance selected from the group consisting of substituted or unsubstituted methylene, ethylene, n-propylene, n-butylene, n-pentylene, n-hexylene,
18. The method or use of claim 14, wherein at least one chain atom of the hydrocarbon chain of L2 is independently replaced with a 6-membered heterocyclyl group with 1-3 ring heteroatoms selected from the group consisting of nitrogen and oxygen; preferably, at least one chain atom of the hydrocarbon chain of L2 is independently replaced with piperidine, piperazine or morpholine; preferably, at least one chain atom of the hydrocarbon chain of L2 is independently replaced with an optionally substituted phenyl group.
19. The method or use of claim 14, wherein L2 is an unsubstituted hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -NRa1-, and each instance of Ral is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group, or optionally two instances of
Ral are taken together with their intervening atoms to form a substituted or unsubstituted heterocyclic or substituted or unsubstituted heteroaryl ring.
20. The method or use of claim 19, wherein at least one instance of Ral is hydrogen, substituted or unsubstituted Ci-6 alkyl (e.g., substituted or unsubstituted methyl or ethyl), or a nitrogen protecting group (e.g., benzyl, t-butyl carbonate, benzyl carbamate, 9-fluorenylmethyl carbonate, trifluoroacetyl, triphenylmethyl, acetyl or p-toluenesulfonamide).
1 The method or use of claim 11, wherein L2 is
, wherein g is 1, 2, 3, 4,
5, or 6. 2. The method or use of claim 11, wherein L2 includes the moiety HC(=0)- or -NH-.
3. The method or use of claim 11, wherein L2 is selected from the group consisting of
24. The method or use of claim 11, wherein the compound of Formula I is of Formula i-i;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
25. The method or use of claim 11, wherein the compound of Formula II is of Formula II- 1;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
26. The method or use of claim 11, wherein the compound of Formula III is of Formula III- 1 ;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
27. The method or use of claim 11, wherein the compound of Formula IV is of Formula IV-1;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
28. The method or use of claim 11, wherein the compound of Formula V is of Formula V-l;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
29. The method or use of claim 11, wherein the compound of Formula VI is of Formula VI- 1;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
30. The method or use of claim 24, wherein the compound of Formula 1-1 is of Formula 1, 5, 6, 8, 10 or 13;
Formula 6
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof; wherein
31. The method or use of claim 30, wherein the compound is of Formula 1, and wherein R1 is H, C1-3 haloalkyl or C1-3 alkoxy; and/or, R" is H, halo, OH, NH2, C1-3 alkoxy,
Ci-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino and C3-5 heterocycloalkyl; and/or, R'"
Ci-3 alkyl; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
32. The method or use of claim 30, wherein the compound is of Formula 5, and wherein R3 is H or C1-3 alkyl; and/or, each A is independently O, NH,
and/or, R is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; and/or, m is 0, 1, 2 or 3; and/or, R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
33. The method or use of claim 30, wherein the compound is of Formula 6, and wherein R3 is H or C1-3 alkyl; and/or, A is O, NH or and/or, m2 is 1, 2, 3, 4, 5, 6
or 7; and/or, R1 is O, NH or
; and/or, R1" is H, OH, C1-3 alkyl, C1-3 alkoxy or halogen; and/or, R is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; and/or, m is 0,
1, 2 or 3; and/or, R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; and/or, n is 0 or 1; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
34. The method or use of claim 30, wherein the compound is of Formula 8, and wherein R3 is H or C1-3 alkyl; and/or, A is O, NH, alkyl, C1-3
alkoxy or halogen; and/or, k is 0 or 1; and/or, R1 is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or Ci-3 alkoxy; and/or, m is 0, 1 or 2; and/or, R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, Ci-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; and/or, n is 0, 1 or 2; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
35. The method or use of claim 30, wherein the compound is of Formula 10, and wherein R3 is H or C1-3 alkyl; and/or, each A is independently O, NH,
xy or
halogen; and/or, k is 0 or 1; and/or, R1 is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; and/or, m is 0 or 1; and/or, R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1.3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; and/or, n is 0 or 1; or the pharmaceutical acceptable salt, the enantiomer, the
non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
36. The method or use of claim 30, wherein the compound is of Formula 13, and wherein R3 is H or Ci-3 alkyl; and/or, A is O, NH, ; and/or, m2 is 1,
2, 3 or 4; and/or, R1 is O, NH, and/or, R" is H, OH, C1-3 alkyl, C1-3
alkoxy or halogen; and/or, R is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; and/or, m is 0, 1, 2 or 3; and/or, R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
37. The method or use of claim 30, wherein the compound of Formula 1 is of Formula i-i;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
38. The method or use of claim 30, wherein the compound of Formula 5 is of Formula
5-1;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
39. The method or use of claim 30, wherein the compound of Formula 6 is of Formula 6-1;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
40. The method or use of claim 37, wherein R3 is H or C1-3 alkyl; A is O, NH,
alkoxy, methylamino, dimethylamino, diethylamino or cyclopropylamino.
41. The method or use of claim 38, wherein R3 is H or C1-3 alkyl; A is O, NH,
is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino and C3-5 heterocycloalkyl.
42. The method or use of claim 39, wherein R3 is H or C1-3 alkyl; A is O, NH,
R'" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen; R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; m is 0, 1, 2 or 3; R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, Ci-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl.
43. The method or use of claim 30, wherein the compound is of Formula 1, 5, 6, 8, 10 or 13, and wherein K is CH and Q is N, or K is N and Q is CH, or both of K and Q are CH; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
44. The method or use of claim 25, wherein the compound is of Formula 3;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
45. The method or use of claim 44, wherein R2 is H, OH, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylamino or NH2; and/or, m6 is 0, 1, 2 or 3; and/or, R1 is O or NH; and/or, R1 is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; and/or, R" is H, halo, OH, NH2, C1-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino; and/or, R'" is H, OH, C1-3 alkyl, C1-3 alkoxy or halogen.
46. The method or use of claim 44, wherein Z is C and U is O or S; or Z is N and U is CH; and/or, K is CH and Q is N, or K is N and Q is CH, or both of K and Q are CH.
47. The method or use of claim 44, wherein the compound is of Formula 3-1;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
48. The method or use of claim 47, wherein R2 is H, OH, Ci-3 alkyl, C1-3 alkoxy, C1-3 alkylamino or NH2; m6 is 0, 1, 2 or 3; R1 is O, NH,
OH, NH2, Ci-3 alkoxy, C1-3 haloalkyl, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino.
49. The method or use of claim 26, wherein the compound is of Formula 15; wherein m2 is 1, 2, 3, 4, 5, 6, or 7; and R1 is O, NH,
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
50. The method or use of claim 49, wherein m2 is 1, 2, 3, 4, 5, 6 or 7; and/or, R1 is O, H,
; and/or, R1" is H, OH, C1-3 alkyl, C1-3 alkoxy or halogen; and/or, R1 is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; m is 0, 1, 2 or 3; and/or, R" is H, halo, OH, NH2, C1-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino.
51. The method or use of claim 27, wherein the compound is of Formula 2, 7, 9, 11, 12 or 14;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof; wherein
52. The method or use of claim 51, wherein the compound is of Formula 2, and
3, 4, 5 or 6; and/or, R1 is O, NH, and/or, R" is H, halo, OH, NH2,
Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; and/or, R1 is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3
alkoxy; and/or, m is 0, 1, 2 or 3; and/or, R'" is H, OH, NH2, C1-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
53. The method or use of claim 51, wherein the compound is of Formula 7, and wherein R3 is H or C1-3 alkyl; and/or, A is O, NH,
3, 4, 5 or 6; and/or, R1 is O, NH, and/or, R" is H, halo, OH, NH2,
Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; and/or, R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; and/or, m is 0, 1, 2 or 3; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
54. The method or use of claim 51, wherein the compound is of Formula 9, and
3, 4, 5 or 6; and/or, R1 is O, NH, ; and/or, R" is H, halo, OH, NH2,
Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; and/or, R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; and/or, m is 0, 1, 2 or 3; and/or, R'" is H, OH, NH2, C1-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
55. The method or use of claim 51, wherein the compound is of Formula 11, and
Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; and/or, R' is H, halogen, OH, C1-3 alkyl, C1.3 haloalkyl or C1.3 alkoxy; and/or, m is 0, 1, 2 or 3; and/or, R'" is H, OH, NH2, C1-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
56. The method or use of claim 51, wherein the compound is of Formula 12, and
; R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; m is 0, 1, 2 or 3; R'" is H, OH, NH2, C1-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
57. The method or use of claim 51, wherein the compound is of Formula 14, and wherein R3 is H or C1-3 alkyl; and/or, each A is independently O, NH
alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or
C3-5 heterocycloalkyl; and/or, R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; m is 0, 1, 2 or 3; and/or, R" is H, OH, NH2, C1-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
58. The method or use of claim 28, wherein the compound is of Formula 4;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
59. The method or use of claim 58, wherein R2 is H, OH, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylamino orML·; and/or, m6 is 0, 1, 2 or 3; and/or, R1 is O, NH,
and/or, R is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; R" is H, halo, OH, NH2, Ci-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino; and/or, R" is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen.
60. The method or use of claim 58, wherein the compound is of Formula 4-1;
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
61. The method or use of claim 29, wherein the compound is of Formula 16 or 17;
wherein m2 is 1, 2, 3, 4, 5, 6, or 7; and R1 is O, NH,
or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
62. The method or use of claim 61, wherein the compound is of Formula 16, and wherein Z is C, U is O or S and T is CH; or, Z is N, U is CH and T is CH; Z is C, T is N and
U is CH; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
63. The method or use of claim 61, wherein the compound is of Formula 17, and wherein Z is C, U is O or S and T is CH; or, Z is N, U is CH and T is CH; Z is C, T is N and U is CH; or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
64. The method or use of any one of claims 1-7, wherein the compound is selected from the compounds listed in Table 2, or the pharmaceutical acceptable salt, the enantiomer, the non-enantiomer, the tautomer, the racemate, the solvate, the metabolic precursor, or the prodrug thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2021/054167 WO2022238737A1 (en) | 2021-05-14 | 2021-05-14 | Compounds for degrading alpha-synuclein aggregates and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4337259A1 true EP4337259A1 (en) | 2024-03-20 |
Family
ID=76034924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21726997.6A Pending EP4337259A1 (en) | 2021-05-14 | 2021-05-14 | Compounds for degrading alpha-synuclein aggregates and uses thereof |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4337259A1 (en) |
JP (1) | JP2024517340A (en) |
KR (1) | KR20240008335A (en) |
CN (1) | CN117377496A (en) |
AU (1) | AU2021444937A1 (en) |
CA (1) | CA3218573A1 (en) |
TW (1) | TW202304516A (en) |
WO (1) | WO2022238737A1 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10300155B2 (en) * | 2015-12-31 | 2019-05-28 | Washington University | Alpha-synuclein ligands |
US11458123B2 (en) | 2016-11-01 | 2022-10-04 | Arvinas Operations, Inc. | Tau-protein targeting PROTACs and associated methods of use |
EP3652329B1 (en) | 2017-07-12 | 2023-10-04 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
US20210253569A1 (en) | 2018-05-09 | 2021-08-19 | Aprinoia Therapeutics Inc. | Heteroaryl compounds and uses thereof |
WO2020041331A1 (en) * | 2018-08-20 | 2020-02-27 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
-
2021
- 2021-05-14 AU AU2021444937A patent/AU2021444937A1/en active Pending
- 2021-05-14 CA CA3218573A patent/CA3218573A1/en active Pending
- 2021-05-14 WO PCT/IB2021/054167 patent/WO2022238737A1/en active Application Filing
- 2021-05-14 EP EP21726997.6A patent/EP4337259A1/en active Pending
- 2021-05-14 CN CN202180098221.5A patent/CN117377496A/en active Pending
- 2021-05-14 KR KR1020237042637A patent/KR20240008335A/en active Search and Examination
- 2021-05-14 JP JP2023570190A patent/JP2024517340A/en active Pending
-
2022
- 2022-05-13 TW TW111118050A patent/TW202304516A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW202304516A (en) | 2023-02-01 |
KR20240008335A (en) | 2024-01-18 |
CA3218573A1 (en) | 2022-11-17 |
CN117377496A (en) | 2024-01-09 |
AU2021444937A1 (en) | 2023-11-30 |
JP2024517340A (en) | 2024-04-19 |
WO2022238737A1 (en) | 2022-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11065231B2 (en) | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | |
AU2017222958B2 (en) | Glycosidase inhibitors | |
AU2017222964B2 (en) | Glycosidase inhibitors | |
JP6851367B2 (en) | IRAK4 Inhibitors and Their Applications | |
US20080188502A1 (en) | New Compounds I | |
WO2018102751A1 (en) | Ire1 small molecule inhibitors | |
TW202000674A (en) | Fused thiophene compounds | |
KR20170083135A (en) | Substituted bridged urea analogs as sirtuin modulators | |
US20220280650A1 (en) | Compounds for degrading alpha-synuclein aggregates and uses thereof | |
CA3167339A1 (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
EP4337259A1 (en) | Compounds for degrading alpha-synuclein aggregates and uses thereof | |
TW201113290A (en) | Novel fused thiazolo and oxazolo pyrimidinones | |
AU2021262281A1 (en) | 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20231213 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |